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ABSTRACT 
 
Since the beginning of the AIDS pandemic, an estimated 78 million people have 
become infected and 35 million people have died from AIDS-related illnesses. Despite 
the existence of effective antiretroviral therapy, 1.1 million people died of AIDS-related 
causes in 2015. A vaccine that could induce broadly neutralizing antibodies (bnAbs) is 
hypothesized to be the most efficient way to halt the AIDS pandemic. However, the 
majority of attempts to elicit bnAbs with HIV-1 vaccine candidates have failed due to the 
extensive variability and complex immune-evasion strategies of HIV-1. Recent 
advances in the isolation of bnAbs from HIV-1 infected individuals have revived interest 
in vaccine development. The membrane proximal external region (MPER) of gp41 and 
the CD4 binding site (CD4bs) of gp120 have become attractive targets for vaccine 
development because they contain highly conserved epitopes recognized by some of 
the broadest neutralizing antibodies. Here, we have designed and characterized 
multiple immunogens and vaccine strategies to induce bnAbs targeted to MEPR or 
CD4bs. Our findings indicate that 1) neighboring domains influence the immunogenicity 
of gp41 MPER, and 2) priming with a small gp41 or gp120 immunogen, then 
subsequently boosting with larger and more native immunogens, may have the potential 
to elicit antibodies towards the appropriate neutralizing epitopes.  
 
Illumina amplicon sequencing is an important tool for the identification and 
quantification of species or variants in metagenomics studies, but sequencing errors 
make it challenging to correctly identify the authentic differences. Many denoising 
	   vi 
algorithms have been developed, but most ignore the quality scores or compress that 
data. We developed ampliclust, an error modeling approach using uncompressed 
sequences and quality scores to infer samples in Illumina amplicon data. Our approach 
showed better accuracy than the popular denoising tool DADA2 when data are not well 
separated. 
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CHAPTER 1 
GENERAL INTRODUCTION 
 
1.1 Dissertation Organization 
This dissertation is divided into seven chapters. Chapter 1 is the “General 
Introduction” describing the history of HIV-1 pandemic, the function of envelope 
glycoprotein, the development of envelope glycoprotein based HIV-1 vaccines. This is 
followed by a review on next generation sequencing techniques, the sequencing 
platforms, the error profiles, and error correction algorithms. 
Chapter 2 is a published manuscript titled “Modulating immunogenic properties of 
HIV-1 gp41 membrane-proximal external region by destabilizing six-helix bundle 
structure”. This manuscript evaluates the immunogenic properties of four gp41 putative 
fusion intermediates. The contribution of each author is as follows: Heliang Shi 
produced HR1-Δ10-54K and HR1-Δ17-54K antigens and Saikat Banerjee produced 
HR1-AA-54Q and HR1-EE-54Q antigens. Heliang Shi and Saikat Banerjee performed 
all experiments together; Habtom Habte and Yali Qin provided help in the antigen 
design; Heliang Shi, Saikat Banerjee, and Michael Cho wrote and revised the 
manuscript. 
Chapter 3 is a published manuscript titled “Evaluation of a novel multi-
immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 
gp41 membrane proximal external region”. This manuscript evaluates a novel multi-
immunogen vaccine strategy to induce 4E10/10E8-like broadly neutralizing antibodies. 
The contribution of each author is as follows: Heliang Shi generated 28x3 antigens, 
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immunized the rabbits, and analyzed the antibody responses; Saikat Banerjee 
immunized the multi-immunogen vaccine group and analyze the antibody responses; 
Saikat Banerjee, Marisa Banasik, and Hojin Moon generated the monoclonal antibodies; 
Andrew Harley helped with the epitope mapping analysis;William Lees and Adrian 
Shepherd performed the NGS analysis; Heliang Shi, Saikat Banerjee, Marisa Banasik, 
and Michael Cho wrote and revised the manuscript. 
Chapter 4 is presented as a manuscript in preparation titled “Evaluation of a 
novel rapid heterologous prime-boost strategy for targeting CD4bs neutralizing epitopes 
on HIV-1 gp120”.  This manuscript evaluates a heterologous prime-boost vaccine 
strategy using rapid immunization schedule to induce CD4bs directed broadly 
neutralizing antibodies. The contribution of each author is as follows: Heliang Shi 
generated the antigens, immunized the rabbits, and analyzed the cross-reactive 
antibodies; Heliang Shi and Saikat Banerjee performed the competitive ELISA; Heliang 
Shi and Aditi Agrawal performed the peptide ELISA; Heliang Shi and Michael Cho wrote 
and revised the manuscript. 
Chapter 5 is presented as a manuscript in preparation titled “Evaluation of a 
multi-immunogen vaccine strategy for targeting CD4bs neutralizing epitopes on HIV-1 
gp120”. This manuscript evaluates a vaccine strategy applying a sequential and phased 
mannered immunization approach with related but antigenically distinct immunogens to 
induce CD4bs directed broadly neutralizing antibodies. The contribution of each author 
is as follows: Heliang Shi produced the protein antigens, conducted the rabbit 
immunization, and performed the cross-reactivity analysis of antibodies; Heliang Shi  
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and Aditi Agrawal conducted peptide ELISA; Heliang Shi and Saikat Banerjee analyzed 
the competitive assay; Heliang Shi and Michael Cho wrote and revised the manuscript. 
Chapter 6 is presented as a manuscript in preparation titled “A Novel Sample 
Inference Method For Illumina Amplicon Data”. This manuscript describes a model-
based approach for the inference of Illumina amplicon data using uncompressed quality 
information. The contribution of each author is as follows: Heliang Shi and Karin 
Dorman developed the model; Heliang Shi and Xiyu Peng performed the programming; 
Heliang Shi evaluated the performance of the model; Heliang Shi and Karin Dorman 
wrote and revised the manuscript. 
Chapter 7 summarizes the general conclusions along with future directions. The 
appendix contains a manuscript in preparation titled “HIV-1 gp41-HR1-HR2 six-helix 
bundle as a Novel Fusion Protein Partner for Efficient Recombinant Protein 
Expression”. This manuscript describes a method to improve the recombinant protein 
expression. Heliang Shi performed all the experiments; Andrew Harley helped with the 
purification of HR1-6H-HR2-TH-54 protein. Heliang Shi and Michael Cho wrote and 
revised the manuscript. 
 
1.2 HIV-1 vaccine research 
 
1.2.1 The HIV-1 pandemic 
The first cases of Acquired Immune Deficiency Syndrome (AIDS) were identified 
in 1981 among gay men in the United States. The cause of this disease will officially be 
known as Human Immunodeficiency Virus Type 1 (HIV-1) originated in non-human 
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primates. (1, 2) HIV-2 was identified in 1986 among patients in Africa, although it was 
morphologically similar to HIV-1, they were proved to be antigenically distinct. (3, 4) 
Simian immunodeficiency viruses (SIVs) were found to be the source of HIV, but SIVs 
are non-pathogenic in their natural hosts. (5)The cross-species transmission of SIVs 
from non-human primates to humans is responsible for the emerging infections. Since 
HIV-2 is in general less virulent and largely restricted to western Africa, HIV-1 has been 
the main target for HIV research efforts.(6) 
HIV-1 has been divided into four distinct clades, groups M (major), O (outlier), N 
(non-M, non-O), and P (pending the identification of further human cases). Group M 
was the fist discovered lineage, represents the pandemic form of HIV-1 and has 
infected millions of people worldwide. Group O (discovered in 1990) represents less 
than 1% of total HIV-1 infections and is mainly found in Cameroon and its neighboring 
countries. Group N (discovered in 1998) is less prevalent than group O and has been 
found only in Cameroon. Group P (discovered in 2009) has so far only been identified in 
a Cameroonian woman living in France. These phylogenic groups are further divided 
into subtypes. For instance, group M has 11 subtypes A to K and group O has 9 
subtypes. (7-9) 
According to UNAIDS, there were approximately 36.7 million HIV-1 infected 
individuals at the end of 2015. Since the beginning of the HIV pandemic, about 78 
million people have become infected and 35 million people have died from AIDS-related 
illnesses (https://www.avert.org/global-hiv-and-aids-statistics#footnote4_l4cbfua). 
Although antiretroviral therapy has been effective in controlling HIV, it  cannot cure or 
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eradicate the virus completely.(10, 11) A safe and effective vaccine remains the most 
efficient way to prevent HIV-1 infection. 
 
1.2.2 HIV-1 envelope 
The HIV-1 envelop glycoproteins (Env) consists of the external protein gp120 
and the transmembrane protein gp41, which are generated by gp160 precursor through 
furin-like protease cleavage. (12, 13) Three gp120 subunits non-covalently associate 
with three gp41 subunits to form trimeric spikes on the virion surface. The Env plays a 
critical role in HIV-1 entry. To infect cells, gp120 binds to the primary cellular receptor 
(CD4), which initiates conformational changes in gp120 and exposes the binding 
domain of co-receptors (CCR5 or CXCR4). Binding of gp120 to a co-receptor would 
trigger the conformational changes in gp41 that allow the fusion peptide to insert into 
target membranes. The heptad repeat regions of gp41 fold into a six-helix bundle that 
drives the fusion of viral and cellular membranes.(14) 
The elicitation of broadly neutralizing antibodies (bnAbs) is a major goal of HIV-1 
vaccine development. The Env trimer on the surface of HIV-1 virions is the only target 
for bnAbs. A large number of potent bnAbs have been isolated from infected patients in 
recent years. They have been placed into five categories based on the location of their 
epitopes on the viral spike. These are the CD4 biding site (CD4bs)-directed antibodies, 
variable region 1 and variable region 2 (V1/V2)-directed antibodies, glycan variable 
region 3 (V3)-directed antibodies, membrane proximal external region (MPER)-directed 
antibodies, and the newly discovered glycan associated bridging region-directed 
antibodies.(15) The bnAbs could efficiently inhibit virus binding or preventing 
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conformational changes needed for virus entry. The great neutralizing capabilities of 
these bnAbs may be attributed to some of their unique features including high rate of 
somatic hypermutation and long heavy chain complementarity determining region 3 
(HCDR3). (16-20) The bnAbs were induced only in a minority of HIV-1 infected 
individuals several years post infection. Although protection by passive transfer of 
bnAbs has been reported,(21-23) there is currently no effective immunization regimens 
could elicit bnAbs. 
 
1.2.3 HIV-1 clinical trials 
Although hundreds of vaccine trials have been conducted so far, (24) only five 
vaccines have advanced to Phase IIb and Phase III clinical trials. The VAX003 
(conducted in Thailand) and VAX004 (conducted in North America and Europe) were 
the world's first phase III trials conducted between 2005 and 2007. They tested bivalent 
recombinant gp120 vaccines using subtypes B/E and B/B, respectively. However, they 
failed to elicit bnAbs and could not efficiently prevent HIV-1 acquisition in the vaccinated 
groups.(25, 26) The STEP (conducted in America and Australia) and Phambili 
(conducted in South Africa) Phase IIb trials were conducted between 2005 and 2007. 
They evaluated an adenovirus serotype 5 (Ad5) vector based vaccine expressing 
multiple HIV antigens comprising group specific antigen (gag), polymerase (pol), and 
negative regulation factor (nef) genes. Disappointingly, both trials failed to demonstrate 
any protection against HIV-1 infection.(27, 28)  The HVTN505 was the most recent trial 
conducted between 2009 and 2013. It evaluated the efficacy of a prime-boost regimen 
consisting of DNA vector encoding HIV-1 clade B Gag, Pol and Nef proteins along with 
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Env proteins (subtypes A, B and C) followed by a recombinant Ad5 boost. (29) This trial 
failed to demonstrate any protective effect. 
So far, the RV144 trial was the only candidate vaccine that displayed protection 
against HIV-1 infection. It was conducted between 2003 and 2006 in Thailand. This trial 
evaluated a prime-boost vaccine regimen consisting of canarypox vector expressing 
Env, Gag and protease (ALVAC-HIV [vCP1521]), and boosted by bivalent recombinant 
gp120 (AIDSVAX B/E).(30) This study demonstrated a modest vaccine efficacy of 31% 
but no bnAbs were induced. Further analysis have revealed that IgG antibodies induced 
against V1/V2 loops of gp120 correlated with the reduced risk of HIV-1 acquisition, IgA 
antibodies elicited against Env associated with the enhanced risk, and the antibody-
dependent cell-mediated cytotoxicity (ADCC) may have contributed to the protection. 
(31, 32) 
The findings of RV144 trial imply that an effective HIV-1 vaccine needs to induce 
both humoral and cellular immunity. The modest success of the RV144 trial suggests 
that a vaccine to prevent the establishment of HIV-1 infection is possible. 
 
1.2.4 Gp41-based vaccine development 
Elicitation of bnAbs is a major HIV-1 vaccine goal. As described earlier, the 
MPER of gp41 is the only neutralizing epitopes present on gp41. It is a very attractive 
vaccine target because it is a linear, unglycosylated, highly conserved, and tryptophan-
rich region playing a crucial role in the membrane fusion step of HIV-1 virus entry.(33) 
Five anti-MPER antibodies have been discovered so far, including 2F5, Z13e1, 4E10, 
10E8, and m66.6. They all target overlapping linear epitopes within MPER. 2F5 and 
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m66.6 recognize the N terminal of MEPR, while 4E10, Z13e1, and 10E8 target the C 
terminal. (34-38) Among all anti-MPER bnAbs, 10E8 is the broadest and most potent 
bnAb. 
A variety of studies have been performed to induce anti-MPER bnAbs. Early 
immunogens tested were MPER peptide-based vaccines containing neutralizing 
epitopes alone or coupling them to carrier proteins. (39-41) They failed to show 
neutralizing activity, possibly due to lack of appropriate conformation of the MPER. 
Different approaches have been applied to display MPER epitopes, including chimeric 
viruses, engineered scaffolds, virus-like particles, and liposomes.(42-47) However, all of 
these studies failed to induce neutralizing antibodies, possibly due to either the 
presence of immunodominant regions outside the MPER or the improper MPER 
conformation. 
The weak to modest neutralizing activities have been reported in a few studies. 
One prime-boost vaccine regimen consisting of rhinoviruses expressing the 2F5 
epitopes and boosted by similar epitopes coupled to carrier proteins have demonstrated 
induction of modest neutralizing activities in immunized guinea pigs. (48) Similar results 
have been observed from another study using a rhinovirus expressing the 4E10 epitope 
(45). In one study, rabbits, which were primed with MPER 60-mer antigens and boosted 
with gp160 DNA, induced weak neutralizing activities against HIV-2/HIV-1 chimeric 
viruses. (49) One study using virus like particles displaying heamagglutinin 
mutation/gp41 chimeric proteins or DNA have induced weak neutralizing antibodies in 
immunized guinea pigs. (50) Thus far, the best MPER-specific neutralization activities 
have been observed from the guinea pigs immunized with gp41 fusion intermediate 
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displayed on liposomal. (51) Although weak to modest neutralizing activities have been 
induced, there is currently no vaccine could elicit anti-MPER bnAbs. Therefore, 
additional efforts are needed to develop effective gp41-based HIV-1 vaccines. 
 
1.2.5 Gp120-based vaccine development 
As described earlier, bnAbs have been induced against five distinct regions on 
the Env. Three of these neutralizing epitopes are located within gp120. Thus far, a 
variety of gp120-based vaccines have been evaluated to induce such bnAbs. 
Early studies evaluating the V3 loop peptide-based vaccines induced 
neutralization activities but limited to Tier-1 viruses only, possibly due to the improper 
conformational epitopes. (52-55) Epitope scaffold immunogens transplanting epitopes, 
including V3 loop, CD4bs, and V3 glycan epitopes, onto heterologous protein scaffolds 
failed to induce an effective neutralization activities in animals. (41, 56, 57) The 
recombinant gp120 immunogens were evaluated in clinical trials, but met with limit 
success. 
Since the immune responses against the inner domain (ID) of gp120 are 
generally non-neutralizing and immunodominant, some studies attempted to develop 
outer domain (OD) based immunogens.(58) However, most of the studies have failed to 
induce neutralization activities. (59-62) Recently, one study reported by our group has 
shown that both OD and ODx3 immunogens, based on an M group consensus 
sequence (MCON6), induced cross-reactive nAb responses against the clade B, C, and 
AE Tier-1 viruses, which was much better than previous studies.(63) Another study has 
designed engineered OD (eOD) immunoges to target bnAbs germline precursors. The 
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first optimized immunogen eOD-GT6, which was fused to Lumazine Synthase that self-
assembles into 60mer nanoparticles, (64) failed to induce neutralizing responses 
according to our recent study. Another improved version eOD-GT8 has induced 
neutralizing activity against autologous viruses and the Tier-2 viruses lacking the glycan 
at position 276 in knock-in mice that carried the mature heavy chain of 3BNC60.(65) 
The Env trimer immunogens have been designed to mimic the native spike. The 
stabilized soluble Evn trimers comprising of gp120 and gp41 ectodomain induced better 
neutralizing responses than gp120, but still failed to induce bnAbs,(66-69) probably due 
to the misfolding of trimer. Another approach has been used to stabilize the Env trimer 
by introducing a disulfide bond (SOS) between gp120 and gp41 and a Ile-to-Pro 
mutation (I559P). (70) Several SOSIP based trimeric immunogens were evaluated, 
BG505 SOSIP.664 trimers is one of the improved immuogens. (71-73) It could mimic 
the native spikes and induce neutralizing responses against Tier 1 viruses and 
autologous Tier 2 viruses, but not against heterologous Tier 2 viruses. (74) 
Although a lot of efforts have been made to develop gp120-based vaccine, little 
success has been achieved. The main challenges are high sequence variability, 
extensive glycosylation, the presence of decoy immunodominant epitopes, and highly 
conformational nature of the bnAbs epitopes. Additional work is needed to overcome 
these challenges and develop an effective HIV-1 vaccine. 
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1.3 Denoising of Next-generation sequencing data 
1.3.1  Next-generation sequencing 
Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) are major biological 
macromolecules that are essential for all known forms of life. Sequencing refers to the 
process of determining the precise order of nucleotides within a DNA molecule in 
genome sequencing or RNA molecule in transcriptome sequencing; it has significantly 
accelerated biological research and discovery.  Sanger sequencing was developed in 
1970s by Frederick Sanger and has been widely used since then. The advent of Sanger 
sequencing gave a huge boost to sequencing field, it could provide high accurate 
sequencing results for long reads .(75) However, Sanger sequencing is labor intensive 
and high cost. The Human Genome Project took 13 years and cost 2.7 billion dollars. Its 
completion triggered the development of next-generation sequencing (NGS) 
technologies that are able to generate high-throughput sequences at a much lower cost. 
Affordable high-throughput NGS has revolutionized genomics, making large 
scale of studies of genetic variation and the sequencing projects that involve large 
number of organisms feasible (76). A series of NGS technologies have been developed, 
the major platforms are 454 pyrosequencing, Illumina/Solexa, SOLiD, Ion Torrent 
Personal Genome Machine (PGM), and Pacific Biosciences (PacBio) single molecule 
real-time sequencing (SMRT). Compared to Sanger sequencing, the NGS technologies 
simultaneously monitor incorporations on millions of templates to enhance the 
sequencing throughput and apply imaging or semiconductor technologies to make rapid 
and highly automated determination of nucleotides. These NGS techniques utilize DNA 
polymerase or ligase to synthesize deoxynucleotides (dNTPs), a fraction of which is 
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labeled. The signals released by bases synthesis are captured by the sequencers and 
translated to reads. Errors could be introduced during the imperfected library 
preparation and sequencing processes. 
As new technologies emerge, new challenges will inevitably arise. NGS platforms 
produce sequences with shorter length and higher error rate compared to Sanger 
sequencing. The major hurdle to overcome for NGS is the high error rate, because long-
read sequencing could overcome the length limitation, although it would be more 
expensive and lower throughput than other platforms(77).  The presence of sequencing 
errors could severely influence the downstream analysis of variant calling (78), genome 
assembly(79), transcript quantification and so forth. Thus, there is a compelling need for 
developing new algorithms for correcting errors in sequencing data. 
 
1.3.2  Denoising of NGS amplicon data 
Each of the platforms tends to have its own error profiles that differ slightly from 
one another due to the differing chemistries. Possibly due to the dominance of Illumina 
sequencers in the market, most error correction methods so far have been designed for 
substitution errors. This dissertation mainly focuses on the development of statistical 
method to denoise Illumina amplicon data. In the remainder of this chapter, we will 
briefly discuss some relevant prior knowledge. 
The amplicon-specific error-correction methods were initially developed for 
pyrosequencing platform (80, 81). More recently, a number of denoising algorithms 
have been developed for Illumina including UNOISE(82), MED(83), IPED(84), 
UNOISE2 (85), and DADA2 (86). The IPED utilizes an artificial intelligent classifier to 
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detect and correct the erroneous positions. The training data is required for this 
machine learning based method. MED divides amplicon reads into partitions and 
iteratively partitions dataset using only the informative nucleotide positions; it has been 
used widely to identify fine-scale variation. UNOISE exploits unique sequence 
abundances to conduct error correction. Among all the available algorithm,s DADA2 has 
been claimed as the best peer-reviewed methods for denoising Illumina amplicon data 
although UNOISE2 has shown its competitive performance. Both DADA2 and UNOISE2 
group all amplicon reads with the same sequence into unique sequences with an 
associated abundance, but their partitioning algorithms are different. UNOISE2 applies 
a one-pass clustering algorithm ignoring quality scores and has only two parameters. 
DADA2 utilizes a Poisson model-based iterative divisive partitioning clustering algorithm 
using quality score and has hundreds of parameters. 
Although many advances have been made for denoising Illumina amplicon 
datasets, there is still ample room for improvement. Most Illumina denoiser algorithms 
often discard quality scores completely or turn to compression. Quality scores are 
related to error rates and informative for error correction, underutilizing them may 
influence the downstream analysis and result to undesirable consequences. Some 
algorithms assign all reads of the same sequence to the same cluster, which may 
influence the clustering accuracy, because some sites within the reads are misreads of 
the true amplicon nucleotides which is possibly due to the low quality score of those 
sites. 
Inspired by DADA2, we proposed ampliclust, an error modeling approach using 
uncompressed data to correct errors and infer samples in Illumina amplicon data. We 
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model the reads as independent components from the model. We compare the error 
correction performance of our method against DADA2 on the Mock, real HIV, and 
simulated data sets. 
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CHAPTER 2 
MODULATING IMMUNOGENIC PROPERTIES OF HIV-1 GP41 
MEMBRANE-PROXIMAL EXTERNAL REGION BY DESTABILIZING SIX-HELIX 
BUNDLE STRUCTURE 
Saikat Banerjee†, Heliang Shi†, Habtom H. Habte, Yali Qin, Michael W. Cho 
†These authors contributed equally. 
 
Abstract 
The C-terminal a-helix of gp41 membrane-proximal external region (MPER; 
671NWFDITNWLWYIK683) encompassing 4E10/10E8 epitopes is an attractive target for 
HIV-1 vaccine development.  We previously reported that gp41-HR1-54Q, a trimeric 
protein comprised of the MPER in the context of a stable six-helix bundle (6HB), 
induced strong immune responses against the helix, but antibodies were directed 
primarily against the non-neutralizing face of the helix.  To better target 4E10/10E8 
epitopes, we generated four putative fusion intermediates by introducing double point 
mutations or deletions in the heptad repeat region 1 (HR1) that destabilize 6HB in 
varying degrees.  One variant, HR1-∆10-54K, elicited antibodies in rabbits that targeted 
W672, I675 and L679, which are critical for 4E10/10E8 recognition.  Overall, the results 
demonstrated that altering structural parameters of 6HB can influence immunogenic 
properties of the MPER and antibody targeting.  Further exploration of this strategy 
could allow development of immunogens that could lead to induction of 4E10/10E8-like 
antibodies.   
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2.1 Introduction 
It is widely hypothesized that a successful AIDS vaccine should induce 
antibodies that can neutralize a large number of HIV-1 isolates from multiple clades.  
However, such broadly neutralizing antibodies (bnAbs) have been observed only in a 
small fraction of HIV-1 infected patients (1, 2), suggesting that the generation of these 
bnAbs is a complex, difficult process.  Nevertheless, efforts to develop immunogens 
and/or vaccine strategies that can elicit bnAbs must continue.   
Recent isolation and characterization of potent bnAbs from patients has helped 
the field of vaccine research immensely by providing better understanding of both the 
epitopes targeted and the unique features of antibodies that contribute to their broad 
neutralizing ability.  Most of the bnAbs that target gp120 recognize highly 
conformational, non-linear epitopes(3).  In contrast, those that target gp41 recognize 
linear epitopes that are structurally simpler and reside in a highly conserved, ~22 amino 
acid long domain called the membrane proximal external region (MPER) (4).  These 
bnAbs are thought to inhibit conformational changes that are critical for fusion between 
viral and cellular membranes.  A more recent discovery of the highly potent and broadly 
neutralizing 10E8 mAb (5), along with previously characterized 2F5, 4E10 and Z13e1 
(6-8), has renewed interests in designing MPER-based immunogens.   
To date, eliciting anti-MPER bnAbs through vaccination has been elusive.  
Several approaches have been examined, including (1) immunization with short MPER 
peptides either alone or coupled to carrier proteins, (2) neutralizing epitopes presented 
on scaffolds, (3) MPER peptides delivered on liposomes, (4) MPER containing 
hybrid/fusion proteins, and (5) chimeric viruses or virus like particles (see (9) and 
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references therein).  Although a handful of studies have shown induction of modest 
levels of neutralizing activity with limited breadth against tier 1 HIV-1 isolates (10-14), 
neither the identity of antibodies responsible for neutralization nor the mechanistic 
nature of inhibition have been further demonstrated.     
Multiple crystal structures of short MPER peptides in complex with bnAbs have 
been solved (15-17).  Despite simpler epitope structures, the difficulty in designing 
immunogens that can induce similar antibodies lies partly on the fact that the MPER 
structure in the context of a native trimeric envelope spike on virus particles remains 
unknown.  In this regard, it is possible that antibody-bound MPER structures do not 
accurately represent the MPER conformation on native trimers.  Furthermore, gp41 
undergoes large structural changes during the fusion process (18), and it is likely that 
the MPER also assumes several different conformations.  Thus, studies that 
characterize the structural and immunological properties of MPER in context of larger 
gp41-based proteins are much needed. 
 As an initial effort, we generated a soluble gp41 construct named gp41-HR1-
54Q consisting of heptad repeat regions 1 and 2 (HR1and HR2, respectively) and the 
MPER (19).  While the HR1 and HR2 domains formed a stable six-helix bundle (6HB), 
much of the MPER domain remained quite flexible and free from association with the 
6HB (19).  Surprisingly, this protein induced strong antibody responses against a 
peptide that encompass 4E10/10E8 epitopes (671NWFDITNWLW680; (9).  Further 
analyses indicated that these antibodies targeted the non-neutralizing face of the C-
terminal a-helix, but partly overlapping with 4E10/10E8 epitopes.  One possible reason 
for the preferential targeting of the non-neutralizing face of the helix could be its 
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orientation when the MPER is presented in the context of a stable 6HB structure, which 
represents a post-fusion conformation.  It had been suggested that MPER might be 
more exposed during the fusion process as gp41 undergoes conformational changes 
(20-25).          
Recent crystal structures of BG505 SOSIP gp140 provided partial information on 
the pre-fusion state of gp41(18, 26).  However, fusion intermediate structures are 
completely unknown.  In particular, there is no information on how the MPER is oriented 
relative to the rest of the protein, and when and whether it make any contact with the 
rest of gp41 or gp120.  The only certainty is that HR1 and HR2 are in the process of 
coming together to form 6HB.  As such, we took an empirical approach of generating 
four variants of gp41-HR1-54Q that might represent different stages of fusion process 
by disrupting 6HB formation in varying degrees.  Biochemical, antigenic, and 
immunogenic properties of these putative fusion intermediates (PFIs) were 
characterized.  Although we did not succeed in inducing bnAbs against the MPER in 
rabbits, the results from the study should facilitate development of improved MPER 
immunogens.    
 
2.2 Results 
2.2.1 Designing gp41-HR1-54Q variants with destabilized 6HB. 
The trimeric structure of gp41-HR1-54Q is stabilized by both inter- and 
intramolecular interactions between HR1 and HR2 (19).  The exact order of molecular 
interactions between HR1 and HR2 that leads to 6HB formation is not known, although 
a leading working model suggests a zipping process along HR1-HR2 that begins at the 
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C- and N-termini of respective domains in an anti-parallel fashion, with a central trimeric 
HR1 core(27).  As such, we hypothesized that it might be possible to generate partially 
opened hairpin loop structures that might simulate fusion intermediates if HR1-HR1 or 
HR1-HR2 interactions were destabilized.     
Four variants were generated by either introducing point mutations or deletions 
(Fig. 1A).  All mutations were restricted to the HR1 only, so as to avoid altering the 
native conformation of the HR2 or MPER domains.  The C-terminal half of HR1 was 
mutated by introducing two point mutations (HR1-AA-54Q and HR1-EE-54Q), whereas 
the N-terminal half of HR1 was mutated more drastically by deletions (HR1∆10-54K and 
HR1∆17-54K).  The HR1-AA-54Q variant contained L565A and L568A mutations with 
an intent of weakening hydrophobic interactions with I635 and Y638 residues on HR2 
(Fig. 1B).  In contrast, HR1-EE-54Q contained L568E and K574E mutations designed 
destabilize 6HB formation by introducing intra- and inter-molecular charge-charge 
repulsions with E634 and E632 residues on HR2, respectively (Fig. 1C).  Deleting the 
N-terminal 10 or 17 amino acids of HR1 is designed to allow initiation of 6HB formation, 
but halt the zipping process in the middle to generate structures that might resemble 
fusion intermediates (Figs. 1D and 1E, respectively).  For these constructs with 
deletions, the terminal 683Q residue was reverted back to the wild type lysine as it was 
later reported to be critical for 10E8 binding (5).  Although we do not know whether any 
of these constructs would mimic true fusion intermediates, they will be referred herein 
as putative fusion intermediates (PFIs) for simplicity.   
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2.2.2 Biochemical and antigenic properties of PFIs.  
As we previously reported, gp41-HR1-54Q is highly resistant to trypsin digestion 
(9), presumably due to its rigid structure.  To determine how mutations might affect the 
protein, trypsin sensitivity of the PFIs was assessed.  As shown in Fig. 2A, gp41-HR1-
54Q was completely resistant to trypsin digestion even after one hour.  In contrast, PFIs 
exhibited varying degrees of trypsin sensitivity.  Not surprisingly, HR1-AA-54Q was least 
sensitive.  Unexpectedly, however, HR1-EE-54Q was most sensitive and that HR1-Δ10-
54K was more sensitive than HR1-Δ17-54K.  The differences in trypsin sensitivity 
among the PFIs suggested that they likely have folded into structures different from 
each other, and certainly different from gp41-HR1-54Q.      
Next, the PFIs were probed with NC-1, a mouse monoclonal antibody (mAb) that 
recognizes post-fusion 6HB structure (28).  NC-1 recognizes amino acid residues from 
643 to 655 within HR2 (29), which is present in all four PFIs.  Thus, any changes in NC-
1 binding should be the result of conformational changes induced by the mutations.  As 
shown in Fig. 2B (left panel), NC-1 binding was completely abolished for HR1-EE-54Q, 
HR1-Δ10-54K and HR1-Δ17-54K.  Although HR1-AA-54Q could be recognized, the 
binding was substantially weaker than gp41-HR1-54Q.  These results indicate that 
introduced mutations were able to disrupt formation of the post-fusion 6HB 
conformation.   
Next, the PFIs were probed with 126-7, a human mAb (an IgG2 version of 126-6) 
that only recognizes a trimeric conformation of gp41 shared between both pre- and 
post-fusion state (29-33).  It recognizes residues from 641 to 648 in the cluster II of 
gp41.  As shown in Fig. 2B (right panel), gp41-HR1-54Q, HR1-AA-54Q and HR1-EE-
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54Q bound nearly equally to 126-7 suggesting that the trimeric conformations of these 
proteins were similar (at least at the 126-7 epitope).  Not surprisingly, 126-7 failed to 
recognize both HR1-Δ10-54K and HR1-Δ17-54K.  The elimination of three and five 
helical turns in HR1, respectively, likely prevented formation of stable trimeric HR1 core.   
To examine whether epitopes recognized by MPER bnAbs remained 
conformationally intact and accessible on PFIs, they were probed with 2F5, Z13e1, 
4E10 and 10E8 by ELISA (Fig. 2C).  For 2F5, there were only minor differences 
between HR1-54Q and PFIs.  The results were similar for Z13e1, although HR1-EE-
54Q showed slightly weaker binding.  The reduced binding to HR1-EE-54Q was more 
pronounced with 4E10 and 10E8.  To a lesser extent, binding was also reduced for 
HR1-AA-54Q.  In general, antibody binding to HR1-Δ10-54K and HR1-Δ17-54K was 
quite similar to HR1-54Q, except for 10E8, for which there was significantly better 
binding.  However, this enhanced binding is most likely due to reverting back to lysine at 
position 683, rather than deletions themselves, since K683 is one of the critical residues 
that 10E8 recognizes.  Taken together, these results suggest that destabilization of 
6HB, depending on the approach taken, could potentially affect MPER structure, which 
could in turn alter conformation or accessibility of epitopes targeted by bnAbs.      
 
2.2.3 Immunogenic properties of PFIs  
Immunogenic properties of PFIs were evaluated in rabbits as we have done for 
gp41-HR1-54Q (9).  For this initial study, two animals were used for each of the four 
PFIs.  Serum samples were collected two weeks after each immunization (on weeks 0, 
4, 9 and 15).  Antibody titers against autologous antigens were assessed by ELISA (Fig. 
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3).  Overall, antibody responses against the PFIs were weaker than gp41-HR1-54Q, 
which induced end point antibody titers greater than 5x106 even after a single 
immunization.  PFIs with point mutations were more immunogenic than the ones with 
deletions, which was more noticeable after the first immunization.  The reduced 
antibody responses could be due in part to elimination of helper T cell epitopes, 
especially for the deletion mutants, in addition to altered conformations or loss of 
epitopes.     
To better understand how mutations on PFIs altered immune responses, 
immunogenic linear epitopes were mapped by ELISA using overlapping biotinylated 
peptides as we previously described (9).  Since mutations and deletions were in the 
HR1 domain, we focused on antibody responses directed against the HR2 and the 
MPER.  Notwithstanding some animal-to-animal variations, the immunogenic epitope 
profile of HR1-AA-54Q was somewhat similar to that of HR1-54Q, with 671 peptide 
(671NWFDITNWLW680) being highly immunogenic in both animals.  Interestingly, 
antibody responses against HR1-EE-54Q were directed towards N-terminus of HR2 and 
the C-terminus of MPER with little to no antibodies against peptides spanning the 
cluster II region (644RLIEESQNQQEKNEQELLAL663) that typically elicits non-
neutralizing antibodies (34-36).  Compared to HR1-54Q, one major difference in 
immune responses against HR1-Δ10-54K is strong antibody responses against the N-
terminal end of HR2.  Although the 671 peptide remained immunogenic, peptides 629 
(629MEWEREISNY638), 632 (632EREISNYTDI641) and 635 (635ISNYTDIIYR634) were 
clearly immunodominant.  By far, the most striking change in immunogenic epitope 
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profile was with HR1-Δ17-54K.  Virtually all of the peptides, except for peptides 665, 
668 and 674, were highly immunogenic in one or both of the rabbits.            
Despite strong antibody responses against the 671 peptide 
(671NWFDITNWLW680) that contained all or most of 4E10 and 10E8 epitopes, none of 
the rabbit sera exhibited neutralizing activity when tested against HIV-1 pseudoviruses 
SF162 (tier 1A, clade B), MW965.26 (tier 1A, clade C), and MN.3 (tier 1A, clade B) in a 
standard TZM-bl assay.   
 
2.2.4 Detailed analyses of antibodies targeting near 4E10/10E8 epitopes. 
Although we did not succeed in inducing bnAbs against gp41 MPER, better 
characterization of antibody responses near 4E10/10E8 epitopes could facilitate 
improving immunogens.  In particular, we were curious to see whether and how epitope 
targeting was altered for PFIs compared to HR1-54Q.  Towards this goal, we conducted 
fine epitope mapping analyses using alanine-scanning mutants of a 13-mer peptide 
(671NWFDITNWLWYIK683), which we previously used to characterize antibody 
responses against HR1-54Q (4, 9).  Initially, antibody reactivity against the wild-type 13-
mer 671 peptide was measured (Fig. 5).  Interestingly, some of the antisera reacted 
poorly to the 13-mer peptide when compared to their reactivity against the 10-mer 671 
peptide (Fig. 4).  This was particularly severe with rabbit #2 immunized with HR1-∆17-
54K, and, to a lesser degree, rabbit #2 immunized with HR1-AA-54Q.  Since ELISA 
using 10-mer peptides (Fig. 4) was done with a mixture of both N- and C-terminally 
biotinylated peptides, and that the 13-mer is biotinylated at the C-terminal K683 residue, 
it was possible that the orientation of the peptide attachment to an ELISA plate, could 
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have affected antibody binding.  However, this might not be the case since antibodies 
reacted strongly to the 10-mer peptide that was biotinylated at the C-terminus (data not 
shown).  Thus, the reason for the discrepancy is unknown at the present time.      
 With the caveat that we would be evaluating only a subset of antibodies targeting 
near 4E10/10E8 epitopes, we proceeded to characterize antibodies using the panel of 
13-mer mutant peptides.  All sera, except from rabbit #2 immunized with HR1-∆17-54K, 
were analyzed.  In doing so, serum samples were first normalized to yield comparable 
signals when bound to the wild-type peptide (Fig. 6A).  For all rabbits tested, D674 
residue was critical for antibody binding, which is likely due to a critical role it plays in 
maintaining a helical conformation of the peptide (5, 37).  For HR1-AA-54Q, the two 
animals exhibited different antibody epitope profiles (Fig. 6B); such animal-to-animal 
variations have been observed with HR1-54Q also (6-9).  Interestingly, similar patterns 
were also observed in animals immunized with HR1-EE-54Q (Fig. 6C).  This might 
suggest structural similarity of the C-terminal MPER for HR1-AA-54Q and HR1-EE-54Q.  
For the both groups, the profile shown on the top panels resembled one of the patterns 
observed from animals immunized with HR1-54Q.  The profile shown on the bottom 
panels (critical residues being D674, W678, L679, and I675 for HR1-AA-54Q) was not 
observed in any of the six animals immunized with HR1-54Q.  Thus, the latter profile 
could be specific to antibody responses against PFIs.  Coincidently, a similar profile was 
observed for a rabbit immunized with HR1-∆17-54K (Fig. 6E).  The same four residues 
were also critical for antibodies induced by HR1-∆10-54K (Fig. 6D).  In addition, 
antibodies induced by HR1-∆10-54K also targeted W672, which may be highly 
significant since this residue was never targeted by antibodies induced with HR1-54Q or 
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with any of the other PFIs.  More importantly, this is one of the critical residues 
recognized by both 4E10 and 10E8.   
To better compare antibodies induced by HR1-54Q and HR1-∆10-54K, amino 
acid residues critical for binding were visualized on a structure of a peptide co-
crystallized with 4E10 (Fig. 7; Cardoso et al., 2007).  This analysis revealed that 
antibodies induced by HR1-∆10-54K targeted nearly the opposite face of the helix 
compared to those induced by HR1-54Q with W678 being targeted by both.  More 
importantly, HR1-∆10-54K-induced antibodies targeted three of the five most critical 
residues for 4E10 binding (W672, F673, I675, T676 and L679).  So, although we were 
not able to induce nAbs, the results of our study demonstrate that it is possible to alter 
immunogenicity of epitopes simply by changing structural context of an immunogen.        
 
2.3 Discussion 
In previous studies, we described structural and immunological properties of 
gp41-HR1-54Q, which likely represents a near-post-fusion conformation of gp41 (9, 19).  
Although antibodies elicited in rabbits by this antigen bound epitopes that partially 
overlap with those targeted by 4E10 and 10E8, they were largely directed against the 
non-neutralizing face of the helix and failed to exhibit neutralizing activity.  It had been 
speculated that anti-MPER bnAbs primarily target fusion intermediate forms of gp41 
(10-14, 22, 23, 38).  However, their structures are not yet known, except for those of 
short peptides bound to the antibodies.  As such, we decided to take an empirical 
approach of generating fusion intermediates with a simple assumption that they would 
have minimal or partial HR1-HR2 pairing and 6HB formation.  We further assumed that 
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the MPER would likely exist in a conformation that is different from the one observed on 
gp41-HR1-54Q.  With these assumptions, four putative fusion intermediates (PFIs) were 
generated by introducing double point mutations or deletions into the HR1 of gp41-HR1-
54Q to destabilize HR1-HR1 and HR1-HR2 interactions, and their biochemical and 
immunological properties were evaluated in this study.   
Although we do not have structural evidence, the increased sensitivity of the PFIs 
to trypsin digestion and their altered reactivity to NC-1 and/or 126-7 mAbs demonstrated 
that the structure of 6HB on PFIs has been disrupted in varying degrees.  Not 
surprisingly, the four PFIs revealed different immunological profiles with respect to the 
overall immunogenicity (i.e. total antibody titers induced; Fig. 3), immunodominance of 
epitopes across the HR2 and MPER (Fig. 4), and specific amino acid residues targeted 
by antibodies directed against the C-terminal region containing 4E10/10E8 epitopes 
(671NWFDITNWLWYIK683; Fig. 6).  Together, these results indicate that immunogenicity 
of HR2 and MPER domains are highly dependent on the structural context in which they 
are presented.     
While we did not succeed in inducing bnAbs, detailed epitope mapping analyses 
revealed a few important findings about antibodies induced by PFIs, HR1-Δ10-54K in 
particular.  First, antibodies induced in both rabbits immunized with HR1-Δ10-54K 
targeted W672.  Targeting of this residue was never observed in any of the six rabbits 
immunized with gp41-HR1-54Q (9, 15-17, 19) or in any of the animals immunized with 
other PFIs.  Replacement of this residue with an alanine has been reported to reduce 
4E10 binding by over 1000-fold, highlighting its overarching importance (19, 37).  W672 
is also critical for 10E8 binding (5, 19).  Second, animals immunized with HR1-∆10-54K 
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and HR1-∆17-54K induced antibodies that bound strongly to I675 and L679, both of 
which line up with W672 along the same side of the helix and contribute significantly to 
4E10 and 10E8 binding (9, 37, 39).  Targeting these three residues highlights a 
remarkable shift from the binding pattern of antibodies elicited by gp41-HR1-54Q.  
Third, while gaining recognition of these three residues, antibodies induced by HR1-
∆10-54K seemed to have lost recognition of F673 and T676, which were quite well 
recognized by antibodies induced with gp41-HR1-54Q and targeted by both 4E10 and 
10E8.   
One cautionary note for interpreting the results of our study is that the epitope 
mapping analyses shown in Fig. 6 were conducted with polyclonal antibodies.  Thus, 
the phenotypic changes we observed are average of all antibodies that bind the peptide.  
Accordingly, when there are many antibodies that bind to different epitopes, we might 
not see significant reduction in antibody binding for mutations at any given position; this 
might be the case for rabbit #1 of HR1-AA-54Q and HR1-EE-54Q.  Significant reduction 
in binding would be seen only when the antibody response is homogeneous or when all 
or most antibodies target same residues.  In this regard, characterizing antibodies at the 
monoclonal level would provide a more accurate assessment. 
In the absence of a crystal structure of HR1-Δ10-54K, it is hard to speculate how 
deleting ten residues from the N-terminal end of HR1 (with a potential contribution from 
K683) influenced the overall MPER conformation to promote such a major shift in 
antibody response.  Nevertheless, our results clearly demonstrated that changes in 
HR1, which in turn affect stability of 6HB, significantly influence how antibodies target 
the MPER.  Considering the difficulties in crystallizing proteins that contain the 
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hydrophobic C-terminal ectodomain of gp41, MPER-based vaccine development may 
have to rely on reiterative, empirical approaches.  Based on the results from this study, 
HR1-Δ10-54K would be an excellent starting point.   
To improve the immunogen, one factor that could be adjusted is the length of 
HR1.  In this study, we deleted 10 or 17 residues, which account for roughly 3 and 5 
helical turns, respectively.  As shown in Fig. 4, the antibodies induced by HR1-∆17-54K 
were drastically different from all others, which we believe is due to complete disruption 
of 6HB, thereby rendering the protein highly flexible and inducing greater diversity of 
antibodies.  By adding two helical turns (HR1-∆10-54K), which likely increased the 
stability of 6HB, antibody responses against HR2 was largely restricted to the N-
terminal end and W672 could be targeted.  This raises a question as to what would 
happen to the antibody response if less than 10 residues were deleted.  Would any of 
them allow targeting of F673 and T676 (as did gp41-HR1-54Q), while also targeting 
W672, I675 and L679?       
Another factor that could be considered for improving antibody responses is to 
minimize immunogenicity of W678.  As shown in Fig. 6, W678 was targeted on all of the 
PFIs as well as on gp41-HR1-54Q (9, 20-25), suggesting its dominant role in 
determining antibody responses.  Most likely, W678 is not exposed during the natural 
course of the fusion process, rendering these antibodies useless.  Thus, preventing 
antibody responses against W678 could improve the chance of inducing bnAbs.  
Perhaps substituting W678 with a less immunogenic residue (e.g. glycine or alanine) 
might redirect the immune system to shift the focus away from W678 towards F673 and 
T676.     
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In all of our immunization studies, we used Zn-chitosan not only as an adjuvant, 
but also as an antigen delivery platform.  Although all of our PFIs, as well as gp41-HR1-
54Q, are soluble proteins, they all have 6xHis tag at the C-terminus, which was used to 
affix the proteins to Zn-chitosan.  Thus, the flexibility of the C-terminal end of the MPER 
was most likely limited.  However, neither the spatial distribution nor the orientation of 
the MPER when it is bound to Zn-chitosan are known.  More importantly, how it would 
affect MPER immunogenicity is completely unknown.  In this regard, it would be 
worthwhile to evaluate immunogenicity of some of the PFIs in the context of lipid 
membranes (e.g. delivered on liposomes or expressed directly on the cell surface), 
which would better resemble the MPER structure and the microenvironment of virus 
particles.      
 
2.4 Materials and Methods 
2.4.1 Cloning, Expression and Purification of PFIs 
To generate PFI constructs with point mutations, the QuikChange® XL Site 
directed mutagenesis kit was used as per the manufacturer’s instructions using the 
original gp41-HR1-54Q plasmid as the template (19).  For HR1-AA-54Q, the mutations 
L565A and L568A were introduced using the sense primer 5’-
GAGGCCCAGCAGCACGCCCTGCAGGCCACCGTGTGGGGCATC-3’ and the 
antisense primer 5’-
GATGCCCCACACGGTGGCCTGCAGGGCGTGCTGCTGGGCCTC-3’.  For HR1-EE-
54Q, the mutations L568E and K574E were introduced using the sense primer 5’-
GCACCTGCTGCAGGAGACCGTGTGGGGCATCGAGCAGGGAGGAGG-3’ and the 
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antisense primer 5’-
CCTCCTCCCTGCTCGATGCCCCACACGGTCTCCTGCAGCAGGTGC-3’.   
For the deletion variants, 10 and 17 residues were deleted from the N terminus 
end of the HR1 domain as shown in Fig 1A.  Both constructs were synthesized from IDT 
(Integrated DNA Technology) in the pUC57 backbone with flanking restriction sites for 
BamHI and EcoRI at the 5’ and 3’ ends of the constructs, respectively.  The sequence 
was also altered to encode terminal 683K residue instead of the 683Q as in gp41-HR1-
54Q.  These constructs were cloned into the pET-21a vector (Novagen; cat#69740-3) 
using BamHI and EcoRI.   All constructs were expressed and purified similar to gp41-
HR1-54Q (5, 19).  The final proteins were dialyzed into 1x PBS (pH 8.0) and stored at -
80 degrees. 
 
2.4.2 Trypsin sensitivity assay 
 All PFIs were incubated with trypsin at 1:100 (enzyme:protein) mass ratio for one 
hour at 37 °C.  3 µg of untreated and trypsin treated samples were then run on a 
Novex® 10-20% tricine gel (Thermo Fisher Scientific; cat# EC6625BOX) 
 
2.4.3 Rabbit immunization  
Eight New Zealand white female rabbits (2.5 to 3 kg) were purchased from 
Charles River (USA), housed under specific pathogen free environments and used in 
compliance with the animal protocol approved by IACUC of Iowa State University.  Two 
animals were immunized with each antigen using Zn-chitosan as an adjuvant.  The 
immunization protocol including the adjuvant preparation, antigen/adjuvant dosage, the 
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immunization and bleeding schedule were all exactly the same as that previously 
described for gp41-HR1-54Q (9). 
 
2.4.4 Enzyme-linked immunosorbent assay (ELISA) 
 All ELISAs were performed using the standard protocol described for gp41-HR1-
54Q (9, 28) except for the use of an alternate blocking buffer consisting of PBS (pH 7.5) 
with 2.5% skim milk and 5% calf sera.    For ELISAs testing the binding of antibodies 
NC-1, 126-7, 2F5, 4E10, Z13e1 and 10E8, coating antigen amounts for all other 
antigens equimolar to 30 ng/well of gp41-HR1-54Q using the same coating conditions 
as described for gp41-HR1-54Q.  In order to determine end point titers, all antigens 
were coated at 30 ng/well. The end-point ELISA titers were defined as serum dilution 
factor that gave readings of average + 2xSD (standard deviation) of the background as 
described previously (29, 40).  Coating for linear epitope mapping using 10-mer 
biotinylated peptides and 13-mer alanine scanning was also performed as previously 
described (9, 29-33).   
 
2.4.5 Neutralization assays 
Neutralization assays were performed in TZM-bl cells as previously described (9, 
40-42).  Viruses tested included SF162 (tier 1A, clade B), MW965.26 (tier 1A, clade C), 
and MN.3 (tier 1A, clade B). Murine leukemia virus Env-pseudotyped virus was used as 
a negative control.  
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2.6 Figures 1	  
 2	  
 3	  
 4	  
Fig 1.  Design of putative fusion intermediates of gp41-HR1-54Q.  (A) A domain 5	  
structure of gp41-HR1-54Q consisting of the T7Tag, heptad repeat region 1 (HR1), 6	  
GGGGS linker, heptad repeat region 2 (HR2), membrane-proximal external region 7	  
(MPER) and the 6x His tag is shown.  The HR1 domain sequence, along with the 8	  
terminal 683Q residue, is indicated for gp41-HR1-54Q.  Point mutations and deletions 9	  
introduced into the HR1 domain to generate variants HR1-AA-54Q, HR1-EE-54Q, HR1- 10	  
∆10-54K and HR1-∆17-54K are indicated.  The terminal 683Q residue was reverted 11	  
back to 683K in HR1-∆10-54K and HR1-∆17-54K.  (B) The mutations introduced in 12	  
HR1-AA-54Q (L565A and L568A) are plotted on the gp41-HR1-54Q crystal structure 13	  
(pdb: 3K9A) (9, 19) to highlight the proximity of these residues to the neighboring I635 14	  
and Y638 residues located on the HR2 domain.  Structures of the unmutated amino 15	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acids are shown.  (C) The mutations introduced in HR1-EE-54Q (L568E and K574E) 16	  
are plotted on the gp41-HR1-54Q crystal structure to display the proximity of these 17	  
residues to E632 and E634 residues.  The truncations introduced at the N-terminal end 18	  
of the HR1 domain are plotted onto the gp41-HR1-54Q structure simply to show the 19	  
point of deletion for (D) HR1-∆10-54K and (E) HR1-∆17-54K.   20	  
 21	  
 22	  
Fig 2.  Biochemical and antigenic properties of putative fusion intermediates.  (A) 23	  
Evaluation of trypsin sensitivity of PFIs in comparison to gp41-HR1-54Q.  (B) ELISA 24	  
with mAbs NC-1 and 126-7 to monitor effects of the mutation on six-helix bundle 25	  
formation.  gp41-HR1-54Q was used as a positive control, while another protein (gp41- 26	  
54Q) that lacks the HR1 domain was used as a negative control.  (C) The antigenic 27	  
integrity of the variants was tested by performing ELISA with bnAbs 2F5, 4E10, Z13e1 28	  
and 10E8. 29	  
 30	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 31	  
Fig 3.  Antibody end-point titers induced by putative fusion intermediates.  Serum 32	  
samples collected two weeks after each immunization were evaluated by ELISA to 33	  
determine the end-point antibody titers against autologous antigens.  Pre-immune 34	  
serum was used as a negative control. 35	  
 36	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 37	  
Fig 4.  PepScan analyses using linear, overlapping peptides.  Serum samples 38	  
collected after the fourth immunization were evaluated for reactivity against biotinylated 39	  
10-mer peptides (a mixture of peptides biotinylated at the N-terminal and C-terminal 40	  
ends) spanning both HR2 and MPER domains.  The amino acid sequence of each 41	  
peptide is indicated by horizontal brackets.  The first and last residue in the peptide 42	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panel is indicated in red as they can differ from the immunogens. The core binding 43	  
epitopes for 2F5, 4E10 and 10E8 bnAbs are also indicated.  Pre-immune serum was 44	  
used as a negative control. 45	  
 46	  
 47	  
 48	  
Fig 5.  Antibody titers against a wild type peptide containing C-terminal 13 amino 49	  
acids.   Serum samples collected after the fourth immunization was evaluated for 50	  
binding biotinylated 13-mer peptide (671NWFDITNWLWYIK683) that contains 4E10/10E8 51	  
epitopes.  Pre-immune serum was used as negative control. 52	  
 53	  
 54	  
 55	  
 56	  
 57	  
 58	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 59	  
 60	  
Fig 6.  Detailed epitope mapping analysis of antibodies against the C-terminal 13 61	  
amino acid residues using alanine-scanning mutant peptides.  (A) Serum samples 62	  
after the fourth immunization were examined for binding biotinylated 13-mer peptide 63	  
(671NWFDITNWLWYIK683).  The analyses were done using normalized serum samples 64	  
to yield comparable binding signal (AA-R1 at 1:2000 dilution; AA-R2 and EE-R2 at 65	  
1:100 dilution; EE-R1 at 1:600 dilution; ∆10-R1 at 1:300 dilution; ∆10-R2 at 1:400 66	  
dilution; and ∆17-R1 at 1:5000 dilution).  (B-E) The same dilutions were tested for 67	  
binding to mutant peptides.  Results are shown as the percentage of binding to the wild 68	  
type peptide observed in panel (A). 69	  
 70	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 71	  
Fig 7.  Comparison of critical binding residues for antibodies induced by HR1- 72	  
∆10-54K and gp41-HR1-54Q relative to 4E10.  (A) Critical binding residues for 4E10 73	  
and antibodies induced by gp41-HR1-54Q are plotted onto the peptide co-crystalized 74	  
with 4E10 (pdb: 2FX7) (17, 34-36).  Residues critical for 4E10 or rabbit antibody only 75	  
are shown in green and red, respectively.  Residues important for both are shown in 76	  
blue. (B) Critical binding residues for antibodies induced by HR1-∆10-54K were also 77	  
plotted onto the same peptide revealing significant difference from the pattern observed 78	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with gp41-HR1-54Q. (C) A lateral view of the peptide displaying critical binding residues 79	  
for 4E10 and HR1-∆10-54K-induced antibodies.  (D) Position of all the HR1-∆10-54K 80	  
critical residues in context of the 4E10 bound peptide.  The heavy and light chains for 81	  
the antibody are indicated as H and L. 82	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CHAPTER 3 
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Abstract 
The membrane proximal external region (MPER) of HIV-1 gp41 is targeted by 
broadly neutralizing antibodies (bnAbs) 4E10 and 10E8.  In this proof-of-concept study, 
we evaluated a novel multi-immunogen vaccine strategy referred to as Incremental, 
Phased Antigenic Stimulation for Rapid Antibody Maturation (IPAS-RAM) to induce 
4E10/10E8-like bnAbs.  Rabbits were immunized sequentially, but in a phased manner, 
with three immunogens that are progressively more native (gp41-28x3, gp41-54CT, and 
rVV-gp160DH12).  Although nAbs were not induced, epitope-mapping analyses indicated 
that IPAS-RAM vaccination was better able to target antibodies towards the 4E10/10E8 
epitopes than homologous prime-boost immunization using gp41-28x3 alone.  MPER-
specific rabbit monoclonal antibodies were generated, including 9F6.  Although it lacked 
neutralizing activity, the target epitope profile of 9F6 closely resembled those of 4E10 
and 10E8 (671NWFDITNWLWYIK683).  B-cell repertoire analyses suggested the 
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importance of co-immunizations for maturation of 9F6, which warrants further evaluation 
of our IPAS-RAM vaccine strategy using an improved priming immunogen.  
 
3.1 Introduction 
To date, dozens of human monoclonal antibodies (mAbs) have been isolated 
from virus-infected patients that can neutralize a large number of HIV-1 variants from 
multiple clades (Huang et al., 2014; 2012; Pejchal et al., 2011; Scheid et al., 2011; 
Walker et al., 2011; 2009; Wu et al., 2010; Zwick et al., 2001). These broadly 
neutralizing antibodies (bnAbs) target a few select conserved sites of vulnerability on 
viral envelope glycoproteins gp120 and gp41 (for reviews, see (Georgiev et al., 2013; 
Haynes et al., 2014; Kwong et al., 2013; Mascola and Haynes, 2013; Mascola and 
Montefiori, 2010; McCoy and Weiss, 2013; van Gils and Sanders, 2013)).  One of these 
targets is the membrane proximal external region (MPER), a highly conserved domain 
of ~22 amino acid residues situated at the C-terminal end of the gp41 ectodomain.  The 
MPER is thought to play a critical role during the fusion between viral and cellular 
membranes (Muñoz-Barroso et al., 1999; Salzwedel et al., 1999).  It is targeted by 
bnAbs 2F5, Z13e1, 4E10 and 10E8 (Huang et al., 2012; Purtscher et al., 1994; Stiegler 
et al., 2001; Zwick et al., 2001).  4E10 and 10E8 are particularly notable as they have 
been shown to neutralize ~98% of the HIV-1 isolates tested (Huang et al., 2012).  4E10 
and 10E8 epitopes lie within the C-terminal 13 residues of the MPER 
(671NWFDITNWLWYIK683) and their crystal structures have been determined (Cardoso 
et al., 2007; Huang et al., 2012).   
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Despite having short, linear, simple alpha-helical epitopes, efforts to develop a 
vaccine that can induce 4E10/10E8-like bnAbs have been unsuccessful (see (Banerjee 
et al., 2016; Habte et al., 2015) and references therein).  Since all of the immunogens 
evaluated could bind 4E10/10E8, the failure to induce similar bnAbs is not because 
antigens could not assume the correct epitope structures.  Rather, it is likely due to the 
difficulty in inducing high levels of MPER-directed antibodies that can bind the 
neutralizing epitopes in the context of a whole trimeric gp120/gp41 complex.  
Unfortunately, this problem cannot be remedied simply by using a trimeric envelope 
complex because the MPER is immunorecessive compared to other epitopes that elicit 
type-specific or non-neutralizing antibodies.  An additional challenge in inducing MPER 
neutralizing antibodies is that the structure of the gp41 subunit is highly dynamic as it 
undergoes significant structural changes to mediate fusion between viral and cellular 
membranes (Melikyan, 2008).  The conformation, orientation and accessibility of the 
MPER neutralizing epitopes likely vary significantly at different stages of the fusion 
process, about which little is known at the present time.  Further, the orientation of the 
MPER relative to the membrane surface or to the rest of the native gp120/gp41 trimeric 
complex is unknown.  These factors make it difficult to design small, sub-domain 
immunogens.   
Taken together, the major challenge in developing an MPER-based vaccine is 
designing immunogens and/or developing vaccine strategies that both force the immune 
system to focus antibody responses towards the MPER and also guide antibody 
evolution so that mature antibodies bind neutralizing epitopes on trimeric envelope 
spikes on the virus particles.  Considering that antibody maturation will have to occur 
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during a relatively short timeframe, we postulated that inducing bnAbs against the 
MPER would be impossible to accomplish with a single immunogen using typical 
vaccine approaches.  To address this problem, we devised a novel vaccine strategy, 
referred to as Incremental, Phased Antigenic Stimulation for Rapid Antibody Maturation, 
or IPAS-RAM.  The basic concept is to prime the immune system using a small MPER-
derived peptide to stimulate a broad spectrum of antibodies against the MPER, then 
selectively amplify those that bind the native structure by boosting with progressively 
more native immunogens.  Although a number of studies recently reported sequential 
immunization with different immunogens, they used only a single immunogen during 
each immunization (Briney et al., 2016; Escolano et al., 2016; Haynes et al., 2012; Sok 
et al., 2016; Tian et al., 2016).  What makes our IPAS-RAM strategy unique is that the 
immune system is exposed to different, but related, immunogens simultaneously in a 
phased manner, such that B cells stimulated by a smaller immunogen can concurrently 
engage common epitopes on a larger, more native immunogen.  By repeating this 
process using incrementally more native antigens, we hypothesized that the immune 
system can better target MPER neutralizing epitopes and that antibodies could undergo 
the maturation process more efficiently.    
In this proof-of-concept study, we evaluated the IPAS-RAM vaccine strategy 
using three immunogens in rabbits: An MPER-based polypeptide, a membrane-bound 
gp41 mini-protein, and a full-length gp160.  We hypothesized that a peptide-based 
priming antigen would be highly effective in eliciting antibodies against the MPER, and 
that boosting with progressively larger and more “native” antigens would enable select 
antibodies to mature into bnAbs capable of binding gp41 as it appears in the native 
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trimer.  Although we did not succeed in eliciting neutralizing antibodies, results of our 
study demonstrate proof-of-principle for the IPAS-RAM vaccine strategy and identify 
ways to improve it.   
 
3.2 Results 
3.2.1 Immunogens. 
To focus antibody responses towards the MPER, we generated an immunogen 
designated gp41-28x3, which consists of three tandem copies of the C-terminal 28 a.a. 
of gp41 ectodomain (Fig. 1A).  The immunogen was produced initially as a fusion 
protein (HR1-HR2-28x3) by adjoining 28x3 to the HR1-HR2 regions of gp41, which 
forms a six-helix bundle (6HB) (Shi et al., 2010).  This was done because we had 
observed that HR1-HR2 6HB allows high level protein expression in E. coli (Fig. 1B; 
unpublished data).  The HR1-HR2 portion was subsequently removed by thrombin 
digestion (Fig. 1C).  Three 28-mer peptides were linked together to increase its 
immunogenicity without requiring conjugation to a heterologous carrier protein.  All of 
the bnAbs tested (2F5, Z13e1, 4E10 and 10E8) bound gp41-28x3 (Fig. 1D).  However, 
10E8 binding was about ~50-fold weaker than 2F5 and ~10-fold weaker than Z13e1 and 
4E10, suggesting that the conformation of the 10E8 epitope may not be optimal.  
The conformation, orientation, and/or accessibility of the neutralizing epitopes on 
the MPER are likely affected by the membrane surface as well as other proximal gp41 
domains.  To present the MPER in a more native-like setting, we generated a second 
immunogen designated gp41-54CT.  It comprises the C-terminal 54 a.a. of the gp41 
ectodomain that includes the HR2 domain and the MPER, along with the 
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transmembrane domain and the cytoplasmic tail (CT).  We hypothesized that this 
immunogen would selectively amplify a subset of antibodies induced by gp41-28x3 that 
could bind the MPER in the context of the membrane surface and HR2.  HEK-293T 
cells transfected with the plasmid encoding gp41-54CT could be detected using 2F5, 
Z13e1 and 4E10 by flow cytometry analyses (Fig. 1E), indicating cell surface expression 
of the protein and correct conformation of neutralizing epitopes.  Both gp41-54CT and 
gp41-28x3 are based on M group consensus sequence (Gao et al., 2005).  For the final 
boost, we generated a recombinant vaccinia virus expressing the full-length gp160 of 
the HIV-1DH12 strain (rVV-gp160DH12).  A schematic diagram showing the relative sizes 
of the three immunogens are illustrated in Fig. 1F.         
 
3.2.2 Immunization and evaluation of antibody responses. 
To evaluate IPAS-RAM vaccine strategy, rabbits (R1, R2 and R3) were first 
immunized with gp41-28x3 only (Fig. 2A).  Four weeks later, a combination of gp41-
28x3 and gp41-54CT was administered, with the latter delivered by DNA 
electroporation.  Instead of immunizing with just gp41-54CT, gp41-28x3 was also 
included because we postulated that immunizing with both immunogens would 
preferentially stimulate antibody responses towards epitopes present on both 
immunogens (i.e. the C-terminal 28 a.a.).  Similarly, on week 11, a combination of gp41-
54CT and rVV-gp160DH12 was administered.  After the first immunization, the antibody 
titers reached >103 and the titers increased by about 100 fold after the second 
immunization (Fig. S1A).  However, because significant increases in antibody 
responses were not observed after the third immunization, a fourth immunization was 
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given on week 29 using gp41-28x3 and rVV-gp160DH12.  The long resting period was 
given so that antiviral immune responses against the vaccinia virus vector induced after 
the third immunization would subside.  Antibody responses increased only slightly after 
the fourth immunization. 
To identify immunogenic linear epitopes, ELISAs were conducted with 
overlapping 10-mer peptide sets biotinylated either at the N- or C-terminal ends as we 
previously reported (Banerjee et al., 2016; Habte et al., 2015).  After the first 
immunization, very little response was detected (Fig. 2B).  However, after the second 
immunization, strong antibody responses were detected against peptides in the cluster 
II immunodominant region just upstream of the 2F5 epitope (peptides 653 and 656; also 
peptide 650 for rabbit R2).  After the third immunization with gp41-54CT and rVV-
gp160DH12, the cluster II region still remained immunodominant.  However, antibody 
responses appeared against other linear epitopes.  R2 showed good binding to peptide 
662ALDKWASLWN671 containing the 2F5 epitope.  This rabbit also showed low level 
reactivity against other C-terminal peptides (665, 668, 671 and 674).  Antiserum from 
R3 bound to peptides 668SLWNWFDITN677 and 671NWFDITNWLW680 that contain parts 
of the 4E10 and 10E8 epitopes.  R1 and R2 also recognized additional peptides within 
the HR2 domain (peptides 629 and 638).  Except for peptides 653 and 656, antibody 
responses against peptides exhibited animal-to-animal variation.  The fourth 
immunization with gp41-28x3 and rVV-gp160DH12 further enhanced anti-MPER 
antibodies in R2 (peptides 668 and 671) and R3 (peptides 671 and 674).  Interestingly, 
antibody responses against many of the upstream peptides (629, 638, 650, 653 and 
656) diminished significantly for R2.    
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To examine whether antibodies induced by the IPAS-RAM vaccine strategy are 
different from those induced by a typical homologous prime-boost immunization, 
another group of rabbits (R4, R5 and R6) was immunized with gp41-28x3 (Fig. 2C).  
Strong antibody responses were induced after the first immunization (~104 to ~105; Fig. 
S1B).  Since these rabbits received the same vaccination as the animals in the IPAS-
RAM group, the higher antibody titers suggest animal-to-animal variations.  Antibody 
titers continued to increase with each successive immunization (Fig. S1B).  Not 
surprisingly, 10-mer peptides 653 and 656 were most immunogenic (Fig. 2D), which 
might be the reason why they were also immunogenic in the IPAS-RAM group.  After 
the fourth immunization, high-level antibodies were detected against peptide 674 all 
three animals.  R4 and R6 mounted strong antibody responses against the 671 peptide 
that contains 4E10/10E8 epitopes.  Overall, the gp41-28x3 homologous prime-boost 
immunization induced more robust antibody responses against gp41 MPER than the 
IPAS-RAM vaccine.  Interestingly, antibodies from rabbit R6 reacted strongly to 
peptides 647 even though gp41-28x3 does not extend this far out into the N-terminus.  
One likely possibility is that antibody responses against 656NEQE659 could be cross-
reacting against 651NQQE654.  Another possibility is that our gp41-28x3 preparation 
could have minor contamination of the HR1-HR2 fragment or undigested HR1-HR2-
28x3.     
 
3.2.3 Antibody responses against the C-terminal 13 a.a. residues of gp41 MPER. 
Despite the overwhelming immunodominance of the cluster II region, antibody 
responses were induced towards the C-terminal end of the gp41 ectodomain, where 
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4E10/10E8 epitopes are located, in five of the six rabbits.  However, no serum 
neutralizing activity was detected (data not shown).  Regardless, we were interested in 
determining whether antibodies against the C-terminal 13 a.a. were qualitatively 
different between the two vaccine groups.  We examined which amino acid residues 
were targeted by ELISA using two panels of alanine mutant peptides.  First, we used 
peptides that were biotinylated at the C-terminal K683 (Fig. 3A and 3B) as previously 
described (Banerjee et al., 2016; Habte et al., 2015).  As noted previously, the D674A 
mutation affects the helical conformation of the peptide (Banerjee et al., 2016; Habte et 
al., 2015); thus, results should be interpreted with some caution.  For R2, the four 
residues that were most affected besides D674 were F673, N677, W678 and L679.  
Residues important in R3 were N671, W672, F673 and N677; the first three of which 
are absolutely critical for 10E8.  Of all the immunogens we evaluated to date (Banerjee 
et al., 2016; Habte et al., 2015), this is the first time we targeted all three of these 
residues.  For R4, the pattern was similar to R3, except that W6762 was not targeted.  
The epitope targeting profile for R5 was quite unique in that antibodies targeted W680 
and Y681.  The overall pattern for R6 resembled that of R2, except for not targeting 
T676 and N677.     
Because peptides that were biotinylated at the C-terminal K683 might not allow 
binding of some antibodies (e.g. those that approach the peptide from the C-terminal 
end), the analyses were repeated using peptides that were biotinylated at the N-
terminus with a two glycine spacer (Fig 3C and 3D).  As expected, somewhat different 
patterns were observed, especially for R3, which showed marked difference (>40%) for 
residues N671, N677, W678, W680, Y681 and K683.  For rabbits R4, R5 and R6, 
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however, many of the targeted residues identified using one peptide set are simply a 
subset of residues identified using the other peptide set.  For example, for R6, the 
important residues were F673, I675, W678 and L679 using peptides biotinylated at the 
C-terminus while additional N677 and W680 were identified using peptides biotinylated 
at the N-terminus.        
 
3.2.4 Generation and characterization of MPER-specific monoclonal antibodies. 
 Although target epitope profiling with whole serum provides some sense of which 
residues are critical for antibody binding, it does not provide clear information due to the 
polyclonal nature of antibodies.  To better evaluate MPER-directed antibodies in R3 that 
might be targeting the 671NWF673 residues, and to gain insights into how we might 
improve immunogens and/or vaccine strategies, MPER-specific mAbs were generated 
and characterized.  Hybridomas were screened initially with gp41-28x3, and then with 
15-mer peptides containing epitopes for 2F5 (657EQELLALDKWASLWN671) and 
4E10/10E8 (669LWNWFDITNWLWYIK683).  Based on the level of reactivity and epitope 
targeting profiles, three hybridomas (6C10, 9F6 and 21B5) were selected for detailed 
characterization.  Based on the binding to various 15-mer peptides, the epitope for 
6C10 was mapped approximately to 657EQELLAL663, just upstream of the 2F5 epitope 
(Fig. 4A).  Since 6C10 epitope is situated within the two 10-mer peptides that were most 
reactive (653QEKNEQELLA and 656NEQELLALDK; Fig. 2), 6C10 could represent the 
most predominant antibody induced. 
Although 9F6 and 21B5 strongly bound 669LWNWFDITNWLWYIK683, both failed 
to bind upstream (665KWASLWNWFDITNWL679) and downstream 
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(673FDITNWLWYIKIFIM686) peptides (Fig. 4A).   This result suggested that the critical 
residues are also present within the four terminal residues at either ends of the 669-
peptide (i.e. LWNW and WYIK).  Alternatively, but not exclusively, the presence of four 
residues on 665- and 673-peptides at the N- or C-terminal ends, respectively (i.e. 
KWAS and IFIM), could be interfering with antibody binding.  Additional mapping 
analyses with shorter peptides indicated that 9F6 epitope resided within 
671NWFDITNWLW680, whereas 21B5 epitope extended further downstream.  21B5 
bound the N-terminally biotinylated GGNWFDITNWLWYIK683 peptide, but not the 
671NWFDITNWLWYIK683 peptide biotinylated at the C-terminal lysine, suggesting that 
the antibody binds near K683 and that biotin sterically interferes with access. 
Interestingly, we isolated twelve 21B5-like hybridomas that bound both the N- and C-
terminally biotinylated 13-mer peptide.     
 
3.2.5 Detailed epitope mapping of 9F6 and 21B5 mAbs. 
To better define the 9F6 and 21B5 epitopes, ELISAs were performed using the 
two panels of scanning alanine mutant peptides as described in Fig. 3.  For comparison, 
4E10 and 10E8 were also analyzed.  As shown in Fig. 4B, mutating N671, W672, F673, 
T676 and N677 residues to alanine markedly diminished 9F6 binding when tested with 
C-terminally biotinylated peptides.  To a lesser degree, mutating W680 also reduced 
binding.  This target profile was remarkably similar to that of 4E10, except for I675 and 
L679, which were recognized by 4E10 but not by 9F6.  Conversely, 9F6 targeted N677 
whereas 4E10 did not.  A similar targeting profile was observed when N-terminally 
biotinylated peptides were used (Fig. 4C).  However, one major difference was the 
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W680A mutation, which showed a severe binding defect for both 9F6 and 4E10 using 
the N-terminally biotinylated peptide.  It should be noted that while mutating W680 only 
moderately reduced peptide binding (Brunel et al., 2006), it is important for 
neutralization by 4E10 (Brunel et al., 2006; Zwick et al., 2005).  Interestingly, the K683A 
mutation reduced 9F6 binding to 60% of the wild type even though the 671 10-mer 
peptide (671NWFDITNWLW680) was sufficient to bind the mAb efficiently.  The results 
are graphically summarized in Fig. 4D, which show significant overlap between 9F6 and 
4E10/10E8 binding.      
Overall, the antibody targeting profile of 10E8 was fairly similar to that of 4E10, 
although there were some notable differences (e.g. L679).  Mutated residues that most 
severely diminished 10E8 binding were N671, W672, F673, I675, T676 and W680.  To 
a lesser extent, mutating N677 and W678 also reduced recognition.  The reduced 
binding by the W678A mutation was somewhat unexpected since it resides on the 
opposite side of the neutralization face, although Huang et al. (Huang et al., 2012) 
reported that mutating this residue reduced peptide inhibition of 10E8 neutralization by 
~20%.  Also unexpected was the reduction of only 40% for the K683A mutation, when 
R683 was critical (Huang et al., 2012).  Similarly, the L679A mutation resulted in only a 
slight reduction when it had previously shown to exhibit a moderate effect (~50% 
reduction in neutralization inhibition) (Huang et al., 2012).  
The five most critical residues for 21B5 binding were W672, N677, W678, W680 
and Y681.  Thus, in contrast to 9F6, 21B5 targeted W678 and Y681, both which are 
located directly on the opposite side of the neutralization face (Fig. 4D).  Conversely,  
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21B5 failed to target N671 and only weakly bound F673, both of which are targeted by 
9F6, as well as 4E10 and 10E8.  Overall, 9F6 better resembled 4E10/10E8 than 21B5.   
 
3.2.6 Sequence analysis of MPER-binding mAbs 
 To determine the origin of MPER-specific mAbs, antibody genes were PCR-
amplified from hybridomas, cloned and sequenced.  Analyses indicated that 6C10 
heavy chain was derived from IGHV1S45*01 germline, while 9F6 and 21B5 originated 
from IGHV1S40*01(Fig. S2A-C). 6C10 and 21B5 kappa chains were derived from the 
IGKV1S32*01 and IGKV1S44*01 germlines, respectively.  Unfortunately, we have not 
been able to recover a productive light chain from the 9F6 hybridoma using known 
primer sets for either kappa or lambda chains, despite exhaustive efforts.  We suspect 
our primers may not bind the 9F6 light chain, due to either somatic mutations in the 
primer-binding site or suboptimal design based on incomplete information about the 
rabbit germline repertoire.  Among the three mAbs, the heavy chain of 9F6 was the 
most conserved to germline, sharing 96.53% nucleotide identity, followed by 6C10 and 
21B5 (91.32% and 87.85%, respectively).  Similarly, the kappa chain of 6C10 was less 
divergent than that of 21B5 (90.32% and 89.25%, respectively). Surprisingly, high levels 
of mutations were observed in FR1 for 6C10 and 21B5.  The importance of these 
mutations in antibody function has not been determined.   
 Of the twelve 21B5-like mAbs that could bind C-terminally biotinylated 671-13mer 
peptide, five representative hybridomas (21B6, 6F9, 31A4, 27A1 and 17-4H2) were 
selected for further characterization.  Sequence analyses showed that all five mAbs 
belonged to the same clonal family as 21B5, as determined by predicted germline, 
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junction, and CDR3 identity (Fig. S2D).  It should be noted, however, that IMGT 
predicted 21B6 heavy chain might be derived from the IGHV1S45*01, which is highly 
related to IGHV1S40*01 and differ only at the very 5’ end of the V-gene.  Although 
convergent affinity maturation of antibodies derived from different germlines is a 
possibility, we suspect a more likely scenario is a gene conversion event between the 
two V genes following V-D-J recombination.  The heavy chains of 21B5-like mAbs were 
less divergent from the germline than 21B5 (91.93%-97.22% identity).  Differences from 
germline were most highly concentrated in the CDR2.  The kappa chains were more 
divergent than the heavy chains, with germline identity ranging from 87.81% to 89.96%.  
Of note, when comparing similarities versus differences of 21B5 to the other clonal 
family members (Fig. S2D, cyan highlights versus yellow), mutations in the kappa chain 
were much more conserved across the family than the heavy chain, where 21B5 
represents a more distinctive sequence.  
3.2.7 Bioinformatics analyses of B cell repertoire and antibody maturation.   
To gain insights into possible maturation pathways of the MPER-specific mAbs, 
the antibody repertoire was analyzed by NGS of PBMC collected four days after the first 
three immunizations (A1, A2, A3), as well as terminal PBMC (TP) and spleen (TS).  A 
total of 13.3M raw reads were obtained, from which 290,848 unique productive heavy 
chain and 89,760 kappa chain sequences were derived (Table S1). The lambda chain 
was not sequenced, as it is underutilized in rabbits (Appella et al., 1974).  Clonally 
related heavy chain sequences were inferred, and the full-length sequences related to 
MPER-specific mAbs were determined (Table S2).  A total of 19,133 clonally related 
sequence clusters were found.  Of these, 10,924 were represented in more than one 
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sample (Fig. S3).  Heavy chains used primarily two V-genes (IGHV1S40 and 
IGHV1S45) and J-gene IGHJ4 (Fig. S4).  D-gene usage was more diverse.  The most 
commonly used V-gene for the kappa chain was IGKV1S32 (Fig. S5).  Note that the 
apparent predominant usage of kappa J-gene IGKJ1-2 is an artifact from amplification 
with a 3’ primer that closely resembles the IGKJ1-2*01 sequence.  
The interrelationships between all sequenced antibody heavy chains (“heavy 
chain antibodyome”) are graphically shown in Fig. 5A, and the clonal families of mAbs 
6C10, 9F6 and 21B5 are highlighted.  CDR3 spectratypes of the heavy and kappa 
chains are plotted in Fig. 5B.  The non-Gaussian distribution of the CDR3 length 
suggests active antibody developments.  While kCDR3 length remained fairly constant, 
peaking at 12 a.a., significant variation in HCDR3 length was observed after each 
immunization, indicating fluctuations in antibody repertoires generated in response to 
different antigenic stimulations.  After the second immunization, when a strong 
anamnestic response against gp41-28x3 was observed (Fig. 2B), the peak HCDR3 
length changed from 13 to 14 a.a. (Fig. 5B).  It is worth noting that, 6C10 has a HCDR3 
length of 14 a.a. (ARDLDDVIGWNFGW), suggesting that the shift in the peak HCDR3 
length could be due to a strong antibody response against the cluster II 
immunodominant region (peptides 653 and 656; Fig. 3).  Consistent with this notion, 
IGHV1S45 and IGKV1S32, from which 6C10 heavy and light chains were derived, 
became the most dominant V-genes used after the second immunization (Fig. S4, S5).  
After the third immunization, there was a notable shift from 14 back to 13 a.a, which 
could be due to antibody responses directed against new antigens (e.g. vaccinia virus  
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antigens).  The dual peaks in the terminal PBMC sample (TP) may be the result of the 
fourth immunization with gp41-28x3 and rVV-gp160DH12. 
The development of the B cell repertoire after the third immunization was 
dominated by novel clonal families (Fig. 5C).  This dominance could also be seen in Fig. 
5A, where a large number of distinct clusters are predominantly associated with the A3 
sample.  The vast majority of the novel clonal families are expected to be antibodies 
against vaccinia virus antigens.  Consequently, the proportions of clonal family sizes of 
the MPER-specific mAbs all contracted.  Evaluation of the size of clonal family sizes 
showed clear immunodominance of 6C10 over both 21B5 and 9F6 epitopes (Fig. 5C).  
Importantly, the development of the 6C10 lineage had already begun after the first 
immunization, whereas significant levels of 9F6 and 21B5 clonal families were observed 
only in terminal samples (TP and TS; Figs. 5C and 5D).  Alternatively, 9F6 and 21B5 
could have begun to expand after the fourth immunization with gp41-28x3 and rVV-
gp160DH12, a sample we were not able to analyze. 
Since 9F6 best targeted the 4E10/10E8 binding site, its maturation process was 
examined in greater detail (Fig. 6).  A total of 12 substitutions were observed compared 
to the inferred naïve germline sequence, of which only six were within the CDRs (Fig. 
6A).  Two of these mutations are potentially the result of a gene conversion event with 
IGHV1S45 (G14E and A15G; Fig. 6B).  Phylogenetic lineage analyses indicated that 
there was another mutation at an early stage of antibody evolution (T102A), which 
reverted back to the germline sequence (A102T).  All substitutions except for V106L 
and T108I are observed in reads from the A1 sample point onwards.  V106L and T108I  
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are observed only in the terminal sample.  The sequence identity/divergence plot of 9F6 
heavy chain illustrates good coverage of the development history of the mAb (Fig. 6C).   
 
3.3 Discussion 
The antigenic repertoire of HIV-1 envelope proteins in virus-infected patients is 
vast, largely due to chronic virus replication continuously generating antigens with 
different amino acid sequences and variable glycosylation patterns.  In addition, a large 
number of protein fragments is likely generated by proteolytic degradation.  This 
antigenic complexity is further increased by the drastic conformational changes that 
occur when the protein mediates fusion between viral and cellular membranes.  The 
transient nature of the gp41 structure makes targeting the MPER neutralizing epitopes 
even more challenging.  Despite this unfavorable antigenic environment, the isolation of 
bnAbs against the MPER from HIV-1-infected patients, albeit rare, demonstrates the 
possibility of inducing such antibodies through vaccination.  An important question is 
whether similar bnAbs can be induced using a single immunogen or whether it requires 
multiple immunogens used in concert.  If the latter, then, how many and which 
immunogens?  Would a single cocktail of all of the immunogens together work, or would 
administering them in a particular, sequential order be better? 
During the past three decades, the vast majority of HIV-1 vaccine efforts focused 
on designing immunogens that can induce bnAbs. The failures to elicit bnAbs using 
immunogens that are deemed antigenically native dictate that more efforts should be 
made in exploring novel vaccine strategies, regimens, and/or formulations.  Typically, 
vaccines consist of the same immunogen(s) administered multiple times (i.e. 
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“homologous prime-boost” immunization; Fig. 7A).  However, as discussed earlier, it 
might be difficult, if not impossible, to induce MPER bnAbs using this strategy with a 
single immunogen.  While a trimeric envelope complex may present the MPER in the 
native conformation, specifically targeting 4E10/10E8 epitopes may be like looking for 
the proverbial needle in a haystack due to the presence of multiple highly immunogenic 
epitopes on gp120.  Even if naïve B cells that encode precursor B cell receptors against 
the neutralizing epitopes can be stimulated, they may fail to expand efficiently due to the 
competitive environment of germinal centers.  Successive immunizations with the same 
immunogen would preferentially amplify antibodies targeting the immunodominant 
epitopes, resulting in the induction of non- or type-specific-neutralizing antibodies. 
In this report, we described our initial effort to explore a novel IPAS-RAM vaccine 
strategy designed to enhance antibody responses against non-immunogenic target 
epitopes and expedite the antibody maturation process.  The strategy is different from 
typical vaccinations in that the immune system is exposed to different immunogens 
sequentially, starting with a small immunogen to focus immune responses towards the 
desired region (e.g. the MPER) and induce a large antibody repertoire against all 
possible epitope conformations (Fig. 7B).  Subsequent immunizations are carried out 
with antigenically distinct, but related, immunogens that are progressively more “native” 
to guide the antibody maturation process.  The final immunization is done with a whole 
envelope protein complex (i.e. trimeric gp120/gp41 on membrane) to increase the 
likelihood that mature antibodies can bind MPER epitopes in the context of native 
envelope spikes.  During the course of the immunization, B cell clones that encode 
antibodies against epitopes that are absent or inaccessible on boosting immunogens 
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are not expected to expand and are filtered out.  The major hallmark of the IPAS-RAM 
vaccine strategy that is uniquely different from a simple “heterologous prime-boost” 
immunization is that immunogens are administered in a phased manner.  Because the 
antigens are phased, anamnestic immune responses against previously administered 
immunogens could rapidly boost antibody responses against related epitopes on new 
immunogens (“concurrent boosting”).  We hypothesized this strategy of “antigenic 
relays” and “antigenic filters” would expedite clonal expansion of target-epitope-specific 
B cells and accelerate antibody maturation, while minimizing antibody responses 
against non-conserved epitopes.  We further hypothesized that the presence of 
different, but related immunogens simultaneously would allow “immunological 
crosstalks” (i.e. B cells stimulated by one immunogen engaging common/similar 
epitopes on different immunogens) that could facilitate antibody maturation. 
To demonstrate proof-of-concept, we examined the IPAS-RAM vaccine strategy 
using three immunogens, gp41-28x3, gp41-54CT, and rVV-gp160DH12.  Although we 
failed to induce neutralizing antibodies, we identified one mAb (9F6) with an epitope 
targeting profile that closely resembled those of 4E10 and 10E8.  As typical for any 
exploratory study, we acknowledge that our study raised more questions than it 
answered.  They include (1) what led to the induction of 9F6 and why does it fail to 
neutralize HIV-1; (2) did we use optimal immunogens; (3) is the complex IPAS-RAM 
vaccine regimen any better than traditional vaccine strategies with simpler regimens; 
and (4) can the IPAS-RAM vaccine strategy be improved?   
Based on NGS analyses (Fig. 5C), we did not see significant levels of either 9F6 
or 21B5-related antibodies until the terminal samples (TP and TS).  While we cannot be 
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certain as to what exactly led to the induction of 9F6, bioinformatics analyses provided 
some insights.  In the A1 sample, % identities of the heavy chain V-gene of 9F6 clonal 
family members to germline ranged from 76.7% to 97.22%, which suggests that 
repertoire diversification had started.  Since we did not have pre-immune samples to 
examine, it is possible that they existed prior to immunization with gp41-28x3.  
However, further expansion of all three mAb clonal families after the second 
immunization (A2) suggests that they were induced by gp41-28x3.  The relative 
expansion of the 9F6 clonal family, as well as that of 21B5 and 6C10, shrank in A3, 
most likely due to dominant immune responses against vaccinia virus antigens.  TP and 
TS samples were taken at the conclusion of the study.  Thus, the marked expansion of 
the 9F6 and 21B5 clonal families could be due to the co-immunization with rVV-
gp160DH12 and gp41-28x3 (fourth immunization) and/or the final immunization with 
gp41-28x3 alone (administered to increase efficiency of generating MPER-specific 
hybridomas).  However, three lines of evidence suggest that co-immunization might be 
responsible: (1) We did not see many 9F6 clonal family members in the A2 sample 
when a strong anamnestic response against gp41-28x3 was induced.  (2) In 
phylogenetic analyses, the closest sequences to the evolutionary development of 9F6 
(shown as intermediate sequences in Figs. 6B and 6C) all came from the TP sample.  
Further, the substitutions V106L and T108I were observed only in the terminal samples. 
(3) Epitope targeting profiles of antibodies induced by homologous prime-boost 
immunization using gp41-28x3 only, did not resemble that of 9F6 (compiled in Fig. 4E).  
Notably, none of the three animals mounted significant antibody responses towards 
W672 and R683.  Thus, while gp41-28x3 may have initiated repertoire diversification, 
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subsequent exposure to both gp41-28x3 and rVV-gp160DH12 simultaneously likely have 
guided the evolution of an 9F6 intermediate to its mature form.  Several studies have 
reported the potential benefits of co-immunizations by combining different vaccine 
modalities (e.g. protein and DNA vaccination; (Jaworski et al., 2012; Krebs et al., 2014; 
J. Li et al., 2013; Patel et al., 2013)).  However, potential benefits could also arise from 
synergy between different immunogens, regardless of the vaccine modality.  At the 
present time, the contribution of gp41-54CT/ rVV-gp160DH12 co-immunization is unclear.   
The major difference in epitope targeting between 21B5 and 4E10/10E8 is that 
21B5 recognizes W678 and Y681, which lie on the opposite side of the neutralizing 
face.  Thus, the lack of neutralizing activity is not unexpected.  In contrast, all of the 
residues critical for 9F6 binding lie within the footprint of 4E10/10E8 (with a possible 
exception of N677).  Therefore, it is not readily apparent why 9F6 fails to exhibit 
neutralizing activity.  It is possible there are steric clashes between 9F6 and other parts 
of the trimeric envelope complex and/or the membrane surface that prevent 9F6 
binding.  Comparing a co-crystal structure of 9F6 bound to an MPER peptide to those of 
4E10 and 10E8 could provide critical insights.  
Linear epitope mapping analyses identified two peptides highly reactive to 
immune sera (653QEKNEQELLA662 and 656NEQELLALDK665; Fig. 2).  This region 
corresponds to the cluster II immunodominant domain of gp41 (Xu et al., 1991), 
suggesting that our vaccine regimen tested in rabbits recapitulated antibody responses 
mounted against gp41 in humans.  A large fraction of the antibodies that bind these 
peptides likely represents clonal family members of 6C10 mAb, which targets 
657EQELLAL663 (Fig. 4A).  Immunodominance of the 6C10 epitope was also evident 
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from the antibodyome data.  After the first immunization, the repertoire of antibodies 
clonally related to 6C10 was about 25-fold greater than those of 9F6 and 21B5 
combined (Fig. 5C).  That increased to about 62-fold after the second immunization.  
Despite partial epitope overlap with 2F5, 6C10 lacked neutralizing activity.  Interestingly, 
the llama mAb 2H10 that recognizes 657EQELLELDK665 has neutralizing activity (Lutje 
Hulsik et al., 2013), suggesting the importance of targeting further downstream of the 
6C10 epitope for inhibiting gp41 function.  Other factors such as antibody footprint size, 
angle of approach, affinity, etc. could also play important roles.  Detailed mapping 
analyses and structural studies of 6C10 could provide additional insights.   
All of the MPER bnAbs (2F5, Z13e1, 4E10 and 10E8) bound gp41-28x3 (Fig. 
1D).  However, 2F5 binding was significantly better than 10E8 (~50-fold) and 
4E10/Z13e1 (~3- to 5-fold).  This might explain why the nearby 6C10 epitope was so 
immunogenic.  Thus, retrospectively, gp41-28x3 may not have been an ideal priming 
immunogen to use for eliciting 4E10/10E8-like antibodies.  An immunogen that has 
better exposure and/or affinity to 10E8, as well as one devoid of the cluster II region, 
might have elicited stronger antibody responses towards 4E10/10E8 epitopes.  In this 
regard, a 4E10 scaffold-based immunogen, T88, which induced non-neutralizing 
antibodies with a target epitope profile similar to 4E10 (Correia et al., 2010), could have 
been a better priming immunogen for our IPAS-RAM vaccine strategy.   
Our NGS analyses of antibody genes largely focused on heavy chain sequences 
related to three mAbs against a few select linear epitopes.  These sequences likely 
represent a tiny fraction of the vast range of clonal families and superfamilies whose 
development were stimulated by immunizations.  We were unable to employ single-cell 
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PCR amplification of antibody genes from FACS-sorted antigen-specific B cells due to 
the lack of suitable markers on rabbit plasmablasts and non-specific binding of MPER 
immunogens to cells.  Isolation of additional mAbs could facilitate and expand the scope 
of analyses.  Alternatively, the NGS analyses could be conducted in conjunction with 
proteomics analyses of antibodies purified using immunogens (Cheung et al., 2012), 
although we would not be able to pair authentic heavy and light chains.  While further 
work is needed to dissect the specific developmental stimuli and mechanisms, these 
analyses have clearly demonstrated the utilities of repertoire sequencing towards better 
understanding of antibody responses in vaccine settings.  Importantly, we have 
demonstrated that rabbits can be a useful animal model to evaluate antigen-specific B 
cell population dynamics using NGS data despite the fact that they use gene 
conversion, in addition to somatic hypermutation, to generate antibody repertoire.  
 
3.4 Conclusions 
In this study, we evaluated a novel IPAS-RAM vaccine strategy to induce 
4E10/10E8-like bnAbs.  Despite our unsuccessful efforts, which we attribute largely to 
the use of a suboptimal priming immunogen, results of the study demonstrate potential 
benefits of sequential immunization with multiple immunogens in a phased manner.  
Thus, further evaluation of the IPAS-RAM vaccine strategy is warranted, perhaps using 
a better priming immunogen.  The target epitope profile of the 9F6 mAb we isolated 
closely resembled those of 4E10 and 10E8.  To our knowledge, 9F6 may be the best 
vaccine-induced mAb that mimics 10E8.  Comparative structural analyses of 9F6 with 
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10E8 could provide insights into why 9F6 lacks neutralizing activity and how we might 
be able to improve our vaccine strategy. 
 
3.5 Materials and methods 
3.5. Immunogen generation.   
The priming immunogen, gp41-28x3, was produced from a pHR1-HR2-28x3 
construct.  This plasmid was constructed from pGEX-2T gp41(30) (Penn-Nicholson et 
al., 2008) through multiple subcloning steps and site-directed mutagenesis, details of 
which will be described elsewhere.  The pHR1-HR2-28x3 construct is based on a pET-
21a vector.  HR1-HR2-28x3 was expressed in E. coli, solubilized with 8M urea, and 
purified using Ni-NTA as we previously described (Banerjee et al., 2016; Habte et al., 
2015; Qin et al., 2014).  The fusion protein was cleaved with thrombin (GE Healthcare; 
cat#27-0846-01) and the gp41-28x3 fragment was purified using Ni-NTA, dialyzed into 
PBS (pH 8.0) and stored at -80°C.  
To clone gp41-54CT construct, a region containing the gene 
(630EWEREISN…..QGLERALL856; numbering based on HXB2) was PCR amplified from 
pcDNA-MCON6gp160 (kindly provided by Dr. Beatrice Hahn (Gao et al., 2005)) using a 
sense primer 5'-cgcggatcc GAG TGG GAG CGC GAG ATC-3’ and an antisense primer 
5’-cggaagc TTA atg gtg atg atg gtg atg CAG CAG GGC GCG CTC CAG-3’.  Six-
histidine tag was incorporated into the primer.  The resulting PCR product was digested 
with BamHI and HindIII (underlined) and inserted into the corresponding sites on a 
vector based on pcDNA*MCON6-gp120-OD described previously (Qin et al., 2014). 
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The recombinant vaccinia virus expressing gp160 of the HIV-1DH12 isolate (rVV-
gp160DH12) was generated from a single virus variant that was plaque-purified from the 
Dryvax vaccine obtained from the CDC.  First, the plaque-purified virus was attenuated 
by disrupting the B8R gene by homologous recombination using a pB8R-IFN-g plasmid 
that encodes a human IFN-g gene in between two segments of the B8R gene, resulting 
in rVV∆B8R-IFN-g.  Next, a second plasmid pNVVDHenv (Cho et al., 2001; 1998), 
which encodes gp160, was used to insert the gene into a thymidine kinase gene of 
rVV∆B8R-IFN-g.  The resulting virus was propagated and purified as described 
previously (Cho et al., 2001; 1998).  The details of pB8R-IFN-g construction, and 
biological properties of rVV∆B8R-IFN-g and rVV-gp160DH12, will be described 
elsewhere. 
 
3.5.2 Rabbit immunization, 
New Zealand white female rabbits (2.5 to 3 kg) were purchased from Charles 
River (USA) and housed under specific pathogen free environments.  All animals were 
tested in compliance with the animal protocol approved by IACUC of Iowa State 
University.  For the IPAS-RAM vaccine group, three rabbits were immunized and 
samples were taken as shown in Fig. 2A.  Rabbits were primed with 200 µg of gp41-
28x3 subcutaneously with zinc-chitosan as an adjuvant as previously described (Habte 
et al., 2015; Qin et al., 2014).  For the second immunization, rabbits were injected 
subcutaneously with 50 µg of gp41-28x3.  Animals were also injected intradermally with 
200 µg of gp41-54CT DNA in PBS, followed by electroporation using the AgilePulse In 
Vivo System (BTX, Harvard Apparatus).  For the third immunization, rabbits were 
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injected with 200 µg of gp41-54CT DNA as described above and with rVV-gp160DH12 
(1x108 PFUs) through intradermal injection.  For the fourth immunization, both 50 µg of 
gp41-28x3 and rVV-gp160DH12 were administered.  For the homologous prime-boost 
vaccine group, three rabbits were immunized subcutaneously with 200 µg of gp41-28x3 
as shown in Fig. 2C.  Serum samples were collected prior to immunization (pre-
immune) as well as two weeks post-immunizations.  PBMC samples were also collected 
4 days after each immunization.  Samples were stored at -80 °C until used. 
 
3.5.3 Hybridoma generation 
Rabbit R3 was injected intravenously using 200 µg of soluble gp41-28x3 in PBS 
without any adjuvant on week 35.  Four days later, the animal was euthanized and the 
spleen was harvested.  Splenocytes were fused to 240E-1 cells (kindly provided by Dr. 
Katherine L. Knight (Spieker-Polet et al., 1995)), as previously described (Qin et al., 
2015; Spieker-Polet et al., 1995).  Hybridoma cell culture media were screened by 
ELISA for specific binding to gp41-28x3 and individual peptides of interest as described 
below.  
 
3.5.4 Enzyme-linked immunosorbent assays (ELISA) 
All ELISA were performed using a protocol described previously (Banerjee et al., 
2016; Habte et al., 2015), except for the use of an alternate blocking buffer containing 
2.5% milk and 5% calf sera in PBS (pH 7.5).  Various coating antigens were used, 
including gp41-28x3 (30 ng/ml), a mixture of 10-mer peptides biotinylated either at the 
N- or C-terminus (Habte et al., 2015), and HIV-1 M group consensus Env peptides (15-
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mer; 100 ng/well) obtained from the NIH AIDS Reagent Program (Cat# 9487).  For the 
fine epitope mapping analyses, two sets of scanning alanine mutant peptides were 
used:  (1) 13-mer 671 peptide (671NWFDITNWLWYIK683) biotinylated at the C-terminal 
lysine, as previously described (Banerjee et al., 2016; Habte et al., 2015); and (2) 13-
mer 671 peptide biotinylated at the N-terminal amine of two glycine linker 
(GG671NWFDITNWLWYIK683).  For all ELISA testing hybridoma binding, goat anti-
rabbit, horseradish peroxidase (HRP)-conjugated antibody (Thermo Scientific; Cat# 
31430) was used as secondary antibody.   
 
3.5.5 Neutralization assays 
Neutralization assays were performed in TZM-bl cells as previously described (M. 
Li et al., 2005; Qin et al., 2014; Wei et al., 2002).  Viruses tested included SF162 (tier 
1A, clade B), MW965.26 (tier 1A, clade C), and MN.3 (tier 1A, clade B). Murine 
leukemia virus Env-pseudotyped virus was used as a negative control.  
 
3.5.6 Hybridoma gene sequence analysis 
Total RNA was extracted from hybridoma cells using the RNeasy Mini kit 
(Qiagen).  RNA samples were treated with DNAse (Invitrogen) according to a 
manufacturer’s protocol.  Samples were subjected to cDNA synthesis using random 
hexamers and SuperScript III Reverse Transcriptase (Invitrogen).  Briefly, 1µL of 
random hexamers (Roche) and 1µL of 10mM dNTPs were added to 11µL of DNAse 
treated RNA.  The mixture was heated to 65oC for 5min, then cooled briefly on ice.  
Subsequently, 4µL of 5x First-Strand Buffer, 1uL of 0.1M DTT, 1uL of RNaseOUTTM 
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(Invitrogen), and 1uL of SuperScript III were added.  Reaction was incubated at 25oC for 
5min, 45oC for 45mins, and 70oC for 15mins. 
Heavy and kappa chain sequences were amplified with Platnium Pfx (Invitrogen) 
according to manufacturer’s recommendations.  Primers were based on a previous 
publication (Lightwood et al., 2006) and were designed for leader sequences (5’ primer) 
or the C-terminus of the junction.  Primers used for heavy chain amplification were 5’-
GATATCAAGCTTACGCTCACCATGGAGACTGGGC-3’ and 5’-
CGCGCGCTCGAGACGGTGACSAGGGTSCCYKGGCCCC-3’.  Primers used for kappa 
chain amplification were 5’-
GATATCAAGCTTCGAATCGACATGGACACGAGGGCCCCC-3’ and 5’-
TCTAGACGTACGTTTGACCACCACCTCGGTCCCTC-3’.  Cycling conditions were as 
follows:  Initial denaturation at 94oC for 5mins; followed by 40 cycles of 94oC for 30sec, 
68oC for 1.5mins; final extension at 68oC for 7mins; hold at 4oC.  PCR products were 
examined via agarose gel to confirm specific amplification.  Products were subcloned 
for DNA sequencing. 
For the 9F6 hybridoma, alternate light chain primers were tested as well.  For the 
kappa chain, 5’ and 3’ primers from a second publication were tested (Rader et al., 
2000).  The two 5’ primers used bound the beginning of the FR1 region:  5’-
GGGCCCAGGCGGCCGAGCTCGTGMTGACCCAGACT-3’ and 
GGGCCCAGGCGGCCGAGCTCGATMTGACCAGACT-3’.  An alternate 3’ primer, 5’- 
AGATGGTGCAGCCACAGTTCGTAGGATCTCCAGCTCGGTCCC-3’, bound a similar 
region in the junction as did our original primer.  An additional 3’ primer which bound the 
3’ untranslated region immediately after the stop codon, 5’-
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TCACTGGCGGTGCCCTGGCAGGCGTCT-3’, was designed in-house based on NCBI 
nucleotide sequences.  The lambda chain primer set described in Rader et al. (Rader et 
al., 2000) was also tested. 
 
3.5.7 PBMC isolation 
For PBMC isolation, EDTA-treated blood was initially spun at 2000xg for 10 min, 
with brakes turned off, to remove plasma and RBC.  The collected cell layer was diluted 
1:3 with PBS.  Diluted blood was layered over Ficoll-PaqueTM PLUS (GE Healthcare) in 
a 4:3 (blood:Ficoll) ratio.  The layered sample was centrifuged at 400xg for 45mins, with 
brakes turned off.  PBMC layer was removed, and washed twice with 10 mL of PBS, 
followed by centrifugation at 600xg for 10min, with brakes.  PBMC were stored in 
freezing media (90% fetal bovine serum and 10% DMSO) at -140oC until RNA isolation.   
 
3.5.8 Antibody gene RT-PCR for NGS analysis 
Total RNA extraction and cDNA synthesis from PBMCs (~6x106 per timepoint) 
was done as described for hybridomas.  cDNA synthesis was scaled up by 6-fold to 
accommodate this amount of starting material.  Resulting cDNA was split into two 
aliquots and subjected to separate antibody heavy and light chain gene amplification 
using Platinum Pfx polymerase (Invitrogen).  Reaction mixture (150uL volume, split into 
3 tubes) was:  60µL of cDNA template, 15µL of 10x buffer, 4.5µL of 10mM dNTPs, 3µL 
of MgSO4, 6µL of each primer (10µM concentration), and 1.2 µL of polymerase.   
Primers and cycling conditions were the same as described for hybridoma sequencing.  
PCR products were examined via agarose gel to confirm specific amplification.  Extra 
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primers and nucleotides were removed using QIAquick PCR Purification Kit (Qiagen).  
Following purification, heavy and light chain concentrations were calculated, and equal 
amounts of each were pooled for library preparation. 
 
3.5.9 Next-generation sequencing 
The TruSeq DNA LT sample prep kit (Illumina) was used to make NGS libraries, 
consisting of both heavy and kappa chain variable region fragments, for a 2x250bp 
read.  The low sample (LS), gel free method was performed according to 
manufacturer’s protocol, with minor modifications.  Following end repair of the cDNA, 
indexing adapters were added using DNA adapter tubes (Illumina).  The library quality 
was determined by Bioanalyzer High Sensitivity DNA chip (Agilent), and quantification 
was performed using a Qubit (Life Technologies).  The sample libraries were run on an 
Illumina MiSeq according to manufacturer’s recommendations.   
 
3.5.10 NGS Read Processing and Quality Control 
Reads from the two sequencing runs were demultiplexed by Illumina software, 
following which they were pre-processed using the Repertoire Sequencing Toolkit 
(pRESTO) (Vander Heiden et al., 2014). Processing consisted of the following steps: (1) 
Reads having a mean Phred quality score <20 were removed.  (2) Paired reads were 
identified from Illumina headers, and aligned. Unpaired reads, and reads with a 
significance threshold calculated by pRESTO of <0.1, or mismatch rate <0.2, were 
removed.  (3) Forward and reverse primers were matched and removed from the reads. 
Reads not matching primers, or which matched with error rate >0.2, were removed.  (4) 
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Duplicate reads were merged.  (5) Reads were split into heavy and light chain sets, 
based on 5’ primer identification.  (6) Where the same sample was processed in 
multiple sequencing runs, the resulting sets were merged to provide a single heavy and 
light chain set per sample.  (7) Resulting read sets were clustered to a minimum identity 
of 97% using uparse (Edgar, 2010).  The NGS data have been deposited to the NCBI 
Short Reads Archives (SRA) as study SRP094044. 
 
3.5.11 Junction Identification and Germline Assignment 
Sequences were parsed with IgBLAST v1.4.0 (Ye et al., 2013) using the IMGT 
germline library for the rabbit (Oryctolagus cuniculus) (M. P. Lefranc and G. Lefranc, 
2001), downloaded 14 March 2015. Subsequent alignments were converted to IMGT 
output format using IgBlastPlus v1.0(Lees and Shepherd, 2015). 
 
3.5.12 Clonal Inference and Analysis 
The cluster diagram (Fig. 5A) was rendered in Gephi v0.9.1 (Bastian et al., 2009).  
For the Streamgraph view (Fig. 5C), heavy chain reads from all samples were combined, 
together with the sequences for the isolated mAbs. Clonally related sequences were 
inferred by clustering junction sequences of the same length and with nucleotide identity 
≥ 90% using a single-linkage algorithm.  The identity threshold was determined by 
consideration of the nearest-neighbor distribution (Fig. S6). Where the same CDR3 
sequence was observed in multiple samples, it was assigned to the earliest sample (or 
leftmost in the diagram for terminal samples). Code for the Streamgraph view was as 
previously described (Laserson et al., 2014). Bands represent clusters of 2 or more 
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CDR3 sequences and the height at each sample point is proportional to the number of 
CDR3 sequences in the cluster. The overall band height at the sample point reflects the 
number of unique CDR3 sequences observed in the sample. Because the sequencing 
depth was uneven, equal samples of 100,000 reads of functional v-regions were drawn 
from each sample, and the number of unique CDR3 sequences was determined. The 
average was determined over 100 random draws. Overall band heights are proportional 
to that average number of unique CDR3 sequences. 
 
3.5.13 Phylogenetic Analysis 
Full-length sequences from blood plasma samples whose CDR3s clustered with 
mAbs of interest were reviewed, and those which did not match the mAb V- and J- 
germline assignments were rejected. To obtain a computationally tractable data set, 
random downsampling was used to limit the maximum number of sequences from each 
sample point to 200. Sequences were codon-aligned using TranslatorX (Abascal et al., 
2010) following which phylogenetic trees were inferred by IQ-TREE v1.2.2 (Minh et al., 
2013). The selection model GTR+G4 was selected by the program from consideration 
of the log-likelihoods of the initial parsimony tree for all available models. Trees were 
rendered using the ETE Toolkit (Huerta-Cepas et al., 2010).  Intermediate sequences in 
the development of mAb 9F6, and its germline junction sequence, were inferred by 
PHYLIP (Felsenstein and Churchill, 1996) and the logo diagram was rendered with  
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Berkley WebLogo (Crooks et al., 2004). Percentage identity to the mAb and divergence 
from the germline was determined using in-house software. 
 
3.5.14 In-House Software 
Software developed in-house for the analysis (clustering, charting of germline 
attribution, spectratypes, germline identity) is available as part of TRIgS 
(http://cimm.ismb.lon.ac.uk/trigs/) (Lees and Shepherd, 2015).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   	  
87 
3.6 Acknowledgments 
We are grateful to Dr. Beatrice Hahn for providing pcDNA-MCON6gp160.  The 
following reagents were obtained through the NIH AIDS Reagent Program, Division of 
AIDS, NIAID, NIH: HIV-1 Consensus group M Env peptides (Cat# 9487), Z13e1 from 
Dr. Michael Zwick (Cat# 11557), 2F5 from Dr. Hermann Katinger (Cat# 130220) and 
4E10 from Dr. Herman Katinger (Cat# 10091).  This work was supported by a Grant 
from the HHS/NIH/NIAID (P01 AI074286) and funding from Iowa State University.  
MWC has an equity interest in NeoVaxSyn Inc., and serves as the CEO/President.  
NeoVaxSyn Inc. did not contribute to this work or the interpretation of the data.    
	  	   	  
88 
3.7 Figures 
 
 
Fig. 1.  Immunogens used in the study.  (A) Schematic diagrams of gp41-28x3 and 
gp41-54CT.  The entire gp41 ectodomain is shown on the top as a reference.  To 
generate gp41-28x3, the T7Tag and HR1-HR2 portion of HR1-HR2-28x3 is removed with 
thrombin.  (B) Expression and purification of HR1-HR2-28x3.  Coomassie stained SDS-
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PAGE gels (U: uninduced; I: induced; P: purified).  (C) Cleavage of HR1-HR2-28x3 with 
thrombin (O: original sample; T: thrombin cleaved; E: eluted from Ni-NTA column; F: 
flow through).  (D) ELISA of gp41-28x3 with 2F5, 4E10, Z13e1 and 10E8.  (E) Flow 
cytometry analyses of cell surface expression of gp41-54CT.  2F5, Z13e1 and 4E10 
were used to probe the antigen.  (F) Structural models of three immunogens are shown 
to illustrate their relative size.  NMR structure of 28-mer peptide (2LP7; (Reardon et al., 
2014)) and BG505 SOSIP gp140 structure (5C7K; (Kong et al., 2015)) were used.  
Structures were rendered using Chimera (Pettersen et al., 2004). 
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Fig. 2.  Immunization schedule and linear epitope mapping analyses.  (A) Timeline 
for IPAS-RAM immunization and sampling.  Rabbits were immunized on weeks 0, 4, 11 
and 29.  Pre-immune, as well as post-immune sera (two weeks post each immunization) 
were taken.  PBMC were collected four days after immunization (except after 4th) for 
antibody repertoire analyses.  To generate hybridomas, Rabbit R3 was immunized 
intravenously on week 35 with gp41-28x3 and spleen was collected four days later.  (B)  
Immunogenic, linear epitopes were identified by ELISA using overlapping “10-mer” 
peptides.  Serum samples collected two weeks after first (A1), second (A2), third (A3) 
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and fourth (A4) immunizations were analyzed.  A mixture of N- and C-terminally 
biotinylated peptides spanning the C-terminal 54 a.a. of gp41 ectodomain was used 
(BGGXXXXXXXXXX and XXXXXXXXXXGGKB, respectively; B=biotin, X=gp41 
sequence).  Pre-immune serum was used as a negative control.  Horizontal brackets on 
top indicate the sequence for each peptide and core-binding epitopes for bnAbs 2F5, 
4E10 and 10E8 are shown.  The numbers on the X-axis indicate the starting a.a. 
position of “10-mer” peptides.  Timeline (C) and epitope mapping analyses (D) for the 
homologous prime-boost immunization group with gp41-28x3.  
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Fig. 3.  Detailed epitope mapping analyses of immune sera.  ELISAs were 
conducted using a set of C- (panels A and B) or N-terminally (panels C and D) 
biotinylated 13-mer alanine mutant peptides to assess impact of the mutation on 
antibody binding in comparison to the unmutated peptide.   Serum samples collected 
after the fourth immunization were used.  Peptides were biotinylated (shown as red 
spheres) at the primary amine of C-terminal lysine or N-terminal glycine.  Graphic views 
of residues that affected binding when mutated are shown.  An axial view of N671 to 
R683 segment of the 28-mer peptide co-crystalized with 10E8 is shown (PDB: 4G6F).  
Residues that showed <70% binding are shown.  Residues that are more critical (<35%) 
are shown in darker tone.  D674 is shown in grey. 
	  	   	  
93 
 
Fig. 4.  Epitope mapping analyses of mAbs.  (A) Linear epitope mapping of 6C10, 
9F6, 21B5 and twelve 21B5-like mAbs using overlapping peptides.  A structure of a 28-
mer peptide co-crystallized with 10E8  (PDB: 4G6F) is shown to illustrate general 
locations of the epitopes.  (B and C) Fine-epitope mapping analyses using C- or N-
terminally biotinylated alanine mutant peptides.  (D) Graphic presentations of residues 
important for 9F6 and 21B5 binding.  4E10 and 10E8 are included for comparison. (E) A 
summary of all residues targeted by antibodies induced by immunization with gp41-
28x3 alone.  Data from all three rabbits (R4, R5 and R6) are compiled.  
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Fig. 5. Clonal and phylogenetic analysis of the heavy chain repertoire. (A) Heavy 
chain antibodyome: Each unique CDR3 sequence is represented as a point, colored by 
its sampling time (A1-A3: PBMC after the first, second and third immunizations; TP: 
terminal PBMC).  Due to large amount of data, the analyses was limited to antibodies 
recovered from PBMC only.  The same color-coding is used throughout the figure.  
Sequences forming clonal families are joined by lines.  The approximate locations of 
6C10, 9F6 and 21B5 mAb families are shown in expanded detail (Note: they are 
zoomed at different levels).  The presence of multiple large clonal families indicates 
diverse responses to immunizations.  Families remote from the isolated mAbs are 
dominated by reads from the A3 sample.  (B) Heavy and kappa chain CDR3 
spectratypes are shown for each sample. The distribution shows distinct and different 
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skews in samples A2 and A3, and a composite of the two in sample TP, suggesting that 
clonal populations stimulated at the earlier timepoints have been integrated into longer 
term memory.  (C) Antibody clone dynamics colored by sampling time and earliest 
identification of clonotypes.  The overall band height at each sample point is 
proportional to the number of novel CDR3 nucleotide sequences in that sample, 
normalized to account for variation in sequencing depth.  The height of each individual 
band (representing a single clonotype) is proportional to the number of novel CDR3 
nucleotide sequences identified in that clonotype.  Black bands indicate the 6C10 and 
21B5 clonal families.  The underlying table shows the percentage of novel CDR3s that 
are clonally related to the indicated mAb.  In both cases, CDR3s found in multiple 
timepoints are counted only in the earliest (or leftmost) sample and clonal relationship is 
inferred by CDR3 sequence identity alone.  (D) Dendrograms of mAb clonal families 
(inferred by CDR3 sequence identity and V-/J-gene origin), in which pie charts indicate 
by size the number of descendants at each node, and by color their timepoint origin 
(only PBMC samples are included). The dendrogram for 6C10 is shown for comparison 
in both the conventional and accumulated (pie chart) form. The limited representation of 
earlier timepoints in the 21B5 and 9F6 charts suggests that development of these clonal 
families occurred almost exclusively after the A3 sampling time. By contrast, the 
dendrogram for the Ab 6C10 clonal family shows development at each timepoint, 
suggesting that refinements have been introduced by successive immunizations.  
Dendrograms for the three mAbs are shown at different zoom levels.  Thus, their size 
should not be compared between different mAbs.   
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Fig. 6. Detailed analyses of 9F6 maturation. (A) Sequence variation of the HCDRs of 
the 9F6 clonal family. The germline sequence is shown at the top.  The 9F6 sequence is 
shown at the bottom, with mutated residues indicated in red. (B) Lineage tree derived 
from representative sequences from the sample, selected to illustrate the inferred 
development of the antibody.  Amino acid changes as a result of a possible gene 
conversion event are highlighted in blue.  (C) Sequence identity/divergence plot of 
heavy chain sequences sharing the 9F6 germline.  Clones shown in panel B are 
indicated, with inferred intermediates marked in red.  The intermediates indicate good 
coverage of the development history.  The contour plot encompasses all full-length 
productive sequences of the IGHV1S40 germline extracted from PBMC samples.  The 
inferred 9F6 germline is marked by a blue cross.   
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Fig. 7. Hypothetical comparison of two vaccine strategies.  (A) A homologous 
prime-boost vaccine strategy using a whole, trimeric gp120/gp41 complex.  Because 
MPER neutralizing epitopes (indicated by asterisks) are immunorecessive, B cells that 
target them are not stimulated sufficiently and are eventually eliminated.  (B) In addition 
to sequential immunization with different immunogens (heterologous prime-boost), the 
unique and a novel feature of the IPAS-RAM vaccine strategy is co-immunization in a 
phased manner, which we expect will allow selective amplification of antibodies against 
common epitopes through immunological crosstalk and concurrent boosting.  It is 
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hypothesized that this could potentially rescue B cells against immunorecessive 
neutralizing epitopes.  
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CHAPTER 4 
EVALUATION OF A NOVEL, RAPID HETEROLOGOUS PRIME-BOOST STRATEGY 
FOR TARGETING CD4 BINDING SITE NEUTRALIZING EPITOPES ON HIV-1 GP120 
 
Heliang Shi, Saikat Banerjee, Aditi Agrawal, Michael Cho 
 
Abstract 
           The CD4 binding site (CD4bs) of HIV-1 gp120 is an attractive broadly 
neutralizing antibody (bnAbs) target. In this proof-of-concept study, we evaluated a 
novel, rapid heterologous prime-boost vaccine strategy to induce CD4bs-directed Abs, 
which we hypothesized would be neutralizing. Rabbits were immunized alternatively 
with either a native trimer-like immunogen (SOSIP gp140) or a small CD4bs-based 
immunogen (eOD-GT6) with short intervals between doses. The induced antibodies 
could neutralize sensitive tier 1 viruses and compete with VRC01 binding. Although the 
sera antibodies exhibited similar neutralizing activities to those of the homologous 
prime-boost immunization using SOSIP gp140 alone, the sera from the alternating 
immunization better recognized epitopes on eOD-GT6.  Epitope mapping analyses 
indicated that nAbs primarily targeted the V3 loop. eOD-GT6 efficiently binds VRC01-
class bnAbs and induced antibodies competing with VRC01 binding on eOD-GT6, but 
the antibodies failed to recognize SOSIP gp140 or exhibit neutralizing activities. Further 
exploration of this novel immunization strategy could facilitate the development of HIV-1 
vaccines that induce CD4bs-directed bnAbs. 
 
	  	  
107 
4.1 Introduction 
           Broadly neutralizing antibody (bnAb) induction is necessary for an effective HIV-1 
vaccine. However, due to extensive variability and complex immune-evasion strategies, 
the majority of attempts to elicit bnAbs with HIV-1 immunogens have failed.(1-4) Recent 
advances in bnAb isolation from HIV-1 infected patients have renewed interest in 
vaccine strategy development.(5-8) The CD4 binding site (CD4bs) is an attractive target 
because it contains the epitopes of several bnAbs. 
           To date, various strategies have been employed for vaccination studies with 
CD4bs-based immunogens (reviewed in (9)). However, efforts to develop a vaccine that 
can induce CD4bs targeting bnAbs have been unsuccessful. Although all of the 
immunogens evaluated could bind VRC01-class bnAbs, they failed to induce similar 
bnAbs, which was possibly due to difficulties in inducing high levels of CD4bs-directed 
antibodies that can bind HIV-1 virions (10, 11). Native-like envelope trimers have been 
developed (e.g. SOSIP gp140), (12-16) but the induced neutralizing activities were 
mainly limited to tier 1 viruses and homologous tier 2 viruses.(16) The major challenge 
in developing a CD4bs-based vaccine is designing and/or developing novel vaccine 
strategies that could force the immune system to focus antibody responses towards the 
appropriate CD4bs and recognize this epitope on native HIV-1 virions. (10) 
           Although the studies of sequential immunization with different immunogens have 
been reported recently, they used relatively long dose intervals and different order of 
immunogens administration. (17-20) We propose that a heterologous prime-boost with 
short dosage intervals and the more optimal selection of immunogens would improve 
this strategy.  In this study, we devised a novel rapid heterologous prime-boost vaccine 
	  	  
108 
strategy. The basic concept is to prime the immune system using a native-like envelope 
trimer immunogen to stimulate antibodies against that could bind epitopes on trimeric 
envelope spikes on the virus particles. Then antibodies that bind the CD4bs would be 
selectively amplified by boosting with a smaller CD4bs-based immunogen that lacks 
distracting non-neutralizing regions within short dose intervals. This prime-boost cycle 
would be repeated to stimulate high levels of antibodies that can bind CD4bs on native 
virus particles and minimize responses against the non-neutralizing immunodominant 
epitopes.  
           In this proof-of-concept study, we evaluated our vaccine strategy using SOSIP 
gp140 (15)and eOD-GT6 in rabbits. eOD-GT6, as described elsewhere (21), is an 
engineered outer domain lacking the V3 loop and large portions of V4 and V5 regions.  
This protein could efficiently bind multiple VRC01-class bnAbs but not V3 specific 
antibodies, and thus seems to be a promising immunogen to induce CD4bs specific 
antibodies. However, the immunogecity analysis of eOD-GT6 has not been reported yet. 
Here we evaluated the immunogecity of eOD-GT6 and also SOSIP gp140 immunogens 
alone as comparison to our combined vaccine strategy. 
 
4.2 Results 
4.2.1 Immunization and evaluation of antibody responses 
       To evaluate the immunogenic properties of eOD-GT6, three rabbits were 
immunized as previously described. To evaluate the rapid heterologous prime-boost 
strategy, as shown in Fig.1, three rabbits were first immunized with SOSIP gp140, then 
alternatively boosted with either eOD-GT6 and SOSIP gp140.  A control group of three 
	  	  
109 
rabbits were immunized with SOSIP 140 only.  Serum samples were collected at the 
indicated time points. 
The antibody responses were evaluated against both eOD-GT6 and SOSIP 
gp140 by ELISA. As shown in Fig.2, the eOD-GT6 specific antibody responses induced 
in eOD-GT6 group was greater than that of the heterologous prime-boost group, 
whereas the heterologous prime-boost group induced greater eOD-GT6 specific 
antibodies than that of the SOSIP gp140 group. It suggests that more antibodies were 
induced to target the eOD-GT6 by using prime-boost strategy. The SOSIP gp140 
specific antibody responses induced in SOSIP gp140 and  prime-boost groups were at 
a similar level, while that of eOD-GT6 group were much weaker. Although many 
antibodies were induced in the eOD-GT6 group, they could not recognize the 
corresponding epitopes on SOSIP gp140 trimer spikes. In summary, these results 
indicate that while eOD-GT6 specific antibody responses were induced in all three 
groups, SOSIP gp140 specific antibody responses were primarily induced in only the 
SOSIP gp140 and prime-boost groups.  This difference in antigen recognition may be 
due to steric hindrance present on the larger SOSIP gp140 antigen that prevent the 
binding of eOD-GT6 elicited antibodies to their epitopes.  Neutralizing activity was 
induced in both the prime-boost and SOSIP gp140 groups, but they were mainly limited 
to sensitive tier 1 viruses.  No neutralization was observed in the eOD-GT6 group (data 
not shown). 
4.2.2 Competition analyses with VRC01 
Since there was a significant level of antibodies that bound eOD-GT6 in all 
immunization groups, we evaluated the induction of antibodies at or near the CD4bs. 
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Antibody competition assays with VRC01 were conducted using eOD-GT6 and SOSIP 
gp140. When tested on eOD-GT6, antibodies from both eOD-GT6 and prime-boost 
groups could compete away approximately 90% of VRC01 at a 1:10 dilution of antisera 
collected after the third immunization and second set of immunizations (after fourth) 
respectively. Antibodies from two rabbits in SOSIP gp140 group could compete VRC01 
at 1:10 dilution of antisera after the third immunization, but with a much lower 
percentage. When tested on SOSIP gp140, antibodies from both the SOSIP gp140 and 
prime-boost groups could compete away a significantly higher percent of VRC01 than 
antibodies from eOD-GT6 group. The most probable reason again could be the inability 
of antibodies induced by eOD-GT6 to access epitopes on SOSIP gp140. Nevertheless, 
these results indicated antibodies were induced targeting near the CD4bs. 
 
4.2.3 Identification of immunogenic linear epitopes within the outer domain 
To better characterize antibody responses and identify immunogenic linear 
epitopes in the outer domain region, we conducted ELISA with overlapping peptides for 
all three groups using immune sera collected after the final immunization. As shown in 
Fig.4, no linear epitope was immunogenic on eOD-GT6. This is not surprising since 
eOD-GT6 lacks the V3 loop and most of the V4 and V5 regions, thus the induced 
antibodies may mostly target the conformational epitopes. For antibodies from SOSIP 
gp140 and prime-boost groups, the most immunogenic linear epitope was the V3 loop, 
especially the N-terminal half of the loop (peptides 9047-CTRPNNNTRKSIRIG, 9048-
NNNTRKSIRIGPGQA and 9049-RKSIRIGPGQAFYAT).  It is important to note that 
antibody responses against peptides exhibited animal-to-animal variation. Rabbit 1 from 
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the prime-boost group recognized peptides within C4 region (9078-
MWQGVGQAMYAPPIE and 9079- VGQAMYAPPIEGKIT), while no anti-C4 antibodies 
were induced in SOSIP gp140 immunized animals. 
 
4.3 Discussion 
In this study, we described the immunogenic properties of two immunogens 
(eOD-GT6 and SOSIP gp140), and evaluated a rapid heterologous prime-boost vaccine 
strategy using these two immunogens. Although a significant amount of antibodies were 
induced near the CD4bs, eOD-GT6 failed to elicit nAbs. SOSIP gp140 successfully 
elicited nAbs, but the neutralizing activity was limited largely to Tier 1 viruses, which is 
consistent with a previous study. The heterologous prime-boost strategy induced nAbs, 
and the neutralizing activity was similar to that of SOSIP gp140 alone. Although we 
failed to induce true bnAbs, results described are still meaningful as no report has 
described the immunogenicity of eOD-GT6 or have evaluated this particular rapid 
heterologous prime-boost vaccine strategy. 
 
That eOD-GT6 failed to induce nAbs may be primarily due to steric hindrance 
surrounding the epitopes of the antibodies on native HIV-1 virions. Since eOD-GT6 is a 
small immunogen and lacks a large portion of the variable regions, the epitopes on 
eOD-GT6 may not represent a true native structure as seen on HIV-1 virion. Antibodies 
induced by eOD-GT6 could not access the epitopes on virions, thus they did not exhibit 
neutralizing activity. This was supported by the results that antibodies induced from 
eOD-GT6 could not recognize native-like SOSIP gp140. 
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The most probable reason why SOSIP gp140 failed to elicit bnAbs is the 
presence of distracting factors. The epitopes on SOSIP gp140 are native-like, therefore 
antibodies induced against the CD4bs should have great potential to exhibit broad and 
potent neutralization. However, SOSIP gp140 contains immunodominant variable 
regions (i.e. V3 loop), which direct the immune responses away from the broadly 
neutralizing epitope on the CD4bs. Although antibodies were induced that competed 
with VRC01 binding, they may target epitopes around CD4bs and prevent VRC01 
binding via steric hindrance.  Therefore, although SOSIP gp140 contains native-like 
CD4bs epitopes, it failed to induce potent bnAbs against CD4bs because of 
immunodominant epitopes and imperfect targeting. 
The prime-boost vaccine regimen induced antibody responses that could 
recognize both eOD-GT6 and SOSIP gp140, and compete with VRC01 binding and 
neutralize Tier 1 sensitive viruses. One possible reason why this strategy could not 
induce bnAbs is that the eOD-GT6 may not be an optimal boosting immunogen. 
Although eOD-GT6 could efficiently bind various VRC01-class antibodies, it failed to 
induce antibodies that could recognize SOSIP gp140 and exhibit neutralizing activity. 
Substituting eOD-GT6 with another immunogen that lacks distracting regions but 
preserves native conformational epitopes, such as the more recent eOD-GT8, may 
enhance the immunogenicity of CD4bs and elicit VRC01-like nAbs. Another possible 
reason why we were unable to induce fairly potent nAbs with our prime-boost vaccine 
strategy is the order of the immunogens administrated. Priming with SOSIP gp140 may 
have driven initial antibody responses against the immunodominant V3 region, which is 
dominant to the immune system and could distract responses from targeting the CD4bs. 
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Perhaps priming with an immunogen lacking immunodominant regions (e.g. eOD-GT6 ) 
may enhance the immunogenicity toward CD4bs.   
 
4.4 Conclusions 
In this study, we described the immunogenicity of eOD-GT6 and evaluated a 
rapid heterologous prime-boost vaccine strategy. Additional studies will be needed to 
better evaluate this rapid vaccination strategy (e.g. substituting eOD-GT6 and changing 
the order of immunogen administration). Developing novel heterologous prime-boost 
vaccine strategies that incorporate multiple immunogens to focus anti-body responses 
to critical neutralizing epitopes should facilitate the development of HIV-1 vaccine. 
 
4.5 Materials and methods 
4.5.1 Immunogen generation 
eOD-GT6 fused to Lumazine Synthase was synthesized commercially (Life 
Technologies) with restriction sites AgeI and KpnI introduced at 5’ and 3’ ends, 
respectively. The synthesized gene was amplified by PCR with EcoR1 and AgeI sites at 
5’ and 3’ ends, respectively. The PCR fragment was cloned into pcDNA3.1 expression 
vector through corresponding restriction enzyme sites. eOD-GT6 expression and 
purification was described previously. The SOSIP gp140 trimer plasmid bearing a His-
tag at the C-terminus and Furin plasmid were provided by Dr. John P. Moore. The 
SOSIP gp140 protein was expressed in 293 F cells with SOSIP gp140 plasmid and 
Furin plasmid at 4:1 mass ratio and purified from cell culture medium by a single-step 
affinity chromatography using Ni-NTA resin. 
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4.5.2 Rabbit immunization 
Nine New Zealand white female rabbits (2.5 to 3 kg) were purchased from 
Charles River (USA), housed under specific pathogen free environments. All animals 
were tested in compliance with the animal protocol approved by IACUC of Iowa State 
University. The rabbits were randomly divided into three groups of three rabbits each. 
For groups 1 and 2 (Fig.1A), rabbits were subcutaneously injected with 200 µg of 
eOD-GT6 or SOSIP gp140 three times (weeks 0, 4, and 9) respectively. Zn-chitosan 
was used as an adjutant. Sera were collected two weeks post each immunization. For 
group 3 (Fig.1A), rabbits were primed subcutaneously with 50 µg of SOSIP gp140, then 
boosted with 10 µg of eOD-GT6 after three and half days. Then repeated this prime-
boost process one more time with 10 µg immunogens. After three weeks, the rabbits 
were alternatively immunized twice with 10 µg of SOSIP gp140 and 10 µg of eOD-GT6. 
Sera were collected according to the immunization schedule (Fig.1). 
 
4.5.3 Enzyme-linked immunosorbent assays (ELISA) 
All ELISAs were performed as described elsewhere, but with an alternate 
blocking buffer of PBS (pH 7.5) with 2.5% skim milk and 5% calf sera. 
 
4.5.4 Neutralization assays 
Neutralization assays were performed in TZM-bl cells as described.  A panel of 
pseudoviruses was tested, including SF162 (tier 1A, clade B), MW965.26 (tier 1A, clade 
C), and MN.3 (tier 1A, clade B). 
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4.6 Figures 
	  	  
Fig .1. Immunization schedule. (A) Timeline for eOD-GT6 (group 1) and SOSIP gp140 
(group 2) immunization and sampling. Rabbits were immunized on weeks 0, 4, and 9. 
Pre-immune, as well as post-immune sera (two weeks post each immunization) were 
taken. (B). Immunization schedule for rapid heterologous prime-boost (group 3) 
immunization. Rabbits were alternatively immunized with SOSIP gp140 and eOD-GT6 
on weeks 0, 0.5, 1, 1.5, 4.5, 5, 5.5, and 6. Sera were collected on weeks 0, 2, 4.5, 5.5, 
6.5, and 10.  
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Fig. 2. Endpoint titers of cross-reactive antibodies. The collected sera were 
monitored for SOSIP gp140 (A) and eOD-GT6 (B) cross-reactive antibodies by ELISA. 
The results are presented as average endpoint titers of three rabbits within each group 
with standard deviation. 
Abs against gp140
0 1 2 3 4 5 6 7 8 9 10 11 12
102
103
104
105
106
107
108
Weeks
A
nt
ib
od
y 
En
dp
oi
nt
 T
ite
r
Abs against eOD-GT6
0 5 10 15
102
103
104
105
106
107
108 Rapid group
eOD-GT6 
SOSIP gp140
Weeks
A
nt
ib
od
y 
En
dp
oi
nt
 T
ite
r
Abs against eOD-GT6
0 5 10 15
102
103
104
105
106
107
108 Rapid group
eOD-GT6 
SOSIP gp140
Weeks
A
nt
ib
od
y 
En
dp
oi
nt
 T
ite
rA B 
	  	  
118 
 
 
Fig. 3. Competition assay against VRC01. Binding of VRC01 to eOD-GT6 or SOSIP 
gp140 was competed with immune sera after the final immunization from the immunized 
rabbits or mock-immunized rabbit (PBS).  
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Fig. 4. Identification of immunogenic linear epitopes using overlapping peptides. 
ELISA was performed with the immune sera after the final immunization. On the top of 
the figure shows a schematic diagram of gp120 outer domain. Peptide numbers stand 
for catalog numbers from the NIH AIDS Region Program.  
  
9
0
3
6
9
0
3
7
9
0
3
8
9
0
3
9
9
0
4
0
9
0
4
1
9
0
4
2
9
0
4
3
9
0
4
4
9
0
4
5
9
0
4
6
9
0
4
7
9
0
4
8
9
0
4
9
9
0
5
0
9
0
5
1
9
0
5
2
9
0
5
3
9
0
5
4
9
0
5
5
9
0
5
6
9
0
5
7
9
0
5
8
9
0
5
9
9
0
6
0
9
0
6
1
9
0
6
2
9
0
6
3
9
0
6
4
9
0
6
5
9
0
6
6
9
0
6
7
9
0
6
8
9
0
6
9
9
0
7
0
9
0
7
1
9
0
7
2
9
0
7
3
9
0
7
4
9
0
7
5
9
0
7
6
9
0
7
7
9
0
7
8
9
0
7
9
9
0
8
0
9
0
8
1
9
0
8
2
9
0
8
3
9
0
8
4
9
0
8
5
9
0
8
6
9
0
8
7
9
0
8
8
9
0
8
9
9
0
9
0
9
0
9
1
9
0
9
2
9
0
9
3
9
0
9
4
9
0
9
5
9
0
9
6
0
0.5
1
1.5
2
2.5
3
3.5
4
A
4
5
0
Peptides (MCONS)
Rappid-R1A5
Rappid-R2A5
Rappid-R3A5
0
0.5
1
1.5
2
2.5
3
3.5
4
A
4
5
0
eOD-GT6-R1A3
eOD-GT6-R2A3
eOD-GT6-R3A3
0
0.5
1
1.5
2
2.5
3
3.5
4
A
4
5
0
SOSIP gp140-R1A3
SOSIP gp140-R2A3
SOSIP gp140-R3A3
	  	  
120 
4.7 References 
 
1. Kwong PD, Mascola JR, Nabel GJ. 2011. Rational design of vaccines to elicit 
broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Med 
1:a007278. 
2. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel 
GJ, Sodroski J, Wilson IA, Wyatt RT. 2004. HIV vaccine design and the 
neutralizing antibody problem. Nat Immunol 5:233–236. 
3. Cohen YZ, Dolin R. 2013. Novel HIV vaccine strategies: overview and 
perspective. Ther Adv Vaccines 1:99–112. 
4. Schiffner T, Sattentau QJ, Dorrell L. 2013. Development of prophylactic 
vaccines against HIV-1. Retrovirology 10:72. 
5. Diskin R, Scheid JF, Marcovecchio PM, West AP, Klein F, Gao H, 
Gnanapragasam PNP, Abadir A, Seaman MS, Nussenzweig MC, Björkman 
PJ. 2011. Increasing the potency and breadth of an HIV antibody by using 
structure-based rational design. Science 334:1289–1293. 
6. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TYK, 
Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, 
Poignard P, Burton DR, Pereyra F, Ho DD, Walker BD, Seaman MS, 
Björkman PJ, Chait BT, Nussenzweig MC. 2011. Sequence and structural 
convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 
333:1633–1637. 
7. Walker LM, Phogat SK, Chan-Hui P-Y, Wagner D, Phung P, Goss JL, Wrin T, 
Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, 
Hammond PW, Protocol G Principal Investigators, Kaminsky S, Zamb T, 
Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing 
antibodies from an African donor reveal a new HIV-1 vaccine target. Science 
326:285–289. 
8. Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, Steindl F, Tauer C, 
Berger R, Barrett N, Jungbauer A. 1994. A broadly neutralizing human 
monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS 
Res Hum Retroviruses 10:1651–1658. 
9. Georgiev IS, Gordon Joyce M, Zhou T, Kwong PD. 2013. Elicitation of HIV-1-
neutralizing antibodies against the CD4-binding site. Curr Opin HIV AIDS 8:382–
392. 
10. Qin Y, Shi H, Banerjee S, Agrawal A, Banasik M, Cho MW. 2014. Detailed 
characterization of antibody responses against HIV-1 group M consensus gp120 
in rabbits. Retrovirology 11:125. 
	  	  
121 
11. Qin Y, Banasik M, Kim S, Penn-Nicholson A, Habte HH, LaBranche C, 
Montefiori DC, Wang C, Cho MW. 2014. Eliciting neutralizing antibodies with 
gp120 outer domain constructs based on M-group consensus sequence. Virology 
462-463:363–376. 
12. Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, Kalyanaraman 
R, Paluch M, Berkhout B, Maddon PJ, Olson WC, Lu M, Moore JP. 2002. 
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein 
complex of human immunodeficiency virus type 1. journal of virology 76:8875–
8889. 
13. Klasse PJ, Depetris RS, Pejchal R, Julien J-P, Khayat R, Lee JH, Marozsan 
AJ, Cupo A, Cocco N, Korzun J, Yasmeen A, Ward AB, Wilson IA, Sanders 
RW, Moore JP. 2013. Influences on trimerization and aggregation of soluble, 
cleaved HIV-1 SOSIP envelope glycoprotein. journal of virology 87:9873–9885. 
14. Hoffenberg S, Powell R, Carpov A, Wagner D, Wilson A, Kosakovsky Pond 
S, Lindsay R, Arendt H, Destefano J, Phogat S, Poignard P, Fling SP, Simek 
M, LaBranche C, Montefiori D, Wrin T, Phung P, Burton D, Koff W, King CR, 
Parks CL, Caulfield MJ. 2013. Identification of an HIV-1 clade A envelope that 
exhibits broad antigenicity and neutralization sensitivity and elicits antibodies 
targeting three distinct epitopes. journal of virology 87:5372–5383. 
15. Sanders RW, Derking R, Cupo A, Julien J-P, Yasmeen A, de Val N, Kim HJ, 
Blattner C, la Peña de AT, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, 
van Gils MJ, King CR, Wilson IA, Ward AB, Klasse PJ, Moore JP. 2013. A 
next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, 
expresses multiple epitopes for broadly neutralizing but not non-neutralizing 
antibodies. PLoS Pathog 9:e1003618. 
16. Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, 
Ozorowski G, Cupo A, Simonich C, Goo L, Arendt H, Kim HJ, Lee JH, 
Pugach P, Williams M, Debnath G, Moldt B, van Breemen MJ, Isik G, Medina-
Ramírez M, Back JW, Koff WC, Julien J-P, Rakasz EG, Seaman MS, Guttman 
M, Lee KK, Klasse PJ, LaBranche C, Schief WR, Wilson IA, Overbaugh J, 
Burton DR, Ward AB, Montefiori DC, Dean H, Moore JP. 2015. HIV-1 
VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. 
Science 349:aac4223. 
17. Zhang M, Zhang L, Zhang C, Hong K, Shao Y, Huang Z, Wang S, Lu S. 2012. 
DNA prime-protein boost using subtype consensus Env was effective in eliciting 
neutralizing antibody responses against subtype BC HIV-1 viruses circulating in 
China. Human Vaccines & Immunotherapeutics 8:1630–1637. 
18. Vaine M, Wang S, Hackett A, Arthos J, Lu S. 2010. Antibody responses elicited 
through homologous or heterologous prime-boost DNA and protein vaccinations 
differ in functional activity and avidity. Vaccines 28:2999–3007. 
	  	  
122 
19. Lu S. 2009. Heterologous prime-boost vaccination. Curr Opin Immunol 21:346–
351. 
20. Escolano A, Steichen JM, Dosenovic P, Kulp DW, Golijanin J, Sok D, Freund 
NT, Gitlin AD, Oliveira T, Araki T, Lowe S, Chen ST, Heinemann J, Yao K-H, 
Georgeson E, Saye-Francisco KL, Gazumyan A, Adachi Y, Kubitz M, Burton 
DR, Schief WR, Nussenzweig MC. 2016. Sequential Immunization Elicits 
Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice. Cell 166:1445–
1458.e12. 
21. Jardine J, Julien J-P, Menis S, Ota T, Kalyuzhniy O, McGuire A, Sok D, 
Huang P-S, MacPherson S, Jones M, Nieusma T, Mathison J, Baker D, Ward 
AB, Burton DR, Stamatatos L, Nemazee D, Wilson IA, Schief WR. 2013. 
Rational HIV immunogen design to target specific germline B cell receptors. 
Science 340:711–716. 
 
	  	  
123 
CHAPTER 5 
EVALUATION OF A MULTI-IMMUNOGEN VACCINE STRATEGY FOR TARGETING 
CD4BS NEUTRALIZING EPITOPES ON HIV-1 GP120 
 
 Heliang Shi, Saikat Banerjee, Aditi Agrawal, Michael Cho   
 
Abstract 
The CD4 binding site (CD4bs) of gp120 is a prime target for the elicitation of 
broadly neutralizing antibodies (bnAbs). In this study, we evaluated a vaccine strategy 
applying a sequential and phased mannered immunization approach with related but 
antigenically distinct immunogens. Rabbits were immunized with a small CD4bs-based 
immunogen (eOD-GT6) and boosted with progressively more native immunogens 
(gp120 and SOSIP gp140). Although bnAbs were not induced, antibody responses 
analysises indicated our vaccination elicited antibodies that could efficiently recognize 
all three administered immunogens. Antibodies could compete VRC01 binding on all 
three immunogens. We may induce antibodies that could recognize the conformational 
consensus of the administered immunogens. Further exploration of our vaccine strategy 
using improved immunogens would enhance the possibility to induce bnAbs against 
CD4bs.   
 
5.1 Introduction 
Development of a safe and effective HIV vaccine remains a global public health 
priority. Recent discoveries of potent and broad neutralizing antibodies (bnAbs) from 
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HIV-1 infected patients have renewed interest in bnAbs induction(1-4). However, the 
elicitation of bnAbs has not been successfully achieved by vaccination in standard 
animal models or humans(5-8).  
The CD4 binding site (CD4bs) of gp120 is a particularly attractive target for the 
elicitation of bnAbs because it is highly conserved and contains epitopes of bnAbs. To 
date, much effort has been made in order to elicit CD4bs-directed bnAbs (reviewed in 
(9) ). However, it has not been successful to elicit such bnAbs by vaccination.  
            The major challenge for the development of a vaccine that is able to induce 
bnAbs towards CD4bs is developing novel immuogens and/or vaccine strategies that 
could enhance the CD4bs specific immune responses and recognize neutralizing 
epitopes on native envelope spikes.(10, 11) We previously described a rapid 
heterologous prime boost vaccine strategy using SOSIP gp140 and eOD-GT6, we 
induced strong antibody responses that could recognize both immunogens and 
compete VRC01 binding, but neutralize mainly tier 1 viruses, which we believed was 
large to suboptimal immunogens or immunogens administration order. We have 
reported another vaccine strategy, IPAS-RAM, using a sequential and phased 
mannered immunization with three immunogens that are progressively more native. 
(12)Although nAbs were not induced, antibodies whose epitopes closely resembled 
those of 4E10 and 10E8 were induced. We believed this strategy could be improved 
with optimal priming immunogen. Inspired by these studies, we developed a vaccine 
strategy to induce bnAbs towards CD4bs.  
            In this study, we evaluated a heterologous prime boost vaccine strategy using 
three related but antigenically distinct immunogens. The basic concept is to prime the 
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immune system using a small CD4bs-based immunogen (eOD-GT6)(13) to produce a 
large antibody repertoire against CD4bs, then boost with progressively more native 
immunogens (gp120 and SOSIP gp140) (11, 14) to specifically amplify antibodies that 
bind the native structure. Although the studies of heterologous prime boost vaccine 
strategy have been reported recently, we applied different set of immunogens along 
with sequential and phase mannered immunization approach. Here we evaluated our 
vaccine strategy in rabbits.  
 
5.2 Results 
5.2.1 Immunization schedule 
The production of all immunogens used in this study has been described before. 
(10, 11, 14)To evaluate our vaccine strategy, six rabbits were used in the study. Three 
rabbits were first immunized with eOD-GT6 only. Four weeks later, a combination of 
eOD-GT6 and Mcon6 gp120 was administered. The eOD-GT6 was also included, rather 
than immunizing Mcon6 gp120 alone, because we hypothesized that immunizing with 
both immunogens would preferentially induce antibody responses targeting epitopes 
present on both immunogens (I.e the CD4bs). Similarly, on week 11, a combination of 
Mcon6 gp120 and SOSIP gp140 was administered. Three more rabbits were immunized 
with eOD-GT6 alone twice with four weeks interval. We hypothesized that priming with 
eOD-GT6 would initialize antibody responses towards the CD4bs and boost one more 
time would make those antibodies dominant the immune system which may help reduce 
the antibody responses against the immunodominant variable loops in the following 
immunogens. The eOD-GT6 and Mcon6 gp120 combination and Mcon6 gp120 and 
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SOSIP gp140 combination were administered on weeks 11 and 15 respectively. On 
week 23, SOSIP gp140 was administered, because we hypothesized that boosting with 
SOSIP gp140 alone would selectively amplify the CD4bs-directed antibodies that could 
recognize the epitopes on native HIV-1 virions.  
 
5.2.2 Evaluation of antibody responses 
The immunogenicity studies of eOD-GT6, Mcon6 gp120, and SOSIP gp140 have 
been described before. To examine whether antibodies induced by our vaccine 
strategies are different from those induced by homologous prime-boost immunization, 
we performed ELISA to evaluate the antibody responses of all groups on different 
immunogens. The eOD-GT6 induced high antibody responses targeting eOD-GT6 after 
first immunization, and the antibody responses were almost saturated after second 
immunization. However, the antibodies bound Mcon6 gp120 very poorly and could not 
recognize SOSIP gp140. These were possibly due to the steric hindrance of antibodies 
on binding on more native immunogens. The epitopes on eOD-GT6 may be more 
similar to those on Mcon6 gp120 than on the native SOSIP gp140, thus they could 
weakly recognize Mcon6 gp120. The antibodies from both Mcon6 gp120 and SOSIP 
gp140 groups could recognize all three immunogens. For Mcon6 gp120 group, the 
antibodies level that recognized SOSIP gp140 was lower than those for Mcon6 gp120 
and eOD-GT6 except one rabbit, whose antibodies failed to bind to eOD-GT6 and was 
possibly due to the animal-to-animal variation. These results indicate there are some 
antibodies that could recognize the epitopes on both eOD-GT6 and Mcon6 gp120 failed  
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to recognize the epitopes on SOSIP gp140, which could be mainly due to the epitopes 
conformation differences. The levels of antibodies induced from SOSIP gp140 
recognizing SOSIP gp140 and Mcon6 gp120 are similar.  
For rabbits in group 1, the antibodies induced after first immunization only 
recognized eOD-GT6. After second immunization, the antibodies could recognize all of 
three immunogens, and the titer of antibodies against eOD-GT6 was highest and those 
against SOSIP gp140 were lowest.  Antibody titers against all three immunogens 
continued to increase after third immunization, among which the antibody titer against 
SOSIP gp140 was slightly lower. For rabbits in group 2, strong antibody responses 
against eOD-GT6 were induced after the first immunization, but no antibody responses 
were detected against neither Mcon6 gp120 nor SOSIP gp140. Antibody titers against 
eOD-GT6 continued to increase after second immunization, and weak antibody 
responses were induced against Mcon6 gp120. After the immunization with a 
combination of eOD-GT6 and Mcon6 gp120, strong antibody responses were induced 
against for both eOD-GT6 and Mcon6 gp120, which was similar to that of group 1 after 
second immunization. But the antibody titer against SOSIP gp140 was lower than that 
of group 1. One possible reason is the existence of strong antibody responses against 
eOD-GT6 may suppress the immune responses against the immunodominant regions 
on SOSIP gp140. Then the antibody titers against eOD-GT6 began to decrease, while 
those against Mcon6 gp120 and SOSIP gp140 continued to increase. Then significant 
changes in antibody responses were not observed after the final immunization. The final 
antibodies binding profiles from group 2 were similar to those from groups 1. In 
summary, these results suggest that strong antibody responses recognizing all three 
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immunogens were induced using our vaccine strategies. The neutralizing activities were 
induced in both groups; however, they were limited to tier 1 viruses (data not shown). 
 
5.2.3 Competition analyses with bnAbs VRC01 
Since strong antibody responses induced from our immunized rabbits could 
recognize all three immunogens, we would like to evaluate the induction of antibodies at 
or near the CD4bs. Antibody competition assays with VRC01 were conducted using 
eOD6-GT6, Mcon6 gp120, and SOSIP gp140. When tested on eOD-GT6, antibodies 
from group 1, group 2, and eOD-GT6 group could compete away approximately over 
70% of VRC01 at a 1:10 dilution of antisera, while antibodies from Mcon6 gp120 could 
not compete away VRC01 and antibodies from SOSIP gp140 group competed VRC01 
weakly.  
One possible reason is the antibodies from eOD-GT6 group have higher affinity 
to eOD-GT6 than those from gp120 and SOSIP gp140 groups since rabbits were 
immunized with the same eOD-GT6. When tested on gp120, antibodies from eOD-GT6 
group failed to compete VRC01 binding, while antibodies from all other groups could 
efficiently compete away VRC01, and the competing antibody level in SOSIP gp140 
was lowest. The reason why antibodies from eOD-GT6 group failed to compete VRC01 
on gp120 is antibodies could not recognize epitopes on gp120.  The lower competing 
antibody levels from SOSIP gp140 is possibly due to the lower binding affinity to gp120 
than other groups since rabbits were immunized with gp120. Similar competing results 
were observed when tested on SOSIP gp140, and competing antibody level in SOSIP 
gp140, instead of gp120, was highest.  
	  	  
129 
5.2.4 Identification of immunogenic linear epitopes within the outer domain 
To identify immunogenic linear epitopes, ELISAs were conducted with 
overlapping MCONS peptide sets as we previously described. Although there are some 
differences in amino acid sequences between MCONS and our immunogens, the 
variant residues are mostly in the variable loops.  Although there were animal-to-animal 
variations within the group, most of the immunoreactive peptides were within the V3, 
C4, and C5 regions.  
The most immunogenic region was the N-terminal of V3 loop (peptides 9047-
CTRPNNNTRKSIRIG, 9048-NNNTRKSIRIGPGQA and 9049- RKSIRIGPGQAFYAT).  
Two peptides in the C4 region (9079-  
VGQAMYAPPIEGKIT and 9080-MYAPPIEGKITCKSN) were highly reactive to 
antibodies induced in group 2 rabbits, and modest level of antibodies against peptide 
9080 was observed from group 1 rabbits.  These anti-C4 antibodies could be resulted 
from Mcon6 gp120 immunization, because no anti-C4 antibodies were induced in both 
eOD-GT6 and SOSIP gp140 immunized rabbits. The C5 region (peptides 9090, 9093 
and 9094 sequences) was reactive to antibodies induced in the rabbits from group 1, 
and the peptides 9093 and 9094 was reactive to antibodies induced from group 2 
immunized rabbits.  This is not surprising since both Mcon6 gp120 and SOSIP gp140 
could induce antibodies recognizing the C5 region.  
 
5.3 Discussions 
In this study, we described a heterologous multi-immunogen prime-boost vaccine 
strategy to enhance antibody responses against non-immunogenic neutralizing 
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epitopes. Multiple related, but antigenically distinct, immuogens were used. We primed 
the immune system with a small immuogen (eOD-GT6) to focus immune responses to 
the desired epitopes (e.g. CD4bs) and produce a large antibody repertoire that could 
recognize all possible epitope conformations. The boost immunizations were performed 
with more “native” immunogens (gp120) to direct the antibody maturation process. The 
final immunizations were carried out with native-like SOSIP gp140 trimer to enhance the 
possibility that mature antibodies can recognize epitopes on native envelope spikes. 
The immunnogens were immunized in a phased manner, because we hypothesized that 
anamnestic immune responses against previously injected immunogens would boost 
related epitopes on new immunogens rapidly and force the immune responses  
to identify a conformational consensus among all immunogens administered. We 
induced antibodies that efficiently compete VRC01 binding and exhibit neutralizing 
activities to Tier 1 viruses.  
Both of our vaccine regimens induced strong antibody responses that could 
efficiently recognize all three immunogens. After immunization with eOD-GT6 alone, 
antibodies barely recognized gp120 and SOSIP gp140. This is possibly due to the 
differences in eptiope conformations among immunogens. After subsequent 
immunizations with more native immunogens, antibodies recognizing all immunogens 
were induced. The ideal epitopes of these antibodies would be the conformational 
consensus of all immunogens, CD4bs. The competitive ELISA with VRC01 was 
performed to assess the antibodies targeting at or near CD4bs. The competing 
antibodies from our vaccine regimens could efficiently compete VRC01 on all three 
immunogens, while antibodies from gp120 and SOSIO gp140  alone groups could not 
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compete away VRC01 on eOD-GT6. This suggested that our vaccine regimens could 
induce antibodies that recognize the common conformational epitopes on all 
immunogens. However, the neutralizing activities were mainly limited to tier 1 viruses. It 
indicated that the common conformational epitopes identified by our vaccine regimens 
may not be CD4bs, and the efficiently competition with VRC01 may be due to the steric 
hindrance of antibody binding to other epitopes rather than CD4bs. Linear epitope 
mapping analysis indicated V3 loop highly reactive to immune sera.  
The most possible reason why we did not elicit bnAbs is the selected 
immunogens are not optimal. Although eOD-GT6 is a small immunogens that could bind 
VRC01-class bnAbs efficiently, it failed to induce antibodies recognizing more native 
immunogens (gp120 and SOSIP gp140) and exhibiting neutralizing activities. Another 
small immunogen with higher binding affinity to VRC01-class bnAbs and more native 
conformation may improve our vaccine regimens. Since V3 loop was very 
immunogenic, substitution of gp120 with a immunogen lacking V3 loop (e.g. gp120-
ΔV3) may reduce the immune responses to the immunodominant V3 region and focus 
immune responses to the common epitopes (e.g. CD4bs).  
 
5.4 Conclusions 
In this study, we evaluated a heterologous prime-boost vaccine strategy to 
induce VRC01-like bnAbs. We induced antibodies that could recognize all administered 
immunogens , competed with VRC01 binding on all immungens, and  exhibited 
neutralizing activities to tier 1 viruses. We did not induce bnAbs, which was largely due 
to the use of suboptimal immunogens. Additional work will be needed to improve our 
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vaccine strategy (e.g. use of optimal priming and boosting immunogens). Developing 
novel heterologous prime-boost vaccine strategies that force the immune system to 
identify the common critical neutralizing epitopes would facilitate the development of 
HIV-1 vaccine. 
 
5.5 Materials and methods 
5.5.1 Rabbit immunization 
The production of all three immunogens was described previously(10, 11, 14). 
Six New Zealand white female rabbits (2.5 to 3 kg) were purchased from Charles River 
(USA) and randomly divided into two groups of three rabbits each. For group 1 (Fig.1A), 
rabbits were subcutaneously injected with 200 µg of eOD-GT6 on week 0, then boosted 
with mixture of 20 µg of eOD-GT6 and 200 µg of Mcon6 gp120 on week 5 and mixture 
of 20 µg of Mcon6 gp120 and 200 µg of SOSIP gp140 on week 11. For group 2 
(Fig.1B), rabbits were primed subcutaneously with 200 µg eOD-GT6 on weeks 0 and 4, 
then boosted subsequently with 20 µg OD-GT6 and 200 µg of Mcon6 gp120 on week 9, 
20 µg of Mcon6 gp120 and 200 µg of SOSIP gp140 on week 15, and 200 µg of SOSIP 
gp140 on week 23.  All immune sera were collected two weeks post each immunization.  
 
5.5.2 Enzyme-linked immunosorbent assays (ELISA) 
All ELISAs were performed as described elsewhere. 
5.5.3 Neutralization assays 
Neutralization assays were performed in TZM-bl cells as described previously in 
other chapters.   
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5.7 Figures
 
Fig .1. Immunization schedule. Timeline for immunization and sampling. Rabbits in 
group 1 were immunized with on weeks 0, 5, and 11. . Rabbits in group 2 were 
immunized with on weeks 0, 4, 9, 15, and 23. The immunogens immunized at each time 
were illustrated as above.  Pre-immune, as well as post-immune sera (two weeks post 
each immunization) were taken.  
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Fig. 2. Cross-reactivity analysis of antibodies. The collected sera were evaluated for 
eOD-GT6, Mcon6 gp120, and SOSIP gp140 cross-reactive antibodies by ELISA. A to E 
represents different immunization studies. The results are presented as average value 
of three rabbits within each group with standard deviation. 
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Fig. 3. Competition assay against VRC01. Binding of VRC01 to eOD-GT6, Mcon6 
gp120, or SOSIP gp140 was competed. The immune sera after 5th immunization for 
group 2 and 3rd immunization for other groups from the immunized rabbits or mock-
immunized rabbit (PBS) were used.  
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Fig. 4. Identification of immunogenic linear epitopes. ELISA was performed using 
overlapping peptides. The immune sera used were after the final immunization. Peptide 
numbers stand for catalog numbers from the NIH AIDS Region Program. 
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CHAPTER 6
A NOVEL SAMPLE INFERENCE METHOD FOR ILLUMINA AMPLICON DATA
Heliang Shi, Xiyu Peng, Karin Dorman
Abstract
Illumina amplicon sequencing is an important and widely used tool for the identi-
fication and quantification of species or variants in mixed samples, but the presence
of errors makes it a challenging problem. Many denoising algorithms have been de-
veloped, but most completely discard the highly informative quality scores or reduce
them to summary statistics to reduce data size. In this study, we develop ampliclust, a
fully probabilistic error modeling approach using uncompressed sequences and qual-
ity scores to denoise Illumina amplicon data. Using artificial, real, and simulated data
sets, the analyses show that our approach has comparable accuracy on data with well-
separated clusters and better accuracy on data with overlapping clusters than DADA2,
a popular state-of-the-art denoising tool.
6.1 Introduction
Current Next Generation Sequencing (NGS) technologies provide an enormous
volume of data at low cost and allow high resolution analysis of genetic diversity, but the
associated error rate is higher than traditional Sanger sequencing [1, 2]. These errors
can interfere with the identification and quantification of species [3] or variants [4, 5]
in mixed sample studies. The high coverage of NGS enables the detection of many
low-frequency species or variants, but the increasing depth also increases the number
of error-containing sequences, making it difficult to distinguish genuine minority vari-
ants from errors. Thus, NGS data needs be denoised to better inference the genuine
genetic diversity [6].
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This chapter focuses on error correction methods for amplicon sequencing, where
several different approaches have been proposed to minimize the effect of errors on
the detection of minority variants. The typical analysis of amplicon sequencing data
is to construct OTUs (operational taxonomic units) based on Hamming distance. One
unique sequence represents each OTU, and abundance is estimated as the number
of reads associating with each OTU. Unfortunately, the OTU method has high false
positive and false negative rates, especially when evaluating fine-scale diversity [7,
8]. A variety of approaches have been proposed to improve accuracy, but they have
shortcomings, such as slow running speed and dependence on ad hoc parameters,
sometimes estimated from required training data [9, 10].
The Hamming distance ignores known complexity in the error process, so some
have proposed to improve accuracy by modeling the error process and evaluating the
individual reads via a probability model. Recently, the Divisive Amplicon Denoising
Algorithm (DADA) [6] and DADA2 [11] combined an error model with heuristic, hier-
archical clustering techniques to achieve fast clustering of reads into species/variant
clusters without use of OTUs. The error-containing reads assigned to a single cluster
are presumed to derive from the same haplotype sequence. The divisive clustering
algorithm and inference of the error parameters are performed alternatively until con-
vergence. DADA2 extends and improves the DADA algorithm for Illumina amplicon
data by incorporating quality scores in the model. DADA2 has shown to infer sample
sequences from Illumina amplicon data with high resolution [11].
However, DADA2 assumes all reads of the same sequence originate from the same
amplicon sequence, which can be violated in practice. To compress the data, DADA2
initially groups all amplicon reads by their unique nucleotide sequence and associates
each unique sequence with an abundance and average quality score profile. By us-
ing only average quality score information, DADA2 underutilizes the information they
provide. To illustrate the loss, suppose there are two amplicon sequences ACCTA and
AGCAA, and we have observed five copies of (errored) read s = AGCTA as shown
in Table 1. Based on the raw quality score information, the most possible assign-
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Table 1: Example data demonstrates how DADA2 compression can result in misclas-
sification of reads to clusters.
Read Quality Scores Assignment?
r1 33 12 40 40 40 ACCTA
r2 40 39 38 8 39 AGCAA
r3 35 7 40 40 40 ACCTA
r4 38 12 40 40 40 ACCTA
r5 38 40 35 15 40 AGCAA
s 38 12 40 40 40 ACCTA
ments for {r1, r3, r4} and {r2, r5} are ACCTA and AGCAA, respectively. The sites with
low quality score are likely misreads of the true amplicon nucleotide. However, the
compressed data would force all five reads to be assigned to the ACCTA amplicon
sequence. Clearly, the raw, uncompressed data would provide more accurate esti-
mates of the abundance of true variants, especially when there are very similar variant
sequences in the original sample.
More technically, the DADA2 model heuristically maximizes the conditional joint
distribution for each cluster of the sequence abundances given the total abundance
and at least one observation of each sequence. To facilitate the calculations, they as-
sume, using the law of rare events, this conditional distribution (scaled multinomial) is
equivalent, up to a constant, to the distribution (scaled Poisson) dropping the condition
on the sum. However, the constant of proportionality actually depends on the model
parameters, and it is not obvious that the constant is insignificant. Thus, there are sev-
eral structural flaws in the DADA2 statistical model, in addition to the discarded quality
score information.
In this study, we describe ampliclust, a fully consistent, model-based approach in-
spired by DADA2 for the inference of haplotypes and their abundances from Illumina
amplicon data using uncompressed quality information. Out method is shown to out-
perform DADA2 in accuracy on several data sets.
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6.2 Methods
6.2.1 Model
Our goal is to identify the number and abundance of unique DNA molecules, hap-
lotypes, in a sample. The observed data consist of a set of amplicon reads R = {r1,
r2, . . . , rn} with the same length l and corresponding quality scores Q = {q1, q2, . . . ,
qn}. Let H = {h1,h2, . . . ,hK} be the collection of unobserved haplotypes, with hkj
the nucleotide at position j of the amplicon. The object of our analysis is the num-
ber of haplotypes K, the identity of haplotypes H and pi = (pi1, · · · , piK), their relative
abundance in the original sample. Let C = (C1, C2, · · · , Cn) be the unknown class
assignment of all reads. The complete data likelihood is
L(θ | R,Q,C) =
n∏
i=1
K∏
k=1
[pikP (Ri = ri,Qi = qi | Ci = k)]1{Ci=k} ,
where θ are the model parameters, including H and pi. We assume pairs (Rij, Qij) of
a read base call in Ri and quality score in Qi are generated independently as
P (Ri = ri,Qi = qi | Ci = k) =
l∏
j=1
P (Rij = rij, Qij = qij | Ci = k).
We parameterize the joint probability of a single base and quality score as the product
of
P (Rij = b | Ci = k,Hkj = h) = δ1{h=b}j [(1− δj)γhb]1{h6=b}
and
P (Qij = q | Rij = b, Ci = k) =

λ0jq hkj = b
λ1jq hkj 6= b,
where b, h ∈ {A,C,G,T} are bases and q ∈ Q is a discrete quality score in the set
Q, which depends on the NGS chemistry. Here, δj is the probability the observed
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nucleotide at read position j is generated from the haplotype without error and γhb is
the probability of misreading haplotype nucleotide h as read nucleotide b 6= h when
there is an error. Both δj and λ·jq currently assume a read position-specific effect.
The complete data likelihood becomes
L(θ | R,Q,C) =
n∏
i=1
K∏
k=1
pik
l∏
j=1
[
δjλ0jqij
]1{hkj=rij} [(1− δj)γhkjrijλ1jqij]1{hkj 6=rij}

1{Ci=k}
,
for parameters θ = {δ,Γ,Λ,pi,H}, where
δ = (δ1, δ2, . . . , δl) Γ = {γhb : b 6= h ∈ {A,C,G,T}}
pi = (pi1, pi2, . . . , piK) Λ = {λ0jq, λ1jq : 1 ≤ j ≤ l, q ∈ Q}
H = (h1,h2, · · · ,hK).
We sum over the hidden C in the complete data likelihood to obtain the observed data
likelihood as
L(θ | R,Q) =
n∏
i=1
K∑
k=1
pik
l∏
j=1
[
δjλ0jqij
]1{hkj=rij} [(1− δj)γhkjrijλ1jqij]1{hkj 6=rij} .
6.2.2 Inference
We will apply the alternating expectation-conditional maximization (AECM) algo-
rithm [12] to update θ. The idea of the AECM algorithm is to partition θ into θ1 and θ2
when it is easy to maximize the likelihood for θ1 given θ2 and vice versa. In this case,
let θ1 = H and θ2 = {δ,Γ,Λ,pi}. The AECM consists of two cycles, each containing an
E-step and a conditional maximization (CM)-step. These two cycles will be alternated
until convergence. Details of the steps are given below.
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In the first E-step, the conditional expected complete data log likelihood at iteration
t+ 1 is
Q1(H; H(t),θ(t)2 ) = E
[
l(H,θ(t)2 | R,Q, C) | R,Q,H(t),θ(t)2
]
=
K∑
k=1
n∑
i=1
P (Ci = k | R,Q,H(t),θ(t)2 )
{
lnpi
(t)
k
+
l∑
j=1
(
1
{
h
(t)
kj = rij
}
ln
[
δ
(t)
j λ
(t)
0jqij
]
+ 1
{
h
(t)
kj 6= rij
}
ln
[
(1− δ(t)j )γ(t)hkjrijλ
(t)
1jqij
])}
,
which requires we compute
e
(t)
ik := P (Ci = k | R,Q;H(t),θ(t)2 )
∝ P (R = ri,Qi = qi | Ci = k;H(t),θ(t)2 )P (Ci = k;H(t),θ(t)2 )
= pi
(t)
k
l∏
j=1
[
δ
(t)
j λ
(t)
0jqij
]1{h(t)kj=rij} [
(1− δ(t)j )γ(t)h(t)kj rijλ
(t)
1jqij
]1{h(t)kj 6=rij}
.
In the first CM-step, we maximize Q1(H;H(t),θ(t)2 ) forH given θ(t)2 =
{
δ(t), .Γ(t),Λ(t),
pi(t)
}
. The maximization of this likelihood yields
h
(t+1)
kj = argmax
h∈{A,C,G,T}
n∑
i=1
e
(t)
ik
(
1 {h = rij} ln
[
δ
(t)
j λ
(t)
0jqij
]
+ 1 {h 6= rij} ln
[
(1− δ(t)j )γ(t)hrijλ
(t)
1jqij
])
for all k ∈ {1, 2, . . . , K} and j ∈ {1, 2, . . . , l}.
In the second E-step, the calculations are virtually identical. We need the same
conditional expectation, now viewed as a function of θ2 and conditioning on updated
H(t+1). Specifically,
Q2(θ2; H(t+1),θ(t)2 ) = E
[
l(H(t+1),θ2 | R,Q, C) | R,Q,H(t+1),θ(t)2
]
,
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which requires
e
(t+0.5)
ik := P (Ci = k | R,Q;H(t+1),θ(t)2 )
∝ P (Ri = ri,Qi = qi | Ci = k;H(t+1),θ(t)2 )P (Ci = k;H(t+1),θ(t)2 )
= pi
(t)
k
l∏
j=1
[
δ
(t)
j λ
(t)
0jqij
]1{h(t+1)kj =rij} [
(1− δ(t)j )γ(t)h(t+1)kj rijλ
(t)
1jqij
]1{h(t+1)kj 6=rij}
.
In the second CM-step, we need to maximize Q(θ2; H(t+1),θ(t)2 ) for θ2 = {δ ,Γ,Λ, pi}
given H(t+1) The update equations are
δ
(t+1)
j =
∑n
i=1
∑K
k=1 e
(t+0.5)
ik 1
{
h
(t+1)
kj = rij
}
n
γ
(t+1)
hb =
∑n
i=1
∑K
k=1 e
(t+0.5)
ik
∑l
j=1 1
{
h
(t+1)
kj = h, rij = b
}
∑n
i=1
∑K
k=1 e
(t+0.5)
ik
∑l
j=1 1{h(t+1)kj = h}
λ
(t+1)
0jq =
∑n
i=1
∑K
k=1 e
(t+0.5)
ik 1
{
h
(t+1)
kj = rij, qij = q
}
∑n
i=1
∑K
k=1 e
(t+0.5)
ik 1
{
h
(t+1)
kj = rij
}
λ
(t+1)
1jq =
∑n
i=1
∑K
k=1 e
(t+0.5)
ik 1
{
h
(t+1)
kj 6= rij, qij = q
}
∑n
i=1
∑K
k=1 e
(t+0.5)
ik 1
{
h
(t+1)
kj 6= rij
}
pi
(t+1)
k =
∑n
i=1 e
(t+0.5)
ik
n
for all b 6= h ∈ A,C,G,T and q ∈ Q.
6.2.3 Data
We evaluated our model using two real datasets, a mock 16S mixture and an HIV-1
sample, as well as simulated data.
6.2.3.1 Mock data
We compare our method and DADA2 on the Extreme mock dataset used to vali-
date DADA2 [11] (Table 2). This dataset contains 2,040,085 reads of an unbalanced
mixture of 27 bacterial species/strains, 24 of which are distinguishable in the amplicon
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Table 2: Extreme data. Dilution levels, number of species or strains at each dilution,
and expected proportion of reads at each dilution level.
Dilution No. Proportion
100 2 0.4265302
10−1 3 0.0426530
10−2 4 0.0042653
10−3 4 0.0004265
10−4 4 0.0000427
10−5 10 0.0000043
region. The authors have provided 61 reference sequences, including various strains
for these species. Thirty-three, including three distinct strains each for B. ovatus and
B. vulgatus, are distinct in the amplicon region. To eliminate contaminant reads, the log
likelihood of generating each read from each of the 33 reference sequences was com-
puted assuming all substitutions are equally likely and the quality score is the true error
probability. Reads with maximum log likelihoods across all reference strains smaller
than −10 were removed. Finally, 1,641,443 reads remained (80.4%), and 10 random
subsets of 3,000 reads were extracted for detailed analysis.
6.2.3.2 HIV data
We also apply both methods to a real data set of amplicon reads from a single
HIV-1-infected patient. The data are 2 × 300 paired-end reads of the V1–V3 envelope
region, generated on an Illumina MiSeq [13]. Specifically, we use the reverse read
data because they contain a 9-nucleotide barcode, which may be useful to assess the
quality of clustering. These data were processed as described in Appendix §, resulting
in a dataset of size 10,344 reads.
6.2.3.3 Simulated data
We also applied the methods to simulated data. We simulate data under a model
that matches neither DADA2 nor our own model. Specifically, given haplotypes H
and a clustering C, we simulate pairs (rij, qij) of read nucleotides and quality scores
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independently as
P (Rij = rij, Qij = qij) = λjqij1 {Ci = k} ×

(
1− 10−qij/10) rij = hkj
10−qij/10γhkjrij rij 6= hkj.
The parameters are estimated from existing data given haplotypes H and clustering C
as
λˆjq =
∑n
i=1 1 {Qij = q}
n
γˆhb =
∑n
i=1
∑l
j=1
∑K
k=1 1 {Ci = k,Hkj = h, rij = b}∑n
i=1
∑l
j=1
∑K
k=1 1 {Ci = k,Hkj = h}
,
where n is the number of sequences in the dataset. We simulate under two settings
of λjq and γhb, one obtained from the first n = 3,000 subset of the mock data, and
another obtained from the n = 10,344 HIV-1 reads. For the mock data, we used the
hard clustering from the K = 12 seeded solution (see §); for the HIV data, we used the
K = 8 solution.
To control the difficulty of clustering, we also simulate data where we alter the hap-
lotypes to control the amount of separation between the clusters. In this case, the hap-
lotypes are simulated independently from an “ancestral haplotype” on a star-shaped
phylogenetic tree, where all branches have the same length given as the expected
number of nucleotide changes. When the expected number of changes η is small, the
expected number of changes between haplotypes should be 2η. To match the simu-
lated nucleotide content to the existing real datasets, we used the amplicon region of
accession KF99671 (see Appendix §) as the ancestral haplotype for the HIV-1 simula-
tion and the consensus sequence of the 33 reference sequences for the mock simu-
lation. In addition to simulations that used the inferred haplotypes, we simulated data
using two branch lengths (0.005 and 0.001) for the mock data and four branch lengths
(0.0025, 0.005, 0.01, and 0.015) for the HIV-1 data. Finally, all simulated datasets were
the same size as the original real datasets prepared in § and §.
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6.3 Running the methods
6.3.1 Initialization and convergence
The choice of initial values is of great importance in EM-based algorithms [14]. It
can influence the convergence rate and the algorithm’s ability to locate the global opti-
mum. GivenK clusters, we obtain initial guesses for the indicatorsC = (C1, C2, · · · , Cn)
using k-modes [15], with the Hamming distance as the distance metric between reads.
The kth mode is used to initialize the kth haplotype H(0)k , and the size of the corre-
sponding cluster initializes pi(0)k . We estimate the remaining parameters in θ
(0)
2 using
the update equations from the second CM-step of AECM, where e(0.5)ik = 1 if the ith
read is assigned to cluster k and 0 otherwise. To initialize k-modes, we implement
several different methods. In Rnd-Ini(I) initialization, we select K distinct reads as
the initial modes, run k-modes for no more than 100 iterations, and select the best of
I such random initializations as judged by the k-modes criterion to initialize AECM.
In Rnd-EM(I, J) initialization [16, 17], we select K distinct reads as the initial modes,
run k-modes for no more than 100 iterations followed by AECM for exactly J iterations,
and selected the best of I such random initializations as judged by the log likelihood
achieved after J iterations to initialize AECM.
We repeat the chosen initialization, possibly multiple times, followed by AECM it-
eration until the rate of change in the log likelihood value between iterations is small.
Specifically, let t+1 =
l(θ(t+1)|R,Q)−l(θ(t)|R,Q)
l(θ(t)|R,Q) be the relative change in the log likelihood
at iteration t+1, where θ(t) is the parameter estimate after the tth iteration. We stop the
AECM iterations when  < 1×10−6. The estimates yielding the maximum log likelihood
across initializations are considered the MLEs.
To maximize the ampliclust model on the mock datasets, we took advantage of the
known reference sequences to avoid the many random initializations required to find
the global maximum. Instead, we provide ampliclust with K reference haplotypes and
then partition the reads by assigning each read to the most likely haplotype sequence.
A read likelihood is computed for each possible haplotype by interpreting quality scores
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as the probability of an error in the read nucleotide and assuming all substitutions are
equally likely, i.e. 10−q/10 is the probability of error for observed quality score q, and
γhb =
1
3
for all b 6= h. We call such an initialization of the AECM the “seeded initial-
ization.” We may also seed with both hapotypes and a partition, in which case the
cluster assignment step is not needed. Given the initial haplotypes and partition, the
parameters are initialized as described in §. For each mock dataset, we first analyze
it with K = 33, providing all 33 reference sequences and without updating the haplo-
types during AECM. The resulting clustering is referred to later as the K33∗ solution.
To select K, we first drop all references with empty clusters in the K33∗ solution. Then,
iteratively, we remove the reference sequence with the smallest estimated abundance
and seed initialize with the remaining reference sequences, now allowing haplotype
updating in the first M step. If more than one reference sequence has the smallest
abundance, each is removed in turn, and the solution achieving the highest log likeli-
hood identifies the next reference to be discarded. The final chosen K is given by the
solution that achieves the minimum Bayesian information criterion (BIC).
For the analysis of the HIV-1 data, 100 Rnd-Ini(1) initializations were performed fol-
lowed by an additional 0–700 Rnd-Ini(10) initializations. For some K, we also tried 100
Rnd-EM(10) initializations. More initializations were run when the solution included null
clusters (clusters with no reads assigned to it in the hard clustering) or the maximum
achieved log likelihood was lower than that of a solution with smaller K. The solution
with the maximum log likelihood at a given K is retained as the final solution for that
K.
6.3.2 Details
Implementation. We have implemented the proposed AECM algorithm in C under
the C11 standard. We call our software and method ampliclust in this chapter.
Filtering and trimming. Unlike the recommended DADA2 pipeline, we did not filter
or trim the reads for low quality data. The intent is to handle such noise via the model.
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We did, as described in Methods §, strongly filter the data for contaminants or non-
amplicon reads, since neither model accounts for such reads in the data.
Running DADA2. Except for not filtering or trimming the reads, DADA2 is run per
published instructions in the DADA2 software manual [11].
Clustering solution. DADA2 produces a hard cluster directly. To obtain a hard clus-
tering from ampliclust, we compute the posterior probability that a read belongs to
each cluster and assign the read to the cluster with the highest posterior probability.
6.4 Results
To measure the performance of our model relative to DADA2, we apply both meth-
ods to mock, real, and simulated data sets.
6.4.1 Mock data
We analyzed 10 random subsets of the mock data, each of size n = 3,000 reads.
With only 3,000 reads, we expect to detect 9 of the 24 species/strains mixed in the mock
sample, but we might also detect distinct strains within the more common species or
one of the more highly diluted species.
While DADA2 estimates the value of K automatically, our method requires the user
to provide K. We use BIC as criteria for choosing K. The best choice of K for each
dataset is marked red in Fig. 1. All the predicted haplotypes from both DADA2 and am-
pliclust at the chosen K perfectly match a subset of the reference sequences. Table 3
shows the average and range of K found by both methods across the 10 datasets. On
the right, we report the number of the original 24 species/strains mixed in the mock
sample found by each method. There appears to be no significant difference in the
number of haplotypes found by the two methods or the number of species/strains re-
covered.
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Figure 1: Plots of BIC against the number of clusters for 10 subsets of the mock data.
The K yielding the smallest BIC value is marked red.
Table 3: Comparison of the inferred haplotypes and identified species/strains for am-
pliclust and DADA2 on the mock data. The mean over 10 subsets of the data is shown,
with the standard error in parentheses.
Haplotypes Species/Strains
Method Min. Mean Max. Min. Mean Max.
DADA2 11 12.4 (0.221) 13 8 9.4 (0.221) 10
ampliclust 11 12.3 (0.213) 13 8 9.3 (0.213) 10
Table 4: The average Adjusted RAND indices comparing the clustering results of
DADA2, ampliclust, and K33∗ across 10 subsets of the mock data. Standard errors in
parentheses.
Ampliclust K33∗
DADA2 0.993 (0.001) 0.988 (0.001)
Ampliclust – 0.990 (0.001)
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Figure 2: AIC and BIC computed for HIV data analyzed with ampliclust using K =
2, 4, 5, . . . , 34.
We further compare the solutions estimated by our methodology and DADA2 by
examining the number of reads assigned to each reference sequence (Table 5). In
general, DADA2 and ampliclust provided very similar clustering results, which is con-
sistent with the adjusted RAND indices [18] (Table 4). Two strains of P. distasonis,
differing by a single nucleotide, were mixed at highly disparate dilutions in the sample,
and both DADA2 and ampliclust sometimes misidentify some strain JCM 13401 reads
as originating from strain JCM 13400. Both methods also detect distinct strains of the
B. ovatus and B. vulgatus species. The K33∗ solutions detected several highly diluted
(dilutions 10−3, 10−4, and 10−5) reference species, including the JCM 13400 strain.
Other than JCM 13400, these may be true reads that were generally not detected by
DADA2 nor ampliclust, although DADA2 predicted the existence of R. inulinivorans, in
subset 5. Both methods do reliably identify 13 common species/strains, including the
misidentified P. distasonis JCM 13400, in near equivalent proportions.
We conclude there is no reproducible difference in the performance of DADA2 and
ampliclust on the mock datasets. Both methods perform very well at identifying the
major species/strains in the sample and have very low rates of misclassification.
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Table 5: The dilution (Dil.), expected number of reads (Exp.), and average number
of reads assigned to each strain in the K33∗, DADA2, and ampliclust solutions. The
mock mixture was formed by applying dilution 10k for the integer k given in the column
to these species (and others not shown). The true proportions of each strain from
species B. ovatus and B. vulgatus are not known. The expected number of reads
is based on the dilution factor and assuming perfect experimental methods with no
bias or contamination. K33∗ is the K = 33 solution with fixed haplotypes obtained as
described in the Methods. DADA2 is the DADA2 solution. Ampliclust is our solution
seeded with reference sequences chosen as described in the Methods.
Species Dil. Exp. K33∗ DADA2 Ampliclust
Bacteroides ovatus 1
0 1279.6
282.3 281.6 283.9
Bacteroides ovatus 2 1.1 0 0
Bacteroides ovatus 3 1117.8 1118.8 1115.9
Bacteroides ovatus total 1401.2 1400.4 1399.8
Bacteroides vulgatus 1
0 1279.6
839.6 842.3 844.1
Bacteroides vulgatus 2 170.3 163.7 172.9
Bacteroides vulgatus 3 144.6 151 140.1
Bacteroides vulgatus total 1154.5 1157 1157.1
Bacteroides cellulosilyticus DSM 14838 -1 128 136.5 136.2 139.5
Clostridium xylanovorans -1 128 128.7 131.4 133.6
Parabacteroides distasonis JCM 13401 -1 128 58.7 52.9 58.6
Parabacteroides distasonis JCM 13400 -5 0 65.7 73.6 67.9
Bacteroides uniformis -2 12.8 13.8 13.2 9.9
Parabacteroides merdae -2 12.8 15.9 15.5 15.5
Clostridium cocleatum -2 12.8 10.3 9.6 10.1
Coprococcus comes ATCC 27758 -2 12.8 10.7 10 8
Bacteroides fragilis -3 1.3 0.9 0 0
Clostridium celatum JCM 1394 -3 1.3 0.9 0 0
Roseburia inulinivorans DSM 16841 -3 1.3 0.8 0.2 0
Bacteroides thetaiotaomicron DSM 2079 -3 1.3 1.2 0 0
Bacteroides massiliensis JCM 12982 -4 0.1 0.1 0 0
Ruminococcus gnavus ATCC 29149 -5 0 0.1 0 0
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D3 GCCTGCCCCC TGTGCCGT 166
A7 .......... ........ 159
D5 A.T.A.TA.. ..C..... 132
A5 A.T.A.TA.. ........ 149
D1 ATTCAT.GTT .....TA. 4132
A4 ATTCAT.GTT .....TA. 2185
D6 .TTCA..GTT .....TA. 549
A3 .TTCAT.GTT .....TA. 2567
D2 .TTCA..AT. GA..TT.C 1218
A6 .TTCA..AT. GA..TT.C 1217
D4 ATTCA..AT. GA..TT.C 1136
A2 ATTCA..AT. GA..TT.C 1133
A0 .TTCA..AT. G..TTT.C 1416
D0 ATTCA..AT. G..TTT.C 3011
A1 ATTCA..AT. G..TTT.C 1518
Figure 3: Alignment showing only the segregating sites of ampliclust inferred hap-
lotypes (A0–A7) and DADA2 inferred centers (D0–D6). After each sequence is the
number of reads assigned to each haplotype.
6.4.2 HIV data analysis
The performance of ampliclust and DADA2 were further evaluated by analyzing the
real HIV-1 data. DADA2 estimated K = 7, while our method found K = 8 is the best
choice based on the BIC criteria (Fig. 2).
Fig. 3 is an alignment of the DADA2 and ampliclust inferred haplotypes, show-
ing only the segregating sites. The methods agree on five haplotypes and disagree
by a single nucleotide difference on two others. In addition, ampliclust identifies an
eighth haplotype A0 that differs at one position from D0, which is itself equivalent to
A1. This difference is not a trivial disagreement, as ampliclust assigns 1,416 reads
to this distinct haplotype using the maximum posterior probability. The 3,011 reads
DADA2 assigns to D0 are split largely between A0 and A1, but a total of 160 reads
are disbursed elsewhere, with at least one read going to each other ampliclust cluster,
and the two ampliclust haplotypes, A0 and A1, attract 83 additional reads from DADA2
clusters D3, D5, and D7. One of the other haplotype mismatches (A3 vs. D6) leads to
a partitioning of the reads assigned to D6, largely to A3 and A4, but two reads each
go to A2 and A5. All together the adjusted RAND index comparing the two solutions is
0.556, showing substantial disagreement between the two methods.
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Figure 4: Box plots of the 10,344 read log likelihoods computed under the DADA2 or
ampliclust, either K = 7 or K = 8, clustering solution. The y-axis is truncated below
at −160, and the log likelihood of one very unlikely read (log likelihood around −300) is
thus not shown.
We do not know the true clusters in the HIV dataset, but we can compute the log
likelihood of each read assuming the cluster solutions provided by DADA2 or ampliclust
and assuming all substitutions are equally likely and the quality scores can be treated
literally. Quality scores are quite accurate representations of the true error probability
(Dorman, personal communication), and although substitutions are not uniform, this
modeling choice does not preferentially match either of the competing methods. Fig-
ure 4 shows that the read log likelihoods are slightly improved under the ampliclust
clustering solution, and the difference is not merely attributable to the increase in K
from 7 to 8. The median log likelihood increases from -8.559 for the DADA2 clustering
solution to -7.506 (K = 7) or -7.415 (K = 8) under the ampliclust solution.
We can also assess the quality of the ampliclust solution by considering the bar-
codes included in the read data. The adapter and barcodes were trimmed before
the reads were clustered (see Appendix §), so the barcodes represent separate se-
quence information that was not used by either DADA2 or ampliclust to cluster the
reads. Reads with the same barcode are supposed to be replicate reads of the same
molecule. Unfortunately, the barcodes themselves are observed with error, and there
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is evidence of recombination during PCR that disrupted the connection between the
barcode and the amplicon sequence. Nevertheless, a preliminary analysis showed
that reads with the same barcode tended to be more similar than reads with different
barcodes (data not shown). Thus, there remains valid clustering information in the
barcodes, which we use to test whether the ampliclust solution is reasonable. In par-
ticular, we examine the DADA2 D0 cluster, which is split largely into ampliclust clusters
A0 and A1. Of the 3,011 reads in cluster D0, 1,366 went into cluster A0. Of the bar-
codes associated with these 1,366 reads, only 27 were also associated with reads left
in cluster A1. Given the distribution of the 639 barcodes in D0 to start, this event is
incredibly unlikely. In 1,000 random selections of 1,366 reads from D1, the minimum
number of such split barcodes was 125. Similarly, when 1,982 reads from cluster D1
were moved into A3, only 96 barcodes were split between A3 and A4. The minimum
number of split barcodes in 1,000 random selections of 1,982 reads from D1 is 183.
Thus, we conclude that the ampliclust solution partitions DADA2 clusters in a way that
respects the clustering of barcodes.
6.4.3 Simulated data analysis
In addition, the two methods were compared on simulated datasets where the true
clustering solution was known. We simulated data similar to both the mock data (sub-
set 1) and the HIV-1 data (see Methods §). To compare the methods, we computed
the adjusted RAND index [18] between the estimated clustering solution and the true
clustering. The ARI means and standard errors over three replications for the mock
data and 15 replications for the HIV-1 data are reported in Table 6. We report two
ampliclust results, one obtained from just 10 Rnd-Ini(10) initializations, and another
obtained by initializing with the true haplotypes and partition.
The mean ARI when initializing with the truth is higher than the mean ARI of the
random initialization, indicating that AECM is generally not finding the global maximum
of the log likelihood in just 10 initializations. Nevertheless, ampliclust was better able
to recover the true clustering even without finding the global maximum under nearly all
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Table 6: Adjusted RAND index (ARI) for simulation results. Separation is the expected
number of nucleotide substitutions along the branch separating the haplotypes from
the ancestral haplotype. The expected number of differences between each haplotype
is roughly twice this number. Rows with – given for separation simulated from the in-
ferred haplotypes for the respective dataset. DADA2 is the DADA2 solution. Ampliclust
is the ampliclust solution using 10 random Rnd-Ini(10) initializations. Ampliclust∗ is the
ampliclust solution using the true haplotypes and cluster assignments for initialization.
The standard error of ARI is shown in parentheses.
Adjusted RAND Index
Based on Data Separation DADA2 Ampliclust Ampliclust∗
Mock data (K = 12)
0.005 0.805 (0.184) 0.842 (0.183) 0.853 (0.187)
0.01 0.959 (0.034) 0.959 (0.028) 0.975 (0.032)
- 0.996 (0.002) 0.918 (0.070) 0.997 (0.002)
0.0025 0.295 (0.257) 0.627 (0.302) 0.645 (0.297)
0.005 0.517 (0.267) 0.724 (0.223) 0.760 (0.226)
HIV data (K = 8) - 0.723 (0.076) 0.987 (0.034) 0.997 (0.001)
0.01 0.970 (0.048) 0.984 (0.027) 0.998 (0.005)
0.015 0.978 (0.069) 0.990 (0.010) 1.000 (0.001)
simulation settings, but especially for overlapping clusters where the haplotypes were
not well-separated. Notably, for data simulated directly from 13 reference sequences
of the mock dataset, DADA2 performed better than the randomly initialized ampliclust.
This simulation produced the easiest data to cluster among all simulations, as indi-
cated by overall ARI levels, suggesting that the clusters in the mock data are very
well-separated. Indeed, the minimum proportion of mutated sites between any pair
of haplotypes is 0.004, the average is 0.21 and the maximum is 0.60, which is large
because of insertions/deletions in 16S. Some real datasets, such as that observed in
the HIV-1 sample, are far more difficult to cluster.
The haplotypes estimated from the K = 8 HIV-1 solution differ at a fraction of sites
between 0.004 and 0.04. This amount of separation appears to confuse DADA2, as the
average ARI is only 0.723, yielding significantly worse recovery of the true clusters than
either ampliclust solution. Both methods suffer as the average amount of separation
drops below this level, but ampliclust continues to perform significantly better. As the
separation increases, both methods improve and when the ampliclust solution is not
properly optimized, DADA2 can outperform ampliclust.
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6.5 Discussion
In this study, we introduce ampliclust, a fully probabilistic model for denoising Illu-
mina amplicon data with the goal of identifying true sequences and their abundances
in mixed samples, such as microbiome samples sequenced in 16S. This method is
inspired by DADA2 [11], but it assumes each read is generated independently and
uses raw quality score information rather than averages on compressed data. It also
corrects some logical inconsistencies in the DADA2 model formulation. We utilize the
AECM algorithm to estimate model parameters and implement it in the C programming
language. Our method ampliclust is shown to better recover the true sequences and
abundances when the sequences are less well-separated.
In the analysis of mock data where various species/strains of bacteria were mixed
in known proportions, the ampliclust solutions are highly similar to those of DADA2.
The adjusted RAND index (ARI) between the ampliclust and DADA2 partitions are
around 0.99. Simulations reveal that the mock data represent well-separated clusters,
a data situation where both methods perform quite well. In fact, DADA2 can outperform
ampliclust in this situation because the latter tends to return local maxima. Indeed, we
conclude that DADA2 is a very efficient algorithm for finding well-separated clusters,
much better AECM with random initialization.
Different clustering results are observed for ampliclust and DADA2 on the real HIV
dataset, and the ampliclust solution has some characteristics that suggest it may be a
better solution. Although ampliclust and DADA2 identify five identical haplotypes and
two that differ by a single nucleotide, their estimated abundances are different and the
ARI comparing the solutions is small. The read likelihoods evaluated under a simple
error model that requires no parameter estimation are slightly better for the ampliclust
clustering compared to that of DADA2, suggesting that ampliclust may better partition
the data. In addition, the ampliclust solution splits two of the DADA2 clusters in a way
that respects the barcodes attached to the amplicon sequences better than random
splitting. Thus, there is limited evidence that the ampliclust clustering solution for the
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HIV-1 data is better than the DADA2 solution, but there is no conclusive support for
ampliclust in the absence of a true clustering.
In the simulation study, ampliclust outperforms DADA2 even after just 10 Rnd-
Ini(10) initializations in almost all simulation scenarios, but especially for data with
clusters that are not well-separated. The simulation study reveals that the clusters in
the mock dataset are well-separated, and considerably more separated than the clus-
ters in the HIV-1 dataset. Apparently, there is little ability to distinguish the accuracy
of clustering performance for such well-separated datasets. The major distinguishing
feature of the two methods is speed, where DADA2 excels.
The difference in the accuracy of ampliclust and DADA2 could be attributed to
DADA2’s underutilization of the quality scores. Compressing the data to unique se-
quences and average quality scores accelerates DADA2, but distorts the error signal
and obscures read-level information that can be used for better cluster placement.
Furthermore, DADA2 uses a greedy algorithm for estimation, so it is not guaranteed
to find a globally optimal solution. Ampliclust may also get trapped in local optima, but
repeated random initializations can help it find a better optimum than DADA2 at the
cost of a longer run time. During the initial stage of the DADA2 algorithm, all reads
are combined in a single cluster, and the error model estimated at this stage nec-
essarily overestimates error probabilities. DADA2 can nevertheless detect separate
clusters if there is a replicated read that is “unusual” in this large cluster, but when
errors are common (as is routine for long reads of diverse samples), there may be few
true haplotypes read without error. Indeed, the HIV dataset consisted of 8,631 unique
sequences out of 10,344 reads, so relatively few sequences were replicated. Further,
true clusters that start absorbed in a larger cluster may not appear unusual if the error
rates are severely overestimated, especially when there is little separation between
haplotypes. For both these reasons, DADA2 may have difficulty forking off clusters.
Indeed in the HIV-1 real data, DADA2 found one less cluster than ampliclust, and in
the simulated data based on HIV, the mean number of clusters for DADA2 was 7.5 for
separation 0.015, 7.1 for separation 0.01, 4.1 for separation 0.005, and 2.8 for sepa-
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ration 0.0025. Ampliclust always found all 8 haplotypes even after just 10 Rnd-Ini(10)
initializations. Of course, ampliclust spent much more time in the effort. Although we
did not do timed runs, anectodally DADA2 took about a minute and ampliclust with 10
Rnd-Ini(10) initializations took about 20 minutes. In addition to possibly missing the
global optimum, DADA2 computes a p-value using a likelihood that is assumed to be
proportional to the actual conditional likelihood, which conditioned on the current clus-
ter sizes. Unfortunately, the neglected proportionality constant is not actually constant
in the parameters, and it is not clear how much this fact can alter the calculations.
These facts also make it more difficult for a user to select an appropriate p-value cut-
off for DADA2, since the computed number is not a true p-value. In summary, because
DADA2 does not optimize the actual likelihood imposed by its modeling assumptions,
it achieves speed at the cost of accuracy, and the accuracy difference is most visible
for overlapping clusters.
We were surprised by the level of contamination in all real datasets. The mock data
contained many high quality reads of apparently unrelated 16S sequences. Another
positive of DADA2 is that it effectively ignores such contamination by refusing to ini-
tiate a cluster unless the founding sequence has been observed at least twice. This
is an algorithmic solution to the problem; the DADA2 model does not actually accom-
modate such contamination. The current ampliclust would handle such contamination
by finding solutions with singleton clusters (clusters with one member) to explain the
contaminant outliers. To avoid this complication, we removed most contaminants from
the mock dataset before analysis. Extensions to both models are needed to properly
account for such contamination if it is to be universally expected in 16S datasets. For
example, ampliclust could be extended to handle “scatter” reads that are produced
under some other generative model, rather than as error from the haplotypes. Con-
tamination with replicated reads from the same contaminating species, such as can be
observed in Fig. 1 of the DADA2 publication [11], would be hard to detect as contami-
nation except in mock datasets. Technically, such contamination is accommodated
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by both DADA2 and ampliclust as additional clusters. It would be a subsequent
challenge, then, to identify which clusters were contaminants.
We had hoped that the mock datasets would provide a unique opportunity to com-
pare the performance of the two methods. Unfortunately, the problem of contamination
and the presence of unrecognized variation within species/strains means that even in
mock datasets, the true number and abundance of clusters is not known. Thus, good
simulation techniques are still needed to compare different clustering solutions. Simu-
lation is also useful for calibrating the difficulty of clustering in real data. For example,
through simulation we reveal that the mock dataset was substantially easier to cluster
than the HIV dataset, even though we could not know the true clusters in the lat-
ter dataset. We have implemented a simulation method in our ampliclust program,
but there is still much room for improvement. Methods to simulate with known levels
of overlap/difficulty and more varied haplotype structures would be desirable. Also,
simulation methods must accurately mimic the true error properties of the Illumina
sequencing machines.
One major challenge to apply ampliclust is the choice of initialization for AECM.
We bypassed this problem in the mock data by initializing with the true haplotypes as
a shortcut to what we hope is the global maximum. The k-modes initialization schemes
we applied to the HIV and simulation data have not been thoroughly tested. In particu-
lar, this initialization method ignores the information in the quality scores, and thus may
ignore critical information for obtaining good starting points for AECM. A simple solu-
tion would be to use a quality-based distance metric instead of the Hamming distance,
but there are also many clever initialization algorithms for k-modes, for example [19].
Thus, ampliclust could further benefit from better initialization methods.
AECM is an EM algorithm, which are notoriously slow to converge. There are
many methods to accelerate EM that could be applied to our AECM algorithm [20, 21,
22], and the EM can be parallelized [23, 24]. However, the very large datasets that
characterize NGS data may not be amenable to any of these techniques, especially
when K is very large. In this case, it is also possible to incrementally handle the data
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such that the whole dataset need not be processed at once [25]. All of these ideas can
be used to speed up ampliclust to make it computationally competitive with DADA2,
while retaining its enhanced accuracy.
In summary, ampliclust is better able to detect the true haplotypes and abundances
when haplotype error clouds are not well-separated. The most important future devel-
opment for ampliclust is to speed it up, particularly with respect to the multiple ini-
tializations that are currently needed to find the global maximum. The singe most
important advantage of other methods is their reduced computational complexity com-
pared to ampliclust. A benefit of our approach is that the fully probabilistic model can
be extended in several directions. To handle contamination, the model may need to
be extended with a scatter component, but we may also want to improve clustering
by utilizing auxiliary information, most importantly the barcode data that are routinely
sequenced along with the amplicons. Since barcodes are uniquely attached to the
original cDNA molecules, they contain valuable information for clustering.
6.6 Appendix
6.6.1 Processing HIV data
To process the HIV data, we propose a model to identify and trim the adapter/primer
and barcodes from the reads. Each valid read begins with 0–2 random nucleotides
followed by the 52bp adapter/primer
GCCTTGCCACACGCTCAGNNNNNNNNNGTTGTAAYTTCTAGRTCCCCTCCTG,
including the 9bp barcode and two ambiguous nucleotides at positions {35, 42}. The
last 25bp are homologous to the C3 region of the HIV-1 env gene and serve as the
primer for reverse transcription. The first 18bp is an adapter for subsequent PCR
amplification and sequencing. We will refer to this 52bp pattern as the (ambiguous)
“primer,” ambiguous because of the unspecified barcode as well as the Y and R. We
will refer to the 43bp pattern excluding the barcode as the (ambiguous) primer sans
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barcode. If we can neglect indels in the reads, then we expect a primer to start at read
position 1, 2, or 3. Let Zi ∈ {0, 1, 2} be the unknown number of random nucleotides
at the start of read ri. Further, let Yi ∈ {0, 1, 2, 3} be the unknown state of the unam-
biguous primer sans barcode with the Y and R resolved. The combined hidden state
indicator Xi ∈ {0, 1, . . . , 12}, defined via the one-to-one mapping where Zi = bXi/4c
and Yi = Xi mod 4.
Dropping read index i, let the probability of read nucleotide r at position j givenX =
x be pjr(x). This probability will vary according to the type of template nucleotide. For
all non-barcode primer positions j ∈ {z+1, z+2, . . . , z+52}\{z+19, z+20, . . . , z+27},
we have
pjr(x) := sPmr =

(1− δj)γPmr r 6= Pm
δj r = Pm,
(1)
where Pm is the unambiguous nucleotide at primer position m = z−j. For the barcode
positions j ∈ {z + 19, z + 20, . . . , z + 27}, we assume
pjr(x) = qbr,
∑
r∈{A,C,G,T}
qbr = 1.
For positions outside the primer in the read, we assume pjr(x) = qsr,
∑
r∈{A,C,G,T} qsr =
1, another distribution over nucleotides that reflects nucleotide content in the virus.
Finally, some reads may not contain the primer anywhere. In this case, we gener-
ated the entire read as iid Multinomial(1, qs) and define X = 12, Z = 3 and ignore the
now meaningless Y . As a results, there are 3 × 4 + 1 = 13 possible hidden states Xi
or (Zi, Yi) for every read ri.
6.6.1.1 Complete data likelihood
Assuming x = (x1, x2, . . . , xn) are iid, zi and yi are a priori independent, pi give the
probabilities of each possible zi ∈ {0, 1, 2, 3} value and η give the probabilities of each
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possible yi ∈ {0, 1, 2, 3} when zi > 0, then the complete data likelihood is
L(θ | R,x) =
n∏
i=1
12∏
x=0
[
pibx/4cη
1{x<12}
x mod 4
li∏
j=1
pjrij(x)
]1{xi=x}
,
where li is the length of read i. For each read i and xi, partition the read positions
{1, 2, . . . , li} into the set of positions JixiP corresponding to the primer sans barcode,
the set of positions JixiB corresponding to the barcode, and the set of all other posi-
tions JixiS. Let mxj be the position in the primer given the read position j and primer
position bxc. Then,
L(θ | R,x) =
n∏
i=1
3∏
z=0
piz
∏
j∈JixiB
qbrij
∏
j∈JixiS
qsrij
∏
y∈N(JixiP )
ηxi mod 4 ∏
j∈JixiP
δ
1{rij=pyj}
j
[
(1− δj)γpyjrij
]1{rij 6=pyj}1{xi mod 4=y}

1{bxi/4c=z}
,
where N(JixiP ) is the index set of all possible primers without ambiguity except at
the barcode {p1,p2, . . .} consistent with the fully ambiguous primer and pyj is the jth
nucleotide in yth primer. We define N(JixiP ) = ∅ when the read contains no primer
site (xi = 12).
6.6.1.2 E-step
In the E-step, we merely need to compute
eix = P (xi = x | ri) ∝
l∏
j=1
pjrij(x).
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6.6.1.3 M-step
In the M-step, the update formulae at iteration t+ 1 are
pi(t+1)z =
∑n
i=1
∑12
x=0 1 {bx/4c = z} e(t)ix∑n
i=1
∑12
x=0 e
(t)
ix
η(t+1)y =
∑n
i=1
∑11
x=0 1 {x mod 4 = y} e(t)ix∑n
i=1
∑11
x=0 e
(t)
ix
δ
(t+1)
j =
∑n
i=1
∑11
x=0 1 {rij = px mod 4,j} e(t)ix∑n
i=1
∑11
x=0 e
(t)
ix
, j ∈ JixiP
γ
(t+1)
N1N2 =
∑n
i=1
∑11
x=0 1 {px mod 4,j = N1, rij = N2} e(t)ix∑n
i=1
∑11
x=0 1 {px mod 4,j = N1, rij 6= N1} e(t)ix
,N1 6= N2, j ∈ JixiP
q
(t+1)
br =
∑n
i=1
∑11
x=0
∑
j∈JixiB 1 {rij = r} e
(t)
ix∑n
i=1
∑11
x=0|JixiB|e(t)ix
q(t+1)sr =
∑n
i=1
∑12
x=0
∑
j∈JixiS 1 {rij = r} e
(t)
ix∑n
i=1
∑12
x=0|JixiS|e(t)ix
,
where JixiS consists of all read positions when xi = 12.
6.6.1.4 Scoring the primer sequence
The EM algorithm is initialized by a random partition of the reads into one of thirteen
classes indexed by Xi. Multiple initializations converged to the same maximum. After
convergence of the EM algorithm and estimation of the MLEs θˆ, we scored the primer
sequence by identifying the most likely position of the primer
zˆi = arg max
z∈{0,1,2}
∑
x∈{0,1,...,11}:bx/4c=z
l(θˆ | ri, x)
and computing the score as the summed log likelihood over all possible primers
Sip =
∑
y∈{0,1,2,3}
∑
x=4zˆi+y
l(θˆ | rix).
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6.6.1.5 Scoring the 3’ end of the read
Because there was extensive mispriming in these data, we also scored the 3’ end
of the read. These data were isolated from a patient in South Africa between 2005
and 2009. To identify the expected sequence at the 3’ end of the read, we identi-
fied an HIV-1 subtype C reference sequence from Zambia in the 2010 Env reference
alignment provided by the HIV Sequence Database hosted at https://www.hiv.lanl.
gov/content/. We used bwa [26] with default parameters except a penalty of 100
for 5’ and 3’ end clipping to align the reads to the subtype C reference sequence.
We selected the first 10,000 of the aligned reads (out of 30,266 total aligned reads
from 58,071 total reads), and used muscle [27] with default parameters to align them
to the reverse complement of the primer sequence and the next 300bp in the ref-
erence sequence. We computed a consensus sequence from the alignment by re-
moving all positions with an insertion in more than 40% of the reads. We blasted
the resulting consensus sequence against the nucleotide collection at NCBI using
megablast [28], and found several 100% identical South African sequences. We
selected the sequence with accession KF996710 as our new reference. The 89bp
located 160bp downstream of the primer site in KF996710 (in the reverse comple-
ment) are s = TCTTATACTTTTTCTTGTATTATTGTTGGGTCTTGTACAATTAATCC
CTACAGATTCATTGAGATGTACTATTATTGTTTTGACATTGT. These 89bp should
be contained in all reads of the correctly primed and amplified amplicon. Assuming an
error rate of 0.02 at all read positions and the MLEs γˆN1N2 estimated from the EM, we
computed a score for the 3’ end of the amplicon as
Si3 =
li∑
j=zˆi+52+160
[
1 {rij = sj} log(0.98) + 1 {rij 6= sj}
(
log(0.02) + log γsjrij
)]
.
6.6.1.6 Filtering and trimming the reads
We filtered the reads by discarding reads shorter than 296 bp, requiring zˆi < 3,
a primer score above -2 and a 3’ end score above -45. Lastly, we trimmed zˆi + 27
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nucleotides from all the 5’ end of all remaining reads. Of the 61,711 reads, 83% were
discarded by this process, leaving 10,344 reads for analysis.
6.7 References
[1] S. Goodwin, J. D. McPherson, and W. R. McCombie. Coming of age: ten years of
next-generation sequencing technologies. Nat. Rev. Genet., 17:333–351, 2016.
[2] H. Y. K. Lam, M. J. Clark, R. Chen, R. Chen, G. Natsoulis, M. O’Huallachain,
F. E. Dewey, L. Habegger, E. A. Ashley, and M. B. and Gerstein. Performance
comparison of whole-genome sequencing platforms. Nat. Biotechnol., 30:78–82,
2012.
[3] Lee C. K., Herbold C. W., Polson S. W., K. E. Wommack, Williamson S. J., and
I. R. and McDonald. Groundtruthing next-gen sequencing for microbial ecology-
biases and errors in community structure estimates from PCR amplicon pyrose-
quencing. PLoS One, 7:e44224, 2012.
[4] X. Chen, J. B. Listman, F. J. Slack, J. Gelernter, and H. Zhao. Biases and errors
on allele frequency estimation and disease association tests of next-generation
sequencing of pooled samples. Genet. Epidemiol., 36:549–560, 2012.
[5] NGS-eval: NGS error analysis and novel sequence VAriant detection tooL.
[6] Rosen MJ, Callahan BJ, Fisher DS, and Holmes SP. Denoising pcr-amplified
metagenome data. BMC Bioinformatics, 13:283–299, 2012.
[7] Kunan V, Engelbrektson A, Ochman H, and Hugenholtz P. Wrinkles in the rare
biosphere: pyrosequencing errors can lead to artificial inflation of diversity esti-
mates. Environ Microbiol, 12:118123, 2010.
[8] Zhou J, Wu L, Deng Y, Zhi X, Jiang Y, Tu Q, Xie J, Nostrand JDV, He Z, and Yang Y.
Reproducibility and quantitation of amplicon sequencing-based detection. ISME
J, 5:13031313, 2011.
169
[9] Quince C, Lanzen A, Curtis TP, Davenport RJ, Hall N, Head IA, Read LF, and
Sloan WT. Accurate determination of microbial diversity from 454 pyrosequencing
data. Nat methods, 6:639641, 2009.
[10] Quince C, Lanzen A, Davenport RJ, and Turnbaugh PJ. Removing noise from
pyrosequenced amplicons. BMC Bioinf, 12:38–44, 2011.
[11] Callahan BJ, Mcmurdie PJ, Rosen MJ, Han AW, Johnson AJ, and Holmes SP.
Dada2: High resolution sample inference from amplicon data. Nature Method,
13:581–587, 2015.
[12] Xiao-Li Meng and David van Dyk. The em algorithm–an old folk-song sung to a
fast new tune. Journal of the Royal Statistical Society. Series B (Methodological),
59(3):511–567, 1997.
[13] Jinal N Bhiman, Colin Anthony, Nicole A Doria-Rose, Owen Karimanzira, Chaim A
Schramm, Thandeka Khoza, Dale Kitchin, Gordon Botha, Jason Gorman, Nigel J
Garrett, Salim S Abdool Karim, Lawrence Shapiro, Carolyn Williamson, Peter D
Kwong, John R Mascola, Lynn Morris, and Penny L Moore. Viral variants that ini-
tiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies.
Nat Med, 21(11):1332–1336, 2015.
[14] Dimitris Karlis and Evdokia Xekalaki. Choosing initial values for the em algorithm
for finite mixtures. Computational Statistics and Data Analysis, 41:577–590, 2003.
[15] Zhexue Huang. A fast clustering algorithm to cluster very large categorical data
sets in data mining. In In Research Issues on Data Mining and Knowledge Dis-
covery, pages 1–8, 1997.
[16] Ranjan Maitra. Initializing partition-optimization algorithms. IEEE/ACM Transac-
tions on Computational Biology and Bioinformatics, 6(1):144–157, 2009.
[17] Volodymyr Melnykov Ranjan Maitra. Simulating data to study performance of
finite mixture modeling and clustering algorithms. Journal of Computational and
Graphical Statistics, 19(2):354–376, 2010.
170
[18] Lawrence Hubert and Phipps Arabie. Comparing partitions. Journal of Classifi-
cation, 2:193–218, 1985.
[19] Fuyuan Cao, Jiye Liang, and Liang Bai. A new initialization method for categorical
data clustering. Expert Systems with Applications, 36(7):10223 – 10228, 2009.
[20] A. Berlinet and C. Roland. Parabolic acceleration of the em algorithm. Statistics
and Computing, 19(1):35–47, 2009.
[21] Ravi Varadhan and Christophe Roland. Simple and globally convergent methods
for accelerating the convergence of any em algorithm. Scandinavian Journal of
Statistics, 35(2):335 – 353, 2008.
[22] Hua Zhou, David Alexander, and Kenneth Lange. A quasi-newton acceleration
for high-dimensional optimization algorithms. Stat Comput, 21(2):261–273, Jan
2011.
[23] Chen W.-C. Model-based clustering of regression time series data via apecman
aecm algorithm sung to an even faster beat. Statistical Analysis and Data Mining,
4:567, 2011.
[24] Wei chen Chen, George Ostrouchov, David Pugmire, Prabhat, and Michael
Wehner. A parallel em algorithm for model-based clustering applied to the ex-
ploration of large spatio-temporal data. Technometrics, 55(4):513–523, 2013.
[25] Ranjan Maitra. Initializing partition-optimization algorithms. IEEE/ACM Trans
Comput Biol Bioinform, 6(1):144–157, 2009.
[26] Heng Li. Aligning sequence reads, clone sequences and assembly contigs with
bwa-mem. In arXiv:1303.3997v2, pages [q–bio.GN], 2013.
[27] Robert C. Edgar. Muscle: multiple sequence alignment with high accuracy and
high throughput. In Nucleic Acids Res., pages 32(5):1792–1797, 2004.
171
[28] Zheng Zhang, Scott Schwartz, Lukas Wagner, and Webb Miller. A greedy al-
gorithm for aligning dna sequences. In J Comput Biol, pages 7(1–2):203–14.,
2000.
[29] A. Ratan, W. Miller, J. Guillory, J. Stinson, S. Seshagiri, and S. C. Schuster. Com-
parison of sequencing platforms for single nucleotide variant calls in a human
sample. PLoS One, 8:e55089, 2013.
[30] Jabara CB, Jones CD, Roach J, Anderson JA, and Swanstrom R. Accurate sam-
pling and deep sequencing of the hiv-1 protease gene using a primer id. Proc
Natl Acad Sci U S A, 108:201662017, 2011.
[31] Sohn KA and Xing EP. Spectrum: joint bayesian inference of population structure
and recombination eventss. BMC Bioinformatics, 23:479–489, 2007.
[32] K. A. Sohn, Z. Ghahramani, , and E. P. Xing. Robust estimation of local genetic
ancestry in admixed populations using a nonparametric bayesian approach. Ge-
netics, 191:12951308, 2012.
[33] P J Green. On use of the EM algorithm for penalized likelihood estimation. Journal
of the Royal Statistical Society, Series B, 52(3):443–452, 1990.
[34] Shelley B. Bull, Juan Pablo Lewinger, and Sophia S. F. Lee. Confidence inter-
vals for multinomial logistic regression in sparse data. Statistics in Medicine,
26(4):903–918, 2007.
[35] http://www.hiv.lanl.gov/.
	  	  
172 
CHAPTER 7 
CONCLUSION 
Elicitation of bnAbs is a major goal of HIV-1 vaccine development. The 
HIV-1 Env are the only target for bnAbs. In this dissertation, we evaluated 
different vaccine approaches to induce bnAbs. The approaches include use of 
putative fusion intermediate state of gp41 and novel heterologous prime-boost 
strategies. Several interesting conclusions have been drawn from our studies.  
The MPER of gp41 is an attractive target for HIV-1 vaccine development. 
We previously described that gp41-HR1-54Q, a post-fusion form of gp41, 
induced strong antibody responses against non-neutralizing face of the helix. To 
refocus immune responses to the neutralizing face of the helix and better target 
4E10/10E8 epitopes, we generated putative fusion intermediates by destabilizing 
six-helix bundle structure through the introduction of mutations or deletions in the 
HR1. One immunogen induced antibodies that targeted the residues on the 
neutralizing face of the helix, which are crucial for 4E10/10E8 recognition. The 
study suggested that the destabilization of six-helix bundle could influence    the 
immunogenicity of the MPER. 
The major challenge in inducing bnAbs is developing immunogens and/or 
immunization strategies that direct the immune responses towards neutralizing 
epitopes and guide the antibody evolution and maturation so that antibodies can 
recognize neutralizing epitopes on the native spikes. It is believed that multiple 
immunizations using a single antigen would be difficult to induce bnAbs. We 
devised two novel strategies to induce bnAbs. One strategy was designed to 
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sequentially immunize animals with progressively more native immunogens. 
Different sets of immunogens have been used to induce anti-MPER bnAbs 
(Chapter 3) and anti-CD4bs bnAbs (Chapter 5). In Chapter 3, this strategy failed 
to induce bnAbs, but was better able to direct antibodies towards the anti-MPER 
bnAbs epitopes than homologous prime-boost immunization using a single 
immunogen. In Chapter 5, this strategy was tested in two groups using gp120 
based immunogens induced strong antibody responses that compete VRC01 
binding and neutralizing activity against Tier 1 viruses, but no bnAbs were 
elicited. Another vaccine strategy was designed to alternatively immunize a 
native like immunogen and a small CD4bs-based immunogen using a rapid 
schedule. In Chapter 4, this strategy was tested using two different immunogens, 
it induced neutralizing antibodies that were limited to Tier 1 viruses. Although we 
failed to induce bnAbs, which was possibly due to the suboptimal immunogens, 
our vaccine strategies showed their potential strength.  Additional studies will be 
needed to better evaluate this vaccine strategy using optimal immunogens.  
  Current Next Generation Sequencing (NGS) technologies could provide 
high throughout data at low cost, but the associated errors can influence the 
downstream analyses. Thus, it is critically important for error correction of 
sequencing data to provide accurate, high-quality sequencing data for further 
downstream analysis. Most error correction methods so far have been designed 
for substitution errors, possibly due to the dominance of Illumina platform in the 
market. Illumina quality scores are related to error rates and informative for error 
correction. However, most Illumina denoiser algorithms underutilize quality score, 
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they usually discard quality score or turn to compression, which may affect the 
downstream analyses and lead to undesirable consequences.  We proposed an 
ampliclust, an error modeling approach using uncompressed data for denoising 
Illumina amplicon data. The study showed that our method has higher accuracy 
than DADA2 for data sets that are not well separated. Our denoising method 
could be further improved using the barcode data, because a barcode is uniquely 
attached to a cDNA molecule, which should be informative for clustering.  
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APPENDIX 
HIV-1 GP41-HR1-HR2 SIX-HELIX BUNDLE AS A NOVEL FUSION PROTEIN 
PARTNER FOR EFFICIENT RECOMBINANT PROTEIN EXPRESSION 
 
Heliang Shi, Andrew Harley, Michael Cho 
 
Abstract 
The demand for recombinant proteins is growing globally due to their great 
application values in medicine, research laboratories, and biopharmaceutical industries.  
Efficient strategies that produce higher yields of recombinant proteins at lower costs are 
needed to achieve commercially viable recombinant proteins production. Here we 
describe a novel method to produce large quantities of recombinant proteins by using 
an N-terminally fused protein partner derived from HIV-1 gp41, and contains the heptad 
repeat 1(HR1) and heptad repeat 2 (HR2) regions. We introduced a thrombin cleavage 
site between gp41-HR1-HR2 and the recombinant proteins to efficiently remove the 
fusion partner through His-tag affinity purification. To purify non-His-tagged recombinant 
proteins from thrombin-cleaved fusion proteins, we further incorporated a 6xHis-tag 
between HR1 and HR2 regions. By linking the fusion partner to the N-terminus of target 
proteins, we demonstrated significant enhancement of both His-tag and non His-tag 
recombinant protein expression yield in Escherichia coli. This novel fusion expression 
system could be used for any application that requires large quantities of recombinant 
proteins.  
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A.1 Introduction 
Recombinant proteins have been widely used in modern applications, including 
treating a number of diseases including cancer, diabetes, and heart failure.(1-4) The 
demand for recombinant proteins has increased significantly, especially in 
biopharmaceutical industries. As of 2015, nearly 400 recombinant protein-based 
products were approved as biopharmaceuticals, and over 1000 protein candidates were 
under development. (5) Thus, the future applications for recombinant proteins are very 
promising.  
Given the increasing demand for recombinant proteins, developing efficient 
strategies for their production will be extremely important. Higher expression yield and 
lower costs are needed to achieve commercially viable large-scale production. 
Currently, bacterial expression is the most common production system for recombinant 
proteins. Among them, Escherichia coli (E. coli) has always been preferred as it grows 
fast, is easy to handle, cost-effective, and usually provides high yield. (6) A variety of 
studies in the  E. coli expression system show that the target protein’s expression level 
could be improved by linking to a highly expressed fusion partner(7-11). In some cases, 
fusion partners could direct the target proteins to the inclusion bodies and simply 
downstream purification.(7, 9, 12). 
In this study, we described a novel method to enhance the expression yield of 
recombinant proteins by using a N-terminally fused protein partner, gp41-HR1-HR2, 
which consists of the heptad regions 1 (HR1) and 2 (HR2) of HIV-1 glycoprotein 41 
(gp41) and could form a stable six-helix bundle (6HB). Two versions of the fusion 
partner were generated.  First, we incorporated a thrombin cleavage site between gp41-
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HR1-HR2 and target proteins to efficiently cleave the fusion protein and liberate the 
target proteins.  Second, we adjusted the location of a His-tag from the C-terminus of 
target proteins to the middle of the HR1 and HR2 regions to produce non His-tagged 
proteins. We successfully generated large quantities of several HIV-1 derived 
recombinant proteins using our fusion partners. The fused proteins were expressed at a 
significantly higher level in E. coli as compared to unfused proteins. Target recombinant 
proteins, including both His-tagged and non His-tagged, were efficiently liberated from 
the fusion partners.  
 
A.2 Results and discussion 
A.2.1 Expression and purification of HR1-HR2-54Q fusion protein 
To detect the effect of gp41-HR-HR2 on protein expression, we compared the 
expression levels of HR1-HR2-54Q and 54Q in parallel.  As shown in Fig.1A, the yield 
of 54Q alone was poor after induction with IPTG (2-4mg/l). In contrast, HR1-HR2-54Q 
was expressed at much higher levels (>120mg/l). The amount of HR1-HR2-54Q is 
estimated to be ~40% of the total bacterial protein content according to the SDS-PAGE. 
The yield of fusion protein was ~40-fold higher than that the original 54Q target protein. 
The enhanced expression observed in HR1-HR2-54Q was possibly due to the N-
terminal fused HR1-HR2, which could form a stable six-helix bundle (6HB) structure. 
From these experiments, we concluded that the gp41-HR1-HR2 fragment could be a 
useful fusion partner to direct target proteins to inclusion bodies and increase 
expression.  
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A.2.2 Cleavage and purification of 54Q peptide 
In our initial construct, trypsin digestion was necessary to remove the HR1-HR2 
portion from the purified fusion protein. A potential problem with trypsin cleavage was 
the presence of cleavage sites within 54Q. As shown in Fig.1B, three major bands were 
observed after trypsin cleavage. From top to bottom, respectively, they represent the 
HR1-HR2 portion, 54Q peptide, and a fragment digested from 54Q. The small fragment 
may contain the 6xHis tag, so it could not be differentiated from 54Q during the Ni-NTA 
affinity chromatography purification process and contaminated the purified 54Q. Thus, 
to better cleave and purify the target protein, a more specific cleavage site should be 
introduced between fusion partner and target protein. 
 
A.2.3 Expression and purification of HR1-HR2-TH based fusion proteins 
To specifically cleave and purify the target protein, we replaced the trypsin site 
with a thrombin site at the C-terminal of HR1-HR2, called HR1-HR2-TH, and the 
expression of a fusion protein was evaluated. As shown in Fig.2A, the yield of HR1-
HR2-TH-54Q (>200mg/ml) is even higher than that of HR1-HR2-54Q. The amount of 
HR1-HR2-TH-54Q was estimated to be ~60%-70% of the total protein content. The 
enhanced expression compared to HR1-HR2-54Q was possibly due to mutated 
residues resulting from the introduction of thrombin cleavage site. 
To evaluate the generality of the exhibited high expression of the HR1-HR2-TH 
fusion partner, we generated a second fusion protein examined the expression 
compared to the unfused protein.  The protein selected was gp41-28x3, which consists 
of three tandem repeats of the C-terminal 28 amino acids of the extracellular region. As 
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shown in Fig.2C, the expression of gp41-28x3 was confirmed by Western blotting, but 
the yield was very poor as it could not be detected through Coomassie stained SDS-
PAGE. However, the expression of gp41-28x3 was significantly enhanced after N-
terminal fusion to HR1-HR2-TH (Fig.2D). Both HR1-HR2-TH based fusion proteins 
described exhibited similarly high expression, suggesting the generality of HR1-HR2-TH 
as an efficient fusion partner for enhancing target protein expression.  
 
A.2.4 Cleavage and purification of target proteins from HR1-HR2-TH based fusion 
proteins 
To liberate target proteins from the HR1-HR2-TH fusion peptide, purified fusion 
proteins were subjected to thrombin cleavage and Ni-NTA affinity chromatography. As 
shown in Fig.2B, HR1-HR2-TH-54Q could be efficiently digested by thrombin and 
purified through His-tag affinity. The eluted 54Q protein was >99% pure based on SDS-
PAGE estimation. Above the 54Q band, two adjacent protein bands were observed in 
the SDS-PAGE lane of thrombin-cleaved HR1-HR2-TH-54Q. There may be another 
thrombin digestion site between the T7-tag and HR1-HR2-TH, but it is not as sensitive 
to cleavage as at the C-terminal site following HR1-HR2-TH. These two protein 
fragments would not affect the purification of the target protein because they do not 
contain His-tag. Similarly, the HR1-HR2-TH portion was successfully removed from 
HR1-HR2-TH-28x3 by thrombin digestion (Fig.2E).  Thus, the introduction of a thrombin 
cleavage site to the C-terminal of HR1-HR2 efficiently increased the target protein 
expression and permitted release of the target proteins from the HR1-HR2-TH fusion 
peptide. 
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A.2.5 Expression of HR1-6H-HR2-TH based fusion proteins 
In some cases, the presence of a His-tag could affect protein structure and/or 
activity, thus non-His-tagged target proteins would be preferred. To generate non-His-
tagged target proteins, an HR1-6H-HR2-TH fusion partner was constructed by adjusting 
the location of 6xHis-tag from the C-terminal of target proteins to between the HR1 and 
HR2 regions. Post-thrombin digestion, the fusion proteins would be subjected to His-tag 
affinity chromatography, and the target proteins would be recovered from the flow 
through due to the absence of the His-tag.  
HR1-6H-HR2-TH-54 fusion protein was constructed in order to generate large 
amount of non-His-tag gp41-54 protein, which consists of the C-terminal 54 amino acids 
of the extracellular portion of HIV-1 gp41.  As shown in Fig.4, HR1-6H-HR2-TH-54 was 
strongly expressed, which is consistent with that of HR1-HR2-TH based fusion proteins, 
indicating the location of His-tag does not significantly affect expression. These data 
suggest that HR1-6H-HR2-TH could serve as an efficient fusion partner to effectively 
generate large amounts of non-His-tagged target proteins. 
 
A.3 Conclusions 
In this study, we described a strategy for generating large quantities of purified 
target proteins by fusing novel fusion peptide partners to the N-terminal end of target 
proteins. We developed two novel fusion partners, gp41-HR1-HR2-TH and gp41-HR1-
6H-HR2-TH, and have successfully applied these fusion partners for the production of 
His-tag and non His-tag target proteins, respectively, derived from HIV-1 gp41. The 
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expression of fusion proteins was significantly higher than that of the unfused target 
proteins, and the fusion partner portion was efficiently removed via thrombin cleavage 
followed by His-tag affinity chromatography. These fusion partners should be applicable 
for the production of other recombinant proteins important for biopharmaceuticals, 
including cytokines, enzymes, vaccines, etc.. Overall, the novel fusion partners 
described in this study will be very attractive for any applications that require significant 
quantities of pure proteins.  
 
A.4 Materials and methods 
A.4.1 Construct generation 
The gp41-54Q and gp41-HR1-54Q proteins were described previously. (13)The 
HR2 fragment was amplified by PCR from gp41-HR1-54Q.The amplified HR2 fragment 
was digested by BamH1 and BglII and then inserted into the pET-gp41-HR1-54Q 
BamH1 site to yield pET-HR1-HR2-54Q. To generate gp41-HR1-HR2-TH-54Q, site-
directed mutagenesis was performed to introduce a thrombin site between the HR2 and 
54Q regions. To construct gp41-HR1-6H-HR2-TH-54, the HR1-6H fragment was 
amplified by PCR from gp41-HR1-54Q. The amplified HR1-6H fragment was digested 
by BamH1 and BglII and then inserted into the pET-HR1-HR2-TH-54TM (unpublished 
data) BamH1 site to yield pET-HR1-6H-HR2-TH-54TM. The 54 fragment was amplified 
by PCR from gp41-54Q with a Q683K (HxB2 numbering) introduced. The amplified 54 
fragment was inserted into pET-HR1-6H-HR2-TH-54TM through Kpn1 and EcoR1 sites 
to yield gp41-HR1-6H-HR2-TH-54.   
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The gp41-28x3 protein was generated based on pGEX-gp41-C30x3, which 
contains a C-terminal 6xHis tag (unpublished data). C30x3 was the template to 
generate pGEX-gp41-C30-28x2 to introduce the GSGSG linker between repeats. The 
QuikChange®XL Site directed mutagenesis kit was used per the manufacturer’s 
instructions with primers 5’- 
GGCTGTGGTACATCAAGGGATCGGGATCGGGAAACGAGCAGGAGCTGCTGG-3’ 
and 5’- 
GCCAGCAGCTCCTGCTCGTTTCCCGATCCCGATCCCTTGATGTACCACAGCC-3’. 
The C30-28x2 fragment was then transferred to pET-21a (Novagen; cat#69740-3) via 
BamH1/EcoR1 digestion. To delete two asparagine residues and introduce a Kpn1 site, 
site directed mutagenesis was performed using primers 5’- 
GGACAGCAAATGGGTCGCGGTACCAACGAGCAGGAGCTGCTGGC-3’ and 5’-
GCCAGCAGCTCCTGCTCGTTGGTACCGCGACCCATTTGCTGTCC-3’.  The resulting 
gp41-28x3 fragment was transferred into another pET construct containing HR1-HR2-
TH.  
 
A.4.2 Protein expression, purification, and characterization 
All constructs were expressed in E. coli and purified through Ni-NTA affinity 
chromatography as we previously described(13-15). The fusion proteins were cleaved 
with thrombin (GE Healthcare; cat#27-0846-01), and the resulting fragments were 
purified via Ni-NTA. The His-tagged proteins gp41-28x3 and gp41-54Q were collected 
in the elution fractions, and the non His-tagged gp41-54 protein was collected in flow 
through fraction. The final purified proteins were dialyzed into PBS (pH 8.0) and stored 
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at −80°C. The purified proteins were subjected to SDS-PAGE or Western blotting 
analysis. Western blotting was performed to detect the expression of gp41-28x3 using 
gp41-54Q immunized rabbit serum (unpublished data) as primary antibodies and goat 
anti-rabbit secondary antibodies. 
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A.5 Figures 
 
Fig.1. Schematic representation of all constructs. The entire gp41 ectodomain is 
shown on the top as a reference. TH represents the thrombin cleavage site and 6H 
represents 6xHis tag.  
gp41 Ectodomain 
HR1-HR2-54Q 
HR1-HR2-TH-54Q 
 
HR1-6H-HR2-TH-54 
 
HR1-HR2-TH-28x3 
 
gp41-28x3 
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Fig.2. Comparison of HR1-HR2-54Q and 54Q expression yield. Expression and 
purification of HR1-HR2 fusion protein.  (A) Expression of HR1-HR2-54Q and 54Q. 
Coomassie stained SDS-PAGE gels (Lane 1: mock sample without induction; Lane 2: 
induced HR1-HR2-54Q; Lane 3: induced 54Q.) (B) Cleavage of HR1-HR2-54Q with 
trypsin (Lane 1: original sample; Lane 2: trypsin cleaved; Lane 3: eluted from Ni-NTA 
column; Lane 4: 54Q). 
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Fig.3. Expression and purification of HR1-HR2-TH fusion proteins. (A) Expression 
of HR1-HR2-TH-54Q. Coomassie stained SDS-PAGE gels (Lane 1: uninduced; Lane 2: 
induced.) (B) Cleavage of HR1-HR2-TH-54Q with thrombin (Lane 1: original sample; 
Lane 2: thrombin cleaved; Lane 3: flow through; Lane 4: eluted from Ni-NTA column.).  
(C) Expression and purification of gp41-28x3. Western blotting (Lane 1: uninduced; 
Lane 2: induced) and coomassie stained SDS-PAGE gel (lane 3: purified). (D) (B) 
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Expression of HR1-HR2-TH-28×3. Coomassie stained SDS-PAGE gel (Lane 1: 
uninduced; Lane 2: induced). (E) Cleavage of HR1-HR2-28×3 with thrombin (Lane 1: 
original sample; Lane 2: thrombin cleaved; Lane 3: eluted from Ni-NTA column; Lane 4: 
flow through). 
 
 
 
Fig.4. Expression HR1-6H-HR2-TH fusion protein. Expression of HR1-6H-HR2-TH-
54. Coomassie stained SDS-PAGE gels (Lane 1: uninduced; Lane 2: induced.). 
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